Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome

Proceedings from the 2023 Aarhus International Turner Syndrome Meeting

Claus H. Gravholt\textsuperscript{1,2,3}, Niels H. Andersen\textsuperscript{4}, Sophie Christin-Maître\textsuperscript{5}, Shanlee M. Davis\textsuperscript{6,7}, Anthonie Duijnhouwer\textsuperscript{8}, Aneta Gawlik\textsuperscript{9}, Andrea T Maciel-Guerra\textsuperscript{10}, Iris Gutmark-Little\textsuperscript{11}, Kathrin Fleischer\textsuperscript{12}, David Hong\textsuperscript{13,14}, Karen O. Klein\textsuperscript{15}, Siddharth K. Prakash\textsuperscript{16}, Roopa Kanakatti Shankar\textsuperscript{17}, David E. Sandberg\textsuperscript{18,19}, Theo C.J. Sas\textsuperscript{20,21}, Anne Skakkebæk\textsuperscript{2,3,22}, Kirstine Stochholm\textsuperscript{1,23}, Janielle A. van der Velden\textsuperscript{24}, the International Turner Syndrome Consensus Group*, and Philippe F. Backeljauw\textsuperscript{11}.

The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from Arab Society for Pediatric Endocrinology and Diabetes, the Asia Pacific Pediatric Endocrine Society, the Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Society for Pediatric Endocrinology, the European Society of Cardiology, the European Society of Human Reproduction and Embryology, the Japanese Society for Pediatric Endocrinology, Latin American Society for Pediatric Endocrinology, and the Society for Endocrinology.

The guidelines have been endorsed by the European Society for Endocrinology, European Reference Network on Rare Endocrine Conditions, the European Society of Human Reproduction and Embryology, the Society for Endocrinology, by the societies of the International Consortium of Pediatric Endocrinology: the Arab Society for Pediatric Endocrinology and Diabetes, the Asia Pacific Pediatric Endocrine Society, the Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, The Japanese Society for Pediatric Endocrinology and the Pediatric Endocrine Society.

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. This is an Open Access article distributed under the terms of the Creative Commons Attribution -NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
1 Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark; 2 Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; 3 Department of Clinical Medicine, Aarhus University, Denmark; 4 Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; 5 Endocrine and Reproductive Medicine Unit, Center of Rare Endocrine Diseases of Growth and Development (CMERCD), FIRENDO, Endo ERN Hôpital Saint-Antoine, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France; 6 Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA; 7 eXtraOrdinarY Kids Clinic, Children's Hospital Colorado, Aurora, Colorado, USA; 8 Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands; 9 Departments of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia; 10 Area of Medical Genetics, Department of Translational Medicine, School of Medical Sciences, State University of Campinas, São Paulo, Brazil; 11 Cincinnati Children's Hospital Medical Center, University of Cincinnati, Ohio, USA; 12 Nij Geertgen Center for Fertility, Department of Reproductive Medicine, Ripsweg 9, 5424 SM, Elsendorp, The Netherlands; 13 Division of Interdisciplinary Brain Sciences, Stanford University School of Medicine, Stanford, CA, USA; 14 Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; 15 Rady Children’s Hospital, University of California, San Diego, California, USA; 16 Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA; 17 Division of Endocrinology, Children’s National Hospital, The George Washington University School of Medicine, Washington, DC 20010, USA; 18 Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA; 19 Division of Pediatric Psychology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA; 20 Department of Pediatric Endocrinology, Sophia Children’s Hospital, Rotterdam, The Netherlands; 21 Diabeter, Centre for Pediatric and Adult Diabetes Care and Research, Rotterdam, The Netherlands; 22 Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark; 23 Center for Rare Diseases, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark; 24 Department of Pediatric Endocrinology, Radboud University Medical Center, Amalia Children’s Hospital, Nijmegen, The Netherlands;
Corresponding authors to request reprints:

Claus H. Gravholt, MD, PhD, Department of Endocrinology and Internal Medicine, and
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark, Telephone +45 78462004, E-mail: claus.gravholt@clin.au.dk

Philippe F. Backeljauw, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA, E-mail: philippe.backeljauw@cchmc.org

Abstract

Turner syndrome affects 50 per 100,000 females, affects multiple organs through all stages of life, necessitating multidisciplinary care. This guideline extends previous ones and includes important new advances, within diagnostics and genetics, estrogen treatment, fertility, comorbidities, and neurocognition and neuropsychology. Exploratory meetings were held in 2021 in Europe and US culminating with a consensus meeting in Aarhus, Denmark in June 2023. Prior to this, eight groups addressed important areas in TS care: 1) diagnosis and genetics, 2) growth, 3) puberty and estrogen treatment, 4) cardiovascular health, 5) transition, 6) fertility assessment, monitoring, and counselling, 7) health surveillance for comorbidities throughout the lifespan, and 8) neurocognition and its implications for mental health and well-being. Each group produced proposals for the present guidelines, which were meticulously discussed by the entire group. Four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with systematic review of the literature. The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the European Reference Network on Rare Endocrine Conditions, the Society for Endocrinology, and the European Society of Cardiology, Japanese Society for Pediatric
Endocrinology, Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, Latin American Society for Pediatric Endocrinology, Arab Society for Pediatric Endocrinology and Diabetes, and the Asia Pacific Pediatric Endocrine Society. Advocacy groups appointed representatives for pre-meeting discussions and the consensus meeting.

Summary of recommendations

The recommendations (R) are worded as recommend (strong recommendation) and suggest (weak recommendation). We formally graded only the evidence underlying recommendations for therapeutic choices. The quality of evidence behind the recommendations is classified as very low (⨁◯◯◯◯), low (⨁⨁◯◯◯), moderate (⨁⨁⨁◯◯), and strong (⨁⨁⨁⨁⨁). See further section ‘Summary of methods used for guideline development’.

1. Diagnosis and genetics

R 1.1 We recommend considering a diagnosis of Turner syndrome (TS) in individuals with female phenotype with a karyotype containing one X chromosome and complete or partial absence of the second sex chromosome, associated with one or more typical clinical manifestations of TS (⨁⨁⨁⨁⨁).

R 1.2 We recommend against considering a diagnosis of TS in individuals with one X chromosome and a deletion distal to Xq24 on the other X chromosome, and in women over the age of 50 years with less than 5% 45,X mosaicism (⨁⨁◯◯◯).

R 1.3 We recommend that the new general surveillance management guideline applies to TS individuals with any karyotype (⨁⨁◯◯◯).

R 1.4 We recommend that the surveillance guidelines also apply to individuals with 45,X/46,XY mosaicism with either ambiguous or male external genitalia, regardless of sex of rearing (⨁⨁◯◯◯).
R 1.5 We recommend testing for TS in a female individual with typical signs of TS (★★★★).

R 1.6 When testing for TS, we recommend that a minimum of 30 metaphases be counted on a chromosome analysis as the first-line test. When a rapid test result is needed (e.g., prenatally, newborn) other methods can be used as a first-line test (e.g., microarray, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR)), with chromosome analysis as a second line confirmatory test (★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★
R 1.13 We recommend that preimplantation testing be offered to individuals with TS who want to use their own oocytes for pregnancies. TS individuals with mosaicism (45,X/46,XX) who become pregnant spontaneously, should be offered prenatal diagnostic testing (ΘΘΘΘΘ).

R 1.14 We recommend screening for Y chromosomal material by PCR or other molecular method in TS individuals with a 45,X karyotype and signs of virilization (ΘΘΘΘΘ).

R 1.15 We suggest that ethical issues, phenotypic variability, methodological limitations, and feasibility of appropriate genetic counseling be considered prior to adopting newborn screening platforms that identify TS (ΘΟΟΟΟ).

2. Growth disorders and their management

R 2.1 We recommend offering growth hormone (GH) treatment early, because growth failure in TS starts before birth and is rapid during the first years of life, and early GH treatment can prevent further loss of height potential. Treatment may be offered from as young as 2 years of age in the following circumstances: evidence of growth failure (rate of growth below normal or declining), short stature, or likelihood of short stature. GH treatment may be offered later, as long as epiphyses remain open (ΘΘΘΘΘ).

R 2.2 We suggest that GH treatment may be continued until little growth potential remains (bone age ≥14 years and/or height velocity <2 cm/year). There is no physiological rationale for continuing GH treatment into the transition period after epiphyseal closure (ΘΘΘΘΘ).

R 2.3 We recommend a starting GH dose of 45–50 µg/kg/day or (1.3–1.5 mg/m2/day) in most instances, increasing to a maximum of 68 µg/kg/day (2.0 mg/m2/day) if response is suboptimal and/or adult height potential remains substantially compromised (ΘΘΘΘΘ).

R 2.4 We recommend monitoring the response to growth-promoting treatment by measurement of height at a minimum every 6 months and plotting on a standard (reference...
female population) and/or TS-specific height chart. Maintenance of height percentile equivalent to, or greater than, the pre-treatment height percentile on a female population-based growth chart or increasing percentile on a TS-specific height chart, provides evidence of treatment effect (⊕⊕бережно).

R 2.5 We recommend monitoring GH therapy by measurement of IGF-I at least annually. We suggest generally maintaining IGF-I within the normal range for age, pubertal stage, and sex. GH dose reduction may be warranted for persistently high IGF-I values (⊕бережно).

R 2.6 We suggest not to routinely add very low-dose estrogen supplementation in the prepubertal years to further promote growth (⊕бережно).

3. Puberty and sex hormone treatment

R 3.1 We recommend measuring luteinizing hormone (LH), follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) at 8-9 years and yearly until 11-12 years to enable timely referral for fertility preservation if appropriate (⊕бережно).  

R 3.2 We recommend initiation of low dose estrogen replacement between 11 and 12 years of age, if FSH is elevated on at least two sequential measurements. Estrogen dosage should be increased slowly to adult replacement dosage over 2-4 years (⊕бережно).  

R 3.3 In individuals with a later diagnosis (>12 years) who have short stature and remaining growth potential, we suggest initiating treatment with low dose 17β-estradiol (E2) simultaneously with GH (⊕бережно).  

R 3.4 We suggest E2 transdermal (TD) route when possible, with oral E2 as second choice. Ethinyl estradiol has more risks but is better than no treatment (⊕бережно).
R 3.5 We recommend adding cyclic progesterone once breakthrough bleeding occurs (mostly this will be after about 18 – 24 months of unopposed estrogen exposure but this can occur later based on pubertal stage, serum E2 and uterine growth, endometrial thickness, and estrogen dose). The preferred option is micronized progesterone 200 mg for 10-12 days per month (⨁⨁⨁⨁).

R 3.6 We suggest combined sequential E2 and progesterone dosing in young women to avoid experiencing abnormal uterine bleeding. A combined continuous regimen is an option when the endometrium is more stable (⨁◯◯◯).

R 3.7 To optimize uterine growth during puberty and bone health in adulthood, we suggest multiple assessments of treatment effect, to include: breast development, height, uterine ultrasound, bone density, serum E2 concentrations, with the goal to achieve E2 concentrations of 100-150 pg/mL (350-500 pmol/L) at full adult replacement (⨁◯◯◯).

R 3.8 We suggest using measurements of endometrial thickness and serum E2 concentrations in adolescents or women experiencing abnormal uterine bleeding to inform adjustments to E2 and/or progesterone doses (⨁◯◯◯).

R 3.9 We recommend continuing cyclic estrogen and progesterone treatment until the usual age of menopause (approximately 50-55 years old) and then re-evaluate for possible continued lower dose of E2 and progesterone (⨁⨁◯◯).

R 3.10 We recommend individualized E2 + progesterone replacement, taking account of patient preference, to aid adherence with their management plans (⨁⨁◯◯).
4. Cardiovascular health

R 4.1 We recommend that if TS is highly suspected or has been confirmed prenatally, a fetal echocardiogram should be performed (☹☹☹○).

R 4.2 We recommend that diagnosis of left-sided congenital heart disease (CHD) in a female fetus or child should prompt a genetic evaluation that includes testing for TS (☹☹☹○).

R 4.3 We recommend that a pediatric cardiologist should be included in the multidisciplinary care team when CHD is detected prenatally in a fetus with TS to provide counseling regarding the anatomy and physiology of the specific defect, the recommended site and mode of delivery, and postnatal cardiovascular management (☹☹○○).

R 4.4 We recommend that a newborn with prenatally diagnosed or suspected TS be examined with transthoracic echocardiography (TTE) at day 2 to 3 of life, sooner if CHD is suspected, even if the fetal echocardiogram or postnatal clinical examination was normal (☹☹☹○).

R 4.5 In settings where postnatal TTE prior to discharge after birth is not available, we recommend clinical cardiac evaluation with 4-extremity blood pressure, pulse oximetry, palpation of femoral pulses, cardiac auscultation, and ECG prior to discharge followed by outpatient TTE within the first weeks of life (☹☹○○).

R 4.6 We recommend that visualization of the origin and proximal course of coronary arteries to identify potential coronary anomalies should be included in the cardiovascular assessment of all individuals with TS (☹☹○○).

R 4.7 We recommend that TTE should be performed at the time of diagnosis in all children and adults with TS, even when a fetal echocardiogram or postnatal clinical examination was normal (☹☹☹○).
R 4.8 We recommend that in the absence of significant cardiovascular disease (hypoplastic left heart syndrome, Shone’s complex, aortic coarctation, bicuspid aortic valve (BAV), aortic dilation, or cardiac shunt) at the initial comprehensive screening, TTE should be performed at age 9-11 years, after growth completion or at transition to adult care, and at least every 5-10 years in adults. (⊕⊕ ○○).

R 4.9 If the heart and aorta are completely visualized and are normal in an infant or child without symptoms that could be attributable to cardiovascular disease, an initial cardiovascular magnetic resonance (CMR) scan is still recommended but can be delayed until it can be performed without general anesthesia (⊕⊕ ○○).

R 4.10 CMR should be performed, in addition to or instead of initial screening echocardiography, in all adolescents and adults newly diagnosed with TS. Imaging should ideally be completed within 12 months, with the exact interval based on initial echocardiography findings (if echocardiography completed first), presence of additional risk factors, and clinical judgement (⊕⊕ ○○).

R 4.11 Computed tomography (CT) is a reasonable alternative when CMR is not tolerated or available. Both CT and CMR scans should include electrocardiogram (ECG)-gated or ECG-triggered assessment of the thoracic aorta (⊕⊕ ○○).

R 4.12 We recommend that individuals with TS, especially with aortic dilation or BAV, should be counseled to seek prompt evaluation if they experience acute symptoms consistent with aortic dissection, such as chest, neck, shoulder, back, or flank discomfort, particularly if it is sudden in onset and severe (⊕⊕ ○○).

R 4.13 Individuals with TS require lifelong cardiovascular surveillance at a frequency that should be determined by their risk factors for aortic dissection (⊕ ○○○).
For children < 15 years old, aortic dilation may be categorized by calculating the TS-specific Z-score (Z). For adults and adolescents > 15 years old, aortic dilation may be categorized by calculating the aortic height index (AHI), the aortic size index (ASI), the TS-specific Z-score, or the general population Z-score (Z).

For adults with TS, we recommend informed, individualized decision-making about the timing of elective aortic surgery, considering risk factors for aortic dissection, including moderate aortic dilation (AHI > 23 mm/m, ASI > 2.3 cm/m², or Z > 3.5) with at least one additional risk factor: BAV, aortic coarctation, hypertension, or a rapid increase in aortic diameter (> 3 mm/year). Dissection risk probably increases if more than one additional risk factor is present. Severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) as a single risk factor should prompt an evaluation for elective aortic surgery (⨁◯◯◯).

For children with TS, the risk of aortic dissection is much lower than in adults. We recommend informed, individualized decision-making about the timing of elective aortic surgery, considering risk factors for aortic dissection including moderate aortic dilation (age < 15 years: Z > 3.5; age ≥ 15 years: AHI ≥ 23 mm/m, ASI > 2.3 cm/m², or Z > 3.5) and hypertension, aortic coarctation, BAV, or a rapid increase in aortic diameter (> 3 mm/year or > 1 Z/year) (⨁◯◯◯).

We recommend annual assessment of blood pressure, preferably using ambulatory blood pressure monitoring (ABPM), and initiation of medical therapies if hypertension is confirmed, for all individuals with TS. (⨁⨁◯◯).

We recommend treatment with a beta-blocker, an angiotensin receptor blocker, or both for individuals with TS who have hypertension and have a dilated aorta (age < 15 years: Z ≥ 2.5; age ≥ 15 years: AHI ≥ 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5) (⨁⨁◯◯).
R 4.19 We suggest that treatment with a beta-blocker, an angiotensin receptor blocker, or both should be considered for individuals with TS who have a dilated aorta (age < 15 years: Z ≥ 2.5; age ≥ 15 years: AHI ≥ 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5), even if they are not hypertensive.

R 4.20 We recommend that medical treatment of hypertension for all individuals with TS who do not have a dilated aorta (age < 15 years: Z < 2.5; age ≥ 15 years: AHI < 20 mm/m, ASI < 2.0 cm/m², or Z < 2.5) should be based on the appropriate pediatric or adult guidelines for medical management of hypertension.

R 4.21 We do not recommend routine screening for blood clotting disorders before initiation of female sex hormone replacement therapy (HRT). The diagnosis, surveillance, and treatment of blood clotting disorders in TS should be based on the appropriate pediatric or adult clinical guidelines for the general population.

R 4.22 We recommend that an initial lipid profile should be obtained no later than the age of initial screening recommended by country-specific guidelines or at transition and repeated every 3 years. The diagnosis and treatment of hyperlipidemia in TS should be based on the appropriate pediatric or adult clinical guidelines for the general population.

R 4.23 We recommend that new onset chest pain, regardless of age, should be assessed by a cardiologist. The diagnosis, surveillance, and treatment of coronary artery disease in TS should be based on the appropriate pediatric or adult clinical guidelines for the general population.

R 4.24 We recommend that a resting ECG should be performed at the time of diagnosis to assess for findings consistent with CHD, an arrhythmia, or conduction abnormality. Follow up ECGs should be obtained and reviewed by a cardiologist at intervals deemed appropriate based on baseline findings, underlying CHD, and clinical course.
R 4.25 We suggest, given prior concern for QTc prolongation in persons with TS, that the QTc should be routinely calculated, ideally using Hodges formula, whenever an ECG is performed on a patient with TS. However, newer research suggests that QTc prolongation is not more prevalent in persons with TS compared to the general population when defining prolongation as QTc > 450 ms in girls (up to 15 years old) and > 460 ms in women and when using Hodges formula (◯◯◯).

R 4.26 We recommend that standard guidelines for the general population should apply to individuals with TS if QTc prolongation > 480 ms by Hodges formula has been detected on at least 2 serial ECGs. In those circumstances, consultation with a cardiologist, possibly an electrophysiologist, should be completed (◯◯◯).

R 4.27 We recommend regular aerobic physical activities as part of a heart healthy lifestyle for all individuals with TS (◯◯◯).

R 4.28 We recommend that the function of the aortic valve, the presence of any other congenital heart lesions, and hypertension should be considered in determining athletic participation recommendations for the individuals with TS and aortic dilation (◯◯◯).

R 4.29 We suggest that for individuals with normal aortic size (age < 15 years: Z < 2.5; age ≥ 15 years: AHI < 20 mm/m, ASI < 2.0 cm/m², or Z < 2.5), it is reasonable to participate in all sports (◯◯◯).

R 4.30 We suggest that for individuals with a mild to moderately dilated aorta (age < 15 years: Z 2.5–3.5; age ≥ 15 years: AHI 20–23 mm/m, ASI 2.0–2.3 cm/m², or Z 2.5-3.5), participation in low and moderate static and dynamic competitive sports may be acceptable but intense weight-training should be avoided (◯◯◯).
We suggest that individuals with a moderately to severely dilated aorta (age < 15 years: Z > 3.5; age ≥ 15 years: AHI > 23 mm/m, ASI > 2.3 cm/m², or Z > 3.5) should be advised not to participate in any competitive sports, intense weight-training, or physical activities with risk of contact injury to the chest (⊕◯◯◯).

We recommend that cardiovascular imaging, ideally CMR or CT, should be performed at least once within two years before planned pregnancy or assisted reproductive methods and repeated closer to pregnancy if recommended by a cardiovascular specialist (⊕⊕◯◯). 

In the presence of aortic dilation (AHI > 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5) or at least one other risk factor for dissection (BAV, aortic coarctation, hypertension, rapid aortic diameter increase), we recommend informed, individualized peripartum cardiovascular care by a multidisciplinary team that ideally should include a maternal–fetal medicine specialist and a cardiologist with expertise in managing women with TS, preferably in a center with expertise in aortic surgery and TS (⊕◯◯◯).

In the presence of severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) and especially when other risk factors for aortic dissection are present (previous aortic surgery, previous aortic dissection, or rapid aortic diameter increase (> 3 mm/year), BAV, hypertension, or aortic coarctation), we suggest that assisted reproductive technologies or spontaneous conception should be avoided (⊕◯◯◯).

We recommend tight blood pressure control to a target of less than 130/80 mm Hg during the peripartum period. Antihypertensive therapies and low dose aspirin for the prevention of adverse pregnancy outcomes due to preeclampsia and related hypertensive disorders should be administered according to current clinical practice guidelines (⊕⊕◯◯).
We recommend obtaining a TTE at least once during pregnancies in low-risk women (AHI < 20 mm/m, Z < 2.5, ASI < 2.0 cm/m² and no BAV, aortic coarctation, hypertension, or rapid aortic diameter increase), ideally around 20 weeks of gestation (☑️☑️◯️). 

In the presence of aortic dilation (AHI > 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5) or at least one other risk factor (BAV, aortic coarctation, hypertension, rapid aortic diameter increase), we suggest TTE at least once every 12 weeks during pregnancy, or more frequently on an individualized basis. Consideration of an additional imaging study in the early third trimester is reasonable and is strongly encouraged if there is any concerning change noted on the second trimester TTE (☑️◯️◯️). 

We recommend that CMR (without contrast medium) should be performed during pregnancy when TTE raises suspicion of rapid aortic dilation. If aortic segments previously known to be dilated cannot be adequately visualized, or if new dilation is suspected, CMR should be used for confirmation (☑️☐️◯️). 

We suggest that rapid aortic diameter increase (> 3 mm compared to pre-conception imaging) should lead to renewed risk assessment and discussion in an expert center with a multidisciplinary team to determine potential modifications of maternal risk factors for aortic dissection, delivery, and postpartum planning, including consideration of prophylactic aortic replacement (☐️◯️◯️). 

We recommend the mode of infant delivery should be based on the safest method to prevent aortic and obstetric complications, individual preferences, and local professional expertise. Preventive measures (epidural anesthesia, expedited second stage of labor) that reduce the risk of aortic dissection should be considered, but are especially recommended in the presence of aortic dilation (AHI > 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5) or additional risk factors for aortic dissection (BAV, aortic coarctation, hypertension, rapid aortic diameter
increase). Cesarean section is preferred for individuals with severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) or a history of aortic dissection (◯◯◯◯). We recommend postpartum cardiac imaging and cardiology consultation due to the continued risk of aortic dissection. For individuals with severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) or a history of aortic dissection, the initial post-partum visit should occur 2-6 weeks after delivery with at least one additional follow up cardiology visit. For individuals with less severe aortic disease, one post-partum visit 4-6 months after delivery may be sufficient before resuming routine follow up intervals (◯◯◯◯). We recommend that individuals who can become pregnant and have left-sided obstructive lesions (subaortic stenosis, aortic valve stenosis, or coarctation) should have regular aortic imaging and cardiovascular follow up with consideration for intervention before pregnancy (◯◯◯◯). We recommend that individuals with severe subaortic or aortic valve stenosis or significant valve disease and reduced cardiac function should be advised against pregnancy (◯◯◯◯).

5. Transition from pediatric to adult care

R 5.1 We recommend an intentional, defined, individualized pathway to transition from pediatric to adult care for adolescents with TS beginning in early adolescence (◯◯◯◯). R 5.2 We suggest a formal assessment of transition readiness at multiple timepoints of the individual and/or caregiver/support person to identify specific needs and barriers to successful transition (◯◯◯◯).
R 5.3 We suggest that developmentally-appropriate, organ systems-based assessment and counseling occurs during transition, ensuring that these elements are documented upon transfer (⊕⊕◯◯).

R 5.4 We suggest that pediatric health care teams transition individuals with TS to adult providers with expertise to manage TS comorbidities (⊕⊕◯◯).

6. Fertility assessment, monitoring, and counselling

R 6.1 We recommend developmentally appropriate disclosure of the potential for reduced fertility in individuals with TS. We recommend disclosing that the probability to conceive is primarily associated with the presence of a 46,XX cell line and spontaneous menarche, and that there is increased risk of maternal and fetal complications in pregnancy compared to the general population (⊕⊕◯◯).

R 6.2 We recommend counselling of TS girls and parents, as early as possible after diagnosis, by the primary care provider, pediatric endocrinologist, or gynecologist, as appropriate, regarding family building options such as fertility preservation, foster care, adoption, surrogacy, egg or embryo donation or the choice to remain childless (⊕⊕◯◯).

R 6.3 We recommend offering a referral to a fertility specialist with specific expertise in TS care to all individuals with TS (or their parents/guardians), when developmentally appropriate, at the time of diagnosis and intermittently over time (⊕⊕◯◯).

R 6.4 We recommend offering AMH measurements to all individuals with TS from diagnosis. AMH should be monitored annually if fertility preservation is considered, along with pre- and post-test fertility counselling (⊕◯◯◯).

R 6.5 We recommend thorough cardiac screening and appropriate counselling by a maternal–fetal medicine specialists and cardiologists with expertise in managing women with TS prior to planning a pregnancy, especially if oocyte or embryo donation is considered. (⊕⊕⊕⊕)
**R 6.6** We recommend controlled ovarian stimulation and oocyte cryopreservation, in females with a fertility potential, as the primary fertility preservation option in post-menarche individuals of appropriate psychological maturity, in centres with sufficient expertise in managing women with TS and the availability of psychosocial support (★★★★

**R 6.7** We recommend that controlled ovarian stimulation and oocyte cryopreservation not be offered to premenarcheal children or individuals not mature enough to understand and undergo the procedure (★★★★

**R 6.8** We recommend in all TS, including minors who cannot make their own decision, that ovarian tissue cryopreservation only be offered in the context of an institutional/ethics board approved research study or with clinical ethics board approval (★★★★

**R 6.9** We suggest shared decision making when addressing fertility preservation and fertility treatment for individuals with TS. (Good Practice Statement)

**7. Health surveillance for comorbidities throughout the lifespan**

**R 7.1** We recommend delivery of a fetus with known or suspected TS occur in a facility equipped to provide neonatal care (★★★★

**R 7.2** We recommend a comprehensive physical examination with particular attention to hip stability and lymphedema, echocardiography, and renal ultrasonography be obtained regardless of prenatal imaging results, ideally prior to discharge (★★★★)
R 7.3 We recommend monitoring pre-feeding blood glucose levels in the first 48 hours of life and ensure that the infant is euglycemic prior to discharge. We suggest heightened awareness for symptoms of hypoglycemia in the early years of life (⊕◯◯◯).

R 7.4 We recommend counseling on, and monitoring for, feeding difficulties and poor weight gain in the first year of life, with collaborative evaluation and treatment by the primary care provider and/or specialists based on the concern and available resources (⊕◯◯◯).

R 7.5 We recommend expectant and new parents/caregivers be offered genetic counseling, referred to specialists in TS care, and be provided resources for local support and advocacy groups (⊕◯◯◯).

R 7.6 We recommend a comprehensive ophthalmologic examination between 6 and 12 months of age, or at the time of diagnosis if older (⊕◯◯◯).

R 7.7 We recommend follow-up ophthalmologic examinations if the initial examination is abnormal or if new visual or ocular concerns arise (⊕◯◯◯).

R 7.8 We recommend otoscopy evaluation for detection of middle ear disease, including effusion and cholesteatoma, annually in childhood and with symptoms (⊕◯◯◯).

R 7.9 We recommend newborn hearing screening be completed, and if this is normal, age-appropriate behavioral audiometric evaluation be conducted every 2-3 years in childhood and adolescence starting as soon as developmentally able (1-2 years of age), every 5 years in adults, and any time decreased hearing is suspected (⊕◯◯◯). (⊕◯◯◯).

R 7.10 We recommend annual tympanometry up to 5 years of age where clinically available (⊕◯◯◯).
R 7.11 We recommend antibiotic treatment should be administered for acute bacterial otitis media per local treatment guidelines (as for a high-risk population) and a repeat examination should be done to ensure resolution (⊕⊕⊙⊙).

R 7.12 We suggest placement of tympanostomy tubes at the early stages of chronic or recurrent middle ear disease in childhood (as for a high-risk population) (⊕⊕⊙⊙).

R 7.13 We recommend rapid intervention with tympanostomy tube insertion or hearing aids for conductive hearing loss due to middle ear disease in childhood (⊕⊕⊙⊙).

R 7.14 We recommend rehabilitation with hearing aids or cochlear implantation for sensorineural hearing loss (⊕⊕⊙⊙).

R 7.15 We recommend counseling on, and monitoring for, balance and vestibular problems in adults with sensorineural hearing loss, and referral to appropriate specialists for vestibular testing and compensatory training if concerns are identified (⊕⊙⊙⊙⊙).

R 7.16 We recommend at least annual dental care from first tooth eruption throughout the lifespan, with particular attention to periodontal health (⊕⊕⊕⊙).

R 7.17 We suggest orthodontic evaluation after permanent tooth eruption for initial consultation and anticipatory management (⊕⊙⊙⊙⊙).

R 7.18 We suggest screening for obstructive sleep-disordered breathing through history and/or validated instruments throughout the lifespan (⊕⊙⊙⊙⊙).

R 7.19 We recommend annual skin assessment (⊕⊙⊙⊙⊙).
R 7.20 We suggest use of compression garments, lymphatic massage, and referral to specialists in lymphedema care for any compromising lymphedema (◯◯◯◯).

R 7.21 We recommend a renal ultrasound at time of diagnosis to identify congenital anomalies of the kidney and urinary tract (◯◯◯◯).

R 7.22 We recommend performing laboratory testing or repeat imaging if there are new renal or urinary concerns, such as urinary tract infections and hypertension. Annual urinalysis for proteinuria is indicated in all individuals with renal agenesis, bilateral hypoplasia, or horseshoe kidney (◯◯◯◯).

R 7.23 We recommend promotion of healthy lifestyles including exercise to address modifiable risk factors of cardiovascular disease (◯◯◯◯).

R 7.24 We recommend screening for diabetes with measurement of hemoglobin A1c or fasting glucose every 1-2 years starting at age 10-12 years or sooner with symptoms of diabetes (◯◯◯◯).

R 7.25 We recommend assessment of diabetes autoantibodies at diagnosis of diabetes in girls and women with TS to determine the type of diabetes as it is not easy to differentiate Type 1 and Type 2 diabetes in this population (◯◯◯◯).

R 7.26 We recommend measuring liver enzymes (alanine aminotransferase (ALT) at minimum) in childhood and every 1-2 years starting at the age of 10 and continuing throughout the lifespan. Aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) should be added in adults (◯◯◯◯).
R 7.27 We suggest that if liver enzymes are elevated at least twice the normal upper limit, reassessment is recommended as fluctuation is common. Persistent liver function abnormalities (LFA) warrant further investigation and referral to a gastroenterologist (⊕⊕⊕⊕).

R 7.28 We suggest that in adults with LFA, the fibrosis-4 (FIB-4) score and/or liver elastography is useful for evaluating the severity of liver damage (⊕◯◯◯).

R 7.29 We recommend that hormone replacement therapy should be continued in the presence of LFA (⊕⊕⊕⊕).

R 7.30 We recommend screening for celiac disease by measuring tissue transglutaminase antibodies (TTG IgA with total IgA) in asymptomatic individuals starting at age 2 years, and subsequently every 2-5 years (⊕⊕◯◯).

R 7.31 We recommend screening for celiac disease if there are gastrointestinal symptoms, poor growth, weight loss, osteoporosis, skin changes, anemia and/or other symptoms present at any age (⊕⊕◯◯).

R 7.32 We suggest measurement of complete blood count to evaluate for anemia every 1-2 years in adolescents and adults (⊕⊕◯◯).

R 7.33 We recommend that all individuals should be counseled on healthy lifestyle measures including dietary intake of calcium and vitamin D, weight-bearing activity, and the role of estrogen replacement for bone health (⊕⊕◯◯).

R 7.34 We recommend routine screening for vitamin D deficiency using a serum 25 (OH) vitamin D level concentration between 9-11 years of age and every 2-3 years ongoing and treating with standard vitamin D supplement as necessary (⊕⊕◯◯).
R 7.35 We recommend obtaining a dual energy X-ray absorptiometry (DXA) scan after completion of growth but prior to 21 years of age and every 5-10 years throughout adulthood (⊙⊙⊙⊙).

R 7.36 We recommend using serial DXA scans to monitor BMD in high-risk women (fractures, inadequate hormone replacement, celiac disease, and other comorbidities) and once reaching menopause or discontinuing estrogen therapy (simulating menopause) (⊙⊙⊙⊙).

R 7.37 We recommend physical examination to identify scoliosis at diagnosis and then at least annually until skeletal maturation (⊙⊙⊙⊙).

R 7.38 We suggest screening for orthopedic anomalies (such as scoliosis, genu valgum, Madelung deformity) which in severe cases, may lead to pain and improve with intervention (⊙⊙⊙⊙⊙).

R 7.39 We recommend adhering to generally accepted population screening guidelines for cancer surveillance in TS (⊙⊙⊙⊙⊙).

R 7.40 We recommend individualized decision-making about gonadectomy/salpingo-oophrectomy in girls and women with TS and Y chromosome material identified on standard karyotyping or FISH analysis. This also includes a discussion of the timing of the procedure weighing risk of gonadoblastoma/dysgerminoma against the potential benefit of gonadal function and fertility (⊙⊙⊙⊙⊙).

R 7.41 We recommend screening for hypothyroidism with measurement of TSH every 1-2 years starting at 2 years of age and continuing through adulthood, and with new symptoms. If TSH is elevated, we suggest testing for anti-thyroid antibodies (⊙⊙⊙⊙⊙).
We recommend counseling on and screening for symptoms of other autoimmune conditions, such as vitamin B12 deficiency, celiac disease, psoriasis, vitiligo, and inflammatory bowel diseases (⊕◯◯◯).

We recommend the clinical care recommendations herein be implemented on an individual basis with consideration of both patient- and system-level factors (Good Practice Statement).

We recommend all individuals with TS receive care from specialists with expertise in genetics (and/or genetic counseling), cardiology, endocrinology, reproductive medicine, audiology/otolaryngology, ophthalmology, neurodevelopment and mental health. Additional subspecialists should be involved as needed, such as dermatology, gastroenterology, nephrology, orthopedics, podiatry, nutrition, and speech/occupational/physical therapy (⊕⊕⊕◯).

We recommend that girls and women with TS attend specialist interdisciplinary or multidisciplinary clinics, when available, for health surveillance in addition to their primary care provider (⊕⊕◯◯)

We suggest that the TS care team provide resources for additional education, self-advocacy, and connecting with other affected individuals such as through TS support and advocacy organizations (⊕⊕◯◯).

We suggest telehealth may supplement medical and/or psychosocial care if it is available and improves access to TS specialists (⊕◯◯◯).
8. Neurocognition and its implications for mental health and well-being

R 8.1 We recommend that cognitive/neuropsychological evaluations and behavioral/social/emotional screenings be integrated into the care of individuals with TS across the lifespan (★★★★◯).

R 8.2 We recommend surveillance of generic risk factors associated with chronic medical conditions that can threaten well-being and quality of life (QoL) (Ungraded Good Practice Statement).

R 8.3 We recommend that evidence-based interventions for cognitive or psychosocial problems in the general population be adapted to meet the needs of girls/women with TS (★★★★◯).

R 8.4 We recommend that a “support plan” be prepared by the patient’s specialist providers as a tool to empower individuals and their caregivers in advocating for all necessary supports, outside the medical environment (e.g., schools, community), to achieve optimal educational and socioemotional development (Ungraded Good Practice Statement).

R 8.5 We recommend counseling regarding TS that emphasizes personal understanding and meaning of the features associated with TS (Ungraded Good Practice Statement).

R 8.6 We recommend that girls and women with TS receive counseling regarding sexual health and sexual well-being (Ungraded Good Practice Statement).

R 8.7 We suggest that individuals with TS and their caregivers be encouraged to network with local/regional/national TS peer support organizations (★★★★★★).
The purpose of the guidelines

These guidelines were developed to ensure that girls and women with TS receive optimal, evidence-based care that meets their needs and improves their health. Building on the 2017 Clinical Practice Guidelines for the care of girls and women with TS, these new guidelines have been updated and expanded to areas not previously addressed, including partnership in care and empowerment of women with TS. Personal characteristics, preferences, culture, social determinants of health, and values are all considered, in addition to resource availability in different settings. The guidelines are offered in support of girls, women and families living with TS and their healthcare providers to optimize diagnosis, assessment, and management of TS.

Introduction

Turner syndrome affects 25-50 per 100,000 female individuals and can involve multiple organ systems through all stages of life, necessitating a multidisciplinary approach to care. Previous guidelines have already addressed this, but numerous important advances have been noted since their publication. These advances cover all specialty fields involved in the care of girls and women with TS. This paper is based on an international effort that started with exploratory virtual meetings in 2021, and culminated with a Consensus Meeting held in Aarhus, Denmark in June 2023. Prior to this meeting, eight groups each addressed important areas in TS care: 1) diagnosis and genetics, 2) growth, 3) puberty and estrogen treatment, 4) cardiovascular health, 5) transition, 6) fertility assessment, monitoring, and counselling, 7) health surveillance for comorbidities throughout the lifespan, and 8) neurocognition and its implications for mental health and well-being. These groups produced proposals for the present guidelines. Additionally, four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with a separate systematic review of the literature. These four questions related to the efficacy and most optimal treatment of short stature, infertility, hypertension, and hormone replacement therapy (HRT). These guidelines were initiated and developed by members of the European Society of Endocrinology (ESE) in Europe, and by the Pediatric Endocrine Society (PES) in the USA, with
important contributions from members from the European Society of Human Reproduction and Embryology (ESHRE), the European Society for Cardiology, the American Heart Association (AHA), the Society for Endocrinology, the European Society for Pediatric Endocrinology, Japanese Society for Pediatric Endocrinology, Australasian Pediatric Endocrine Group, Latin American Society for Pediatric Endocrinology (SLEP), Arab Society for Pediatric Endocrinology and Diabetes, and Asia Pacific Pediatric Endocrine Society.

Funding bodies should recognize that although TS is a relatively rare condition, it presents with multi-system effects and therefore deserves diversified and increased efforts to support research in the years to come.

Methods

Guideline development consensus working group

The work on these guidelines was sponsored primarily by ESE and co-sponsored by European Society for Paediatric Endocrinology and the European Reference Network on Rare Endocrine Conditions (Endo-ERN), Project ID No 101084921, co-funded by the European Union within the framework of the EU4H Programme. Endo-ERN Reference Centre (RC) individual contributions is acknowledged. Furthermore, PES supported their own delegates for the meeting, and additional support was obtained from an unconditional grant from Novo Nordisk and a gift from Ascendis Pharma, as well as certain TS advocacy groups (Turner Syndrome Support Society of the United Kingdom, Turner Syndrome Center Denmark). The chairs of the consensus working group, Claus H. Gravholt and Philippe F. Backeljauw, were confirmed by the ESE Clinical Committee and PES, respectively. Other members of the working and writing group were: Niels H. Andersen (adult cardiologist), Sophie Christin-Maitre (adult endocrinologist), Shanlee Davis (pediatric endocrinologist), Anthonie Duijnhouwer (adult cardiologist), Aneta Gawlik (pediatric endocrinologist), Andrea T Maciel Guerra (clinical geneticist), Iris Gutmark-Little (pediatric endocrinologist), Kathrin Fleischer (gynecologist and fertility specialist), David Hong (child psychiatrist), Karen O. Klein (pediatric endocrinologist), Siddharth Prakash (adult cardiologist), Roopa Kanakatti Shankar (pediatric endocrinologist), David E. Sandberg (health psychologist), Theo C.J. Sas (pediatric endocrinologist), Anne Skakkebæk (clinical geneticist), Kirstine
The working group had one in-person meeting (June 2023 where all participants were present) and numerous virtual meetings. Consensus was reached upon discussion; minority positions were considered in the rationale behind the recommendations. Some working groups included members from the TS advocacy community. These individuals provided a valuable and nuanced perspective. All participants completed conflict-of-interest forms (Appendix 1).

A draft of the guideline was submitted for external review and commentary with/without endorsement by the professional societies. All comments and suggestions were discussed and implemented as appropriate by the working/writing group. Responses to the comments are summarized in Appendix 2.

Target group

This guideline document is developed for all health-care providers of individuals with TS, i.e., both primary care providers (pediatricians, family doctors, internal medicine specialists), as well as sub-specialists, such as various specialist pediatricians, geneticists, endocrinologists, cardiologists, gynecologists and fertility specialists, clinical psychologists, and neuropsychologists.

Aims

The overall purpose of the updated guidelines is to provide practical clinical recommendations for TS care, with focus on daily management across the lifespan. We also aimed to address health-care issues not previously addressed.

Summary of methods used for guideline development

The methods used have previously been described in greater detail (3). In short, the guidelines used GRADE as a methodological base for four clinical questions. The first step was to define these questions followed by a systematic literature search. After including relevant articles, we:
1) estimated an average effect for specific outcomes (if possible); and 2) rated the quality of the evidence. Formal evidence syntheses were performed and graded only for these questions. For the GRADE questions we considered: 1) quality of the evidence, 2) balance of desirable and undesirable outcomes, and 3) values and preferences (patient preferences, goals for health, costs, management inconvenience, feasibility of implementation, etc.). Additional recommendations based on good practice were graded based on expert opinion. All other recommendations were derived from majority consensus of the guideline development working group, but, if members had substantive disagreements, this is acknowledged in the manuscript. For transparency, all recommendations provided are accompanied by a text explaining why specific recommendations were made. The recommendations are worded as recommend (strong recommendation) and suggest (weak recommendation). The quality of evidence behind the recommendations is classified as very low (⨁◯◯◯◯), low (⨁⨁◯◯◯), moderate (⨁⨁⨁◯◯) and strong (⨁⨁⨁⨁◯) (6). This approach was used for all other recommendations as well. For “all other classifications” not formally submitted for GRADE, the recommendations were proposed by selected members of the working group and accepted by the remaining members of that working group, and as such represent good clinical practice based on the limited available evidence, but still supported by individuals with considerable expertise in TS care.

Clinical questions, endpoint definitions and eligibility criteria

The guideline panel formulated four clinical questions for which a separate systematic literature search was performed, and for which available evidence was synthesized. For each question, the eligibility criteria, endpoint definition, search strategy and main findings are described below.

What is the effect of growth promoting treatment in TS? (GRADE question 1)

Short stature, present in most individuals with TS, has been treated with GH, with or without oxandrolone (a non-aromatizable androgen), with the main outcome objective to increase adult
height. We systematically searched for randomized clinical trials (RCTs) published after 1990 on the effects of GH with or without the addition of oxandrolone. The following outcomes were considered: height change and adult height outcome, QoL, mortality, cardiovascular side effects, and masculinization (due to oxandrolone treatment). The following studies were not eligible: non-randomized studies, studies not reporting height, studies only comparing different doses of one drug, and cross-over trials.

What is the probability of achieving viable pregnancy after oocyte donation in TS? (GRADE question 2)

TS is usually accompanied by infertility due to premature ovarian insufficiency. Women with TS can be offered oocyte donation if they desire pregnancy. We searched for studies that reported on the probability of a live birth or viable pregnancy after oocyte donation in TS. Outcomes considered important were live-born children, risk of miscarriage, and complications (e.g., pre-eclampsia and aorta dissection). We also searched for studies that compared the effectiveness of achieving a viable pregnancy with different protocols for oocyte donation.

What are the effects of blood pressure treatment on clinical outcomes in TS? (GRADE Question 3)

TS is often accompanied by hypertension, which has been linked to the development of aortic dilation or dissection, both observed with strikingly increased frequency in TS. Some experts have advocated for stricter blood pressure control in individuals with TS. Therefore, two questions were formulated: (1) At what blood pressure threshold should hypertension in TS be treated? (2) What anti-hypertensive treatment is most effective in TS? We searched for studies comparing different blood pressure targets and different blood pressure treatments. Cardiovascular disease and mortality were considered relevant endpoints. Randomized as well as non-randomized studies were considered; cohort studies without control arm and case series were ineligible.
What is the optimal approach to estrogen replacement in TS (GRADE question 4)

TS is usually accompanied by hypergonadotropic hypogonadism and primary or secondary amenorrhea. Most TS individuals will therefore need HRT – first for induction of puberty and later for maintaining secondary sex characteristics, attaining peak bone mass, normalizing uterine growth (for possible pregnancy later). This leads to the following question: What is the optimal HRT, mainly focusing on dosing throughout adolescence and adulthood?

Description of search and selection of literature

In cooperation with a trained librarian, a search strategy was composed for seven of the subgroups, specifically to include any research published since the last guideline meeting in 2016. The following databases were searched: PubMed, Embase (OVID-version) and COCHRANE Library. The number of articles retrieved are shown in the flowchart (Figure S1). Screening and exclusion of articles were carried out by the individual subgroups. Three of these subgroups opted to use Covidence software for systematic reviews (https://www.covidence.org/) for this process. For the newly added transition group, literature published before 2016 was also included. This group conducted their own search. A complete list of the literature reviewed is available upon request.

Guideline recommendations with rationale

1. Diagnosis and genetics

1.1 Definition and Diagnosis

R 1.1 We recommend considering a diagnosis of Turner Syndrome (TS) in individuals with female phenotype with a karyotype containing one X chromosome and complete or partial absence of the second sex chromosome, associated with one or more typical clinical manifestations of TS ( KeyEvent ).

R 1.2 We recommend against considering a diagnosis of TS in individuals with one X chromosome and a deletion distal to Xq24 on the other X chromosome, and in women over the age of 50 years with...
less than 5% 45,X mosaicism ($\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta$).

**R 1.3** We recommend that the new general surveillance management guideline applies to TS individuals with any karyotype ($\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta$).

**R 1.4** We recommend that the surveillance guidelines also apply to individuals with 45,X/46,XY mosaicism with either ambiguous or male external genitalia, regardless of sex of rearing ($\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta$).

**R 1.5** We recommend testing for TS in a female individual with typical signs of TS ($\Theta\Theta\Theta\Theta\Theta$).

**R 1.6** When testing for TS, we recommend that a minimum of 30 metaphases be counted on a chromosome analysis as the first-line test. When a rapid test result is needed (e.g., prenatally, newborn) other methods can be used as a first-line test (e.g., microarray, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR)), with chromosome analysis as a second line confirmatory test ($\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta\Theta$).

### 1.1.1 Definition

TS is a sex chromosome disorder that affects phenotypic *female individuals* who have one intact X chromosome and complete or partial absence of the second sex chromosome (Table 1) in association with one or more clinical manifestations \(^1\). The traditional definition of TS implies the presence of physical features such as the characteristic facial appearance, with neck webbing and peripheral lymphedema \(^5,6\). However, the 2017 Guidelines \(^1\) broadened the clinical manifestations of TS to include features such as linear growth failure (short stature), ovarian insufficiency (pubertal delay), early sensorineural hearing loss, distinctive congenital cardiovascular, skeletal and renal anomalies, a particular neurodevelopmental profile, and a constellation of other conditions with a higher prevalence in TS including hypothyroidism and celiac disease.

As stated in the 2017 TS guidelines, smaller X chromosome deletions may cause distinct features, which are not included in the definition of TS (Table 2). Female individuals with small
distal deletions of the short arm of the X chromosome (Xp22.33) where the *SHOX* (short stature homeobox) gene resides, frequently have short stature and other TS-associated skeletal anomalies associated with a *SHOX* deletion, but do not appear to have a higher risk for cardiac anomalies, neurocognitive issues, or ovarian insufficiency. Those who have a deletion distal to Xq24 frequently have primary or secondary amenorrhea without short stature or other TS features and should be referred to as having premature ovarian insufficiency. In addition, a diagnosis of TS should not be used in women over the age of 50 years with less than 5% 45,X cells in case of symptoms, because 45,X mosaicism may develop in older women due to age-related loss of one of the X chromosomes. In women less than 50 years of age, there has been no specific lower limit for 45,X that defines TS, although many have used 5%. In addition, it has not been determined whether there is a “cut-off” point of the percentage of 45,X below which surveillance does not apply. Individuals with 45,X/46,XY mosaicism who do not have typical female external genitalia are also excluded from the diagnosis, although we recommend that the guidelines also apply to these individuals due to a similar comorbidity profile (see below).

**1.1.2 Indication for testing**

Certain features alone would prompt chromosome analysis, including fetal cystic hygroma or hydrops, unexplained short stature, left-sided outflow congenital heart defects (excluding bicuspid aortic valves (BAV)), unexplained delayed puberty/ menarche, failure to progress puberty or secondary amenorrhea, characteristic facial and physical features, and infertility (Table 3). Combinations of other features (at least two) are also an indication for testing. These include early sensorineural hearing loss together with short stature, Madelung deformity, renal abnormalities, neurocognitive problems and/or psychiatric issues, multiple typical and/or melanocytic nevi, dysplastic or hyperconvex nails, and other congenital heart defects (including BAV).
1.1.3 Diagnostic strategy

Karyotyping is the gold standard test to diagnose TS. We recommend that a minimum of 30 metaphases be counted on a chromosome analysis as the first-line test which can detect approximately 10% mosaicism with 95% confidence limits, consistent with the original 2010 ACMG (American College of Medical Genetics and Genomics) laboratory guideline and the European guidelines for constitutional cytogenomic analysis (2019). TS may also be diagnosed using newer methods such as microarray, and exome- and genome sequencing. Microarray can provide better resolution compared to karyotyping, but has limitations in detecting low level 45,X mosaicism (< 10%, though studies show detection as low as 5%)20, and in interpreting structural variants (i.e., mosaic isodicentric Xp chromosome). Exome/genome sequencing have the potential to detect mosaicism as low as 5% and the ability to detect smaller Y-chromosome material, as current methods use SRY or centromeric markers.

1.1.4 Karyotype-phenotype analysis

TS is associated with significant phenotypic variability ranging from individuals with classic traits to individuals without apparent observable traits. This clinical heterogeneity constitutes a diagnostic challenge to clinicians. Comparative studies of karyotype-phenotype in TS are challenged by relatively small cohorts, differences in patient ages, variability in the definition of the clinical features, and general uncertainty regarding the extent of mosaicism in different tissues 1. It has been hypothesized that all individuals with TS with a 45,X karyotype who survive to birth must have some degree of cryptic mosaicism for a normal cell line in the body, although there is no conclusive evidence for this. Although phenotypic heterogeneity exists also within the different karyotype subgroups, some general karyotype-phenotype associations have been established.

- Overall, individuals with TS and a 45,X karyotype have a significantly higher frequency of comorbidities and a higher mortality compared to individuals with other TS karyotypes.
• In general, individuals with TS and a 45,X/46,XX mosaic karyotype present with a milder phenotype with left-sided congenital heart defects, obesity and hypertension being less frequent, age at menarche being near-normal and are more likely to experience spontaneous menarche and pregnancies compared to individuals with TS and 45,X.\(^{26,30}\).

• In general, individuals with TS and 45,X/47,XXX karyotype also have a milder external and cardiovascular phenotype compared to 45,X, but neurodevelopmental disabilities and mental health domains remain a concern\(^{31}\).

• Overall, individuals with TS and isochromosome Xq present with an intermediate phenotype regarding left-sided congenital heart defects and spontaneous menarche, and also seem to have a lower incidence of aortic coarctation \(^{26,30}\).

• Individuals with TS and with 45,X/46,XY seem to have the lowest incidence of autoimmune thyroid disease and severe hearing loss and a low incidence of aortic coarctation\(^{26}\).

• TS individuals with a ring X chromosome without functional loss of XIST seem to have an increased risk of metabolic syndrome compared with TS individuals with 45,X but in contrast, they appear to have the lowest risk of BAV\(^{26}\). In TS individuals with a ring X chromosome and functional loss of XIST, a more severe cognitive phenotype may be seen.

1.1.4.1 45,X/46,XY mosaicism with either ambiguous or male external genitalia

Although several high-quality studies and reviews\(^{32-36}\) were available at the 2016 Cincinnati Conference, they did not address management of individuals with 45,X/46,XY with atypical female or male external genitalia. 45,X/46,XY mosaicism and its variants (45,X/47,XXY, structural abnormalities of the Y chromosome) have an estimated prevalence of 3 to 15 per 100,000 newborns\(^{37,38}\), with new data showing a prevalence of 5.6 per 100,000 liveborn phenotypically male infants and 2.1 per 100,000 liveborn phenotypically female infants. Diagnosis is delayed to a median age of 29 years (male individuals) and 13 years (female individuals)\(^{39}\), and these karyotypes are associated with various phenotypes, accompanied by elevated morbidity\(^{40}\) and mortality\(^{39}\). In most cases, which may remain undiagnosed, there are
bilateral testes and a male phenotype. There may also be bilateral streak gonads and a female phenotype, leading to the diagnosis of TS, or a streak gonad with a contralateral testis, or bilateral testes associated with atypical genitalia. In the latter, patients are classified as having mixed gonadal dysgenesis. Regardless of the gonadal and genital phenotype, the presence of a 45,X cell line may be associated with short stature and anomalies which are typically seen in TS, including cardiovascular, renal, and autoimmune disorders (supplementary tables 1-4). However, studies have shown that individuals with 45,X/46,XY mosaicism and ambiguous or male genitalia are less likely to receive appropriate counseling and assessments, highlighting disparities in clinical practice. In addition, when this form of mosaicism is associated with genital ambiguity, there are a series of issues related to gender assignment, surgical procedures, risk of gonadal neoplasms, puberty, hormone replacement and fertility that have been studied within the scope of DSD and that are outside the scope of these guidelines.

1.2 Prenatal diagnosis

**R 1.7** We recommend that fetal echocardiography be performed in case of prenatal diagnosis of TS (.assertNull(null)).

**R 1.8** We recommend that prenatal diagnosis of TS should be confirmed by postnatal karyotyping on blood ( assertNull(null)).

The availability of screening for TS and screening modalities varies in different countries. TS can be suspected prenatally by abnormal ultrasound, as a secondary finding of abnormal combined first trimester screening low pregnancy associated plasma protein-A (PAPP-A)/increased nuchal translucency, abnormal ductus venosus flow, or high-risk NIPT for TS. The diagnosis of TS can be confirmed prenatally by chorionic villous sampling, amniocentesis, or cordocentesis. If the parents decline invasive testing, the diagnosis should be confirmed postnatally on newborn blood. Regardless of the indication, test procedure, or specific result, genetic counseling by a geneticist, genetic counselor, or pediatric endocrinologist should be offered before and after any prenatal test procedure.
Even though fetuses with TS may exhibit no abnormality on prenatal imaging, ultrasonography plays an essential role in prenatal diagnosis of TS. Abnormalities can be present already in the first trimester and may regress with advancing gestational age. In the first trimester, markedly increased nuchal translucency (especially in cases of associated cardiac anomalies) is common in fetuses with TS, but is also observed in other genetic conditions, especially chromosome abnormality syndromes and RASopathies, or with fetal structural anomalies. However, the presence of a frank cystic hygroma increases the likelihood of diagnosing TS. Other ultrasound findings suggestive of TS include left-sided cardiac anomalies, partial anomalous pulmonary venous return/connection and persistent left superior vena cava, renal anomalies, small omphalocele, short femur and fetal growth restriction. Depending on fetal TS karyotype, cardiac anomalies are described in 7.8-72% of prenatal series. Due to this high prevalence, fetal echocardiogram should be performed timely after the prenatal diagnosis of TS. Although non-mosaic 45,X fetuses with marked cystic hygroma and/or fetal hydrops often result in miscarriage, these findings are also compatible with delivery of a viable newborn. In the absence of ultrasound anomalies, fetuses with mosaic TS diagnosed prenatally as an incidental finding are expected to have a milder phenotype than the ones ascertained postnatally. Abnormal results in prenatal serum screening (PAPP-A as part of combined first trimester screening, triple or quadruple test) even though not specifically intended to screen for TS, may also suggest this condition. However, these tests may be normal together with normal nuchal translucency thickness. Up to 42% of TS fetuses are being detected prenatally by first trimester screening.

1.2.1 Non-invasive prenatal testing

**R 1.9** We recommend that when sex chromosomes are included as part of noninvasive prenatal testing (NIPT), counseling should include information about the clinical validity/performance (なのです。

**R 1.10** If NIPT indicates a high risk for TS, we recommend thorough non-directive genetic counselling (informed decision-making) (のです。

37
If NIPT indicates a high risk for TS, we recommend that a detailed ultrasound should be performed, and invasive diagnostic testing be offered (⊕⊕⊕）。

In case of a high-risk NIPT result for TS and a normal fetal ultrasound where invasive diagnostic testing is not performed or shows a normal result, we recommend offering the pregnant woman karyotyping for maternal sex chromosome aneuploidies (⊕⊕⊕）.

NIPT has had an enormous impact on the field of prenatal diagnosis and is currently the first prenatal screening test to also include TS and other sex chromosome abnormalities. It will potentially increase the number of cases with TS incidentally diagnosed in utero. A recent meta-analysis showed that for TS sensitivity is 98.8% and specificity is 99.4% ⁶¹, whereas positive predicted value (PPV) varies widely (range: 9–85.2%; mean: 25.4%). However, with an abnormal ultrasound the PPV may be over 85%. The PPV for TS is generally lower than for other SCAs, due to factors such as confined placental mosaicism, maternal constitutional or somatic mosaicism and vanishing twin ⁶², ⁶³. Professional medical societies or organizations have provided guidelines regarding the use of NIPT (Supplementary table 5) including the ACMG, which has recently recommended screening for sex chromosome abnormalities for patients with singleton pregnancies ⁶⁴. However, all societies emphasize the importance of qualified pre- and posttest counselling and recognize the complexity of prenatal counseling (Supplementary table 5).

Important aspects that are specific to NIPT for TS include the limited test validity/performance, and the possibility of incidental detection of a maternal sex chromosome abnormality. Parental emotional distress may result from a false positive result as well as limited predictability of postnatal phenotype ⁶⁵. The high number of false positive results leads to an undesirable increase in invasive testing ⁶⁶. NIPT should always be offered in conjunction with a detailed ultrasound scan ⁶⁶, ⁶⁷. In case of fetal anomalies or increased nuchal thickness, diagnostic genetic tests should be offered and NIPT should only be considered after extensive counseling or parental demand ⁶⁸.
Counseling should emphasize that NIPT is a screening test, and not a diagnostic test. When TS is suspected by circulating free DNA, the possible interpretations may include confined placental mosaicism, TS in the fetus, or TS in the mother and co-twin demise of a fetus with TS. Additional diagnostic genetic testing should be offered after extensive genetic counselling and may include chorionic villous sampling in the setting of a fetal anomaly and early NIPT, or amniocentesis in case of a normal ultrasound and maternal karyotype. Because constitutional karyotype of individuals with prenatally diagnosed TS are uncertain, especially in patients with mosaicism, postnatal confirmation by standard chromosome analysis performed on a peripheral blood sample is indicated, irrespective of prenatal ascertainment.

1.2.2 Pre-implantation genetic testing

**R 1.13** We recommend that preimplantation testing can be offered to individuals with TS who want to use their own oocytes for pregnancies. TS individuals with mosaicism (45,X/46,XX), who become pregnant spontaneously, should be offered prenatal diagnostic testing. Pre-implantation genetic testing is currently offered to women with recurrent pregnancy loss or repetitive implantation failure after in vitro fertilization procedures although the clinical benefit is an ongoing topic of discussion. Pre-implantation genetic testing can be offered in case of a women with TS and the desire to have children. However, a sufficient ovarian reserve to obtain sufficient embryos for testing is a prerequisite for applying pre-implantation genetic testing.

1.2.3 Prenatal diagnosis of TS and genetic counselling

When TS is diagnosed prenatally, decision making about pregnancy continuation can be difficult, and it is critical that the best available information is provided to parents. Physicians and genetic counselors involved in pre- and post-diagnostic counseling need to be fully informed about the prognosis, complications, and quality of life (QoL) of individuals affected with TS, as well as of recent advances in management. The input of a physician with
experience in the long-term follow-up of individuals with TS will be valuable to put
management of the different comorbidities in perspective. The discussion should include the
known variability of the TS clinical features, even within a particular genotype. Of course, the
discussion should be tailored to the specific findings of the fetus because decisions regarding
termination are often influenced by the presence and severity of an abnormal phenotype.\textsuperscript{53, 79}.
Discussion with support groups, families of girls and women with TS can be very helpful. This is
often accomplished through contact with TS support organizations.

1.2.4 Decisions on pregnancy termination
Legislation on termination of pregnancy varies considerably between countries and lack of
consensus regarding choice of termination for TS among fetal medicine experts within countries
have been reported\textsuperscript{80}, highlighting the existence of ethical and cultural differences. In countries
where termination of pregnancy is allowed, rates of termination of pregnancy following
prenatal diagnosis of TS vary between 15.4% and 100%\textsuperscript{59, 81, 82}. Several factors have been found
to influence the prospective parents’ decision to continue or terminate a pregnancy with a TS
fetus. These include fetal ultrasound abnormalities, incidental findings, presence or absence of
mosaicism, gestational age at diagnosis, parental age, number of previous children, possibility
of infertility, parents’ fear/anxiety, parents’ socioeconomic status and religious background,
ethnicity, but also genetic expertise of the health care provider and the mode, delivery, and
explanation of the results\textsuperscript{81, 83, 84}, pointing to the importance of a balanced and comprehensive
non-directive counseling.

1.3 Postnatal diagnosis

\textbf{R 1.14} We recommend screening for Y chromosomal material by PCR or other molecular method in TS
individuals with a 45,X karyotype and signs of virilization (♀♂○○○).

Individuals with suspected TS should have a standard 30-metaphase karyotype as the first-line
test (see R.1.6 and section 1.1.3 diagnostic strategy). In cases where the chromosome analysis
is normal, and when mosaicism is suspected, additional metaphases should be analyzed.

Usually, karyotyping is performed on a peripheral blood sample; however, if blood karyotype reveals 46,XX, but there is a high clinical suspicion of TS based on the phenotype, karyotyping or FISH analysis of a second tissue (e.g., skin, buccal epithelium, urine) is indicated.

If a rapid postnatal test result is needed (e.g., newborn) other methods than standard karyotyping can be used as a first-line test (e.g., microarray, FISH, PCR), with chromosome analysis as a second line confirmatory test (see R.1.6 and section 1.1.3 diagnostic strategy).

In 10-12% of individuals with TS, a normal or structurally abnormal Y chromosome can be detected by karyotyping, FISH using Y-chromosome probes, PCR with Y-specific probes, or array-comparative genomic hybridization (array-CGH). An abnormal Y chromosome can initially be described as a marker chromosome and may require additional analysis. PCR is more sensitive in detecting Y material than FISH and should therefore be performed in TS individuals with a 45,X karyotype and signs of virilization. Searching for Y chromosome material in all 45,X individuals is not endorsed ¹.

1.3.1 Newborn screening

We suggest that ethical issues, phenotypic variability, methodological limitations, and feasibility of appropriate genetic counseling be considered prior to adopting newborn screening platforms that identify Turner syndrome (♀○○○○).

Although there seems to be a tendency towards earlier diagnosis, missed and delayed diagnoses of TS continues to be a challenge. Despite the widespread use of NIPT, this does not routinely include screening for sex chromosome abnormalities necessitating postnatal recognition and testing. When girls with TS are not identified in infancy by characteristic features such as lymphedema and webbed neck, the diagnosis is often made years after growth failure ensues, and sometimes little or no growth potential remains ²⁸, ⁸⁵-⁸⁸. In general, the later GH therapy is initiated, the larger the growth deficit and the lower the likelihood of normal adult stature. This can also delay age-appropriate initiation of therapies for pubertal
development. Early diagnosis can also improve QoL by allowing for timely screening and intervention for complications such as strabismus, hearing loss, renal and cardiac abnormalities, hypothyroidism, celiac disease and neurodevelopmental disabilities and mental health concerns. It may also allow for improved fertility in some individuals with TS by enabling earlier oocyte or ovarian tissue harvesting before too many follicles are lost. Greater recognition of the disorder through education and/or population screening is required to encourage earlier diagnosis.

Optimally, existing newborn screening programs would include TS. While karyotyping is the gold-standard technique for diagnosing TS, it has major limitations as a screening tool. This requires specialized personnel and entails a long processing time and greater expense. Alternatively, several molecular methods have been proposed for neonatal screening of TS, the most promising of which thus far are pyrosequencing and real-time PCR. According to a recent study, real-time PCR testing for TS detection costs $15 per test. Employing PCR of the ARSE and MAGEH1 genes, all but one patient with TS was detected (albeit only 10 patients with mosaicism were tested) for a detection sensitivity of 95%, and only 0.6% of the newborns required recall for karyotypes. Subsequently, reverse transcription PCR (RT-PCR) of the combination of SHOX, SRY, and VAMP7 was evaluated. Sensitivity and specificity for detection of SRY was 100%, with SHOX and VAMP being important in detection of structural anomalies and SRY for karyotypes with Y material. The technique was determined to be highly reliable for all sex chromosome abnormalities. Whole-exome sequencing has also been shown to accurately diagnose TS, including cases with low-level mosaicism, isochromosome Xq, and cryptic Y material. If molecular screening for TS is offered, positive findings will need prenatal or postnatal confirmation with a karyotype. Like other disorders diagnosed on newborn screening, it will be crucial to develop infrastructure for follow-up, treatment, and support of the newborns diagnosed with TS. A potential downside to screening includes the likelihood that some girls identified with TS will have mild or no apparent TS features and experience minor or no clinical consequences. This may result in unnecessary stigmatization or concern. In the process of screening for TS, other sex chromosome abnormalities, such as
Klinefelter syndrome (if both phenotypic male and female individuals are tested), may also be diagnosed and will also need appropriate follow-up.

In the United States, nomination of a condition to the Recommended Uniform Newborn Screening Panel requires a high certainty that screening for the targeted condition would lead to a significant net benefit, that screening has high-to-moderate feasibility and that most state screening programs would be able to implement screening within three years. Studies are needed to evaluate the benefits of newborn screening for TS. The optimal molecular techniques for diagnosis likewise need to be established. We conclude that prior to considering newborn screening for TS, additional improvements in methodology and systems will be required.

1.3.2 Improving postnatal diagnosis

Improved diagnostics will result from pediatricians, family physicians, and pediatric specialists becoming more aware of TS as a diagnosis. After the 2007 TS guidelines were published in part to optimize the screening for TS, the median age at diagnosis has remained high. The 2017 TS guidelines were developed for a pediatric specialty audience and focusing on general pediatricians as well as neonatologists may improve time to diagnosis. Furthermore, counseling of otolaryngologists to achieve an increased awareness for dysmorphic signs of the external ear and the increased prevalence of hearing impairment due to both conductive and sensorineural hearing loss in TS might also allow for an earlier diagnosis. Given that the most common indication for diagnosis in children is short stature, a guideline addressing growth disorders for primary care physicians may be helpful as noted in a recent Dutch publication. It remains to be seen whether an automated population-based screening will allow earlier detection of TS-characteristic growth disturbances. In addition, TS can be recognized in the newborn period by features of lymphedema/neck-webbing, cardiac anomalies, and renal anomalies. It is important that these are recognized, and that chromosomal testing be ordered promptly to ensure that the appropriate medical monitoring and follow up be initiated.

In resource limited countries, facial analysis technology has proven effective in diagnosing TS. Kruszka et al. used the DeepGestalt model to differentiate TS from unaffected controls and controls with Noonan syndrome in diverse populations.
Clinical recognition of signs and symptoms has been the traditional method of diagnosis for rare diseases; however, as noted in TS, clinicians frequently miss diagnoses. A potential solution is using the data in patient records to identify undiagnosed individuals with TS. One study used an algorithm-driven electronic health record approach to search for girls with TS who were initially diagnosed with idiopathic short stature. The algorithm successfully found that 6% of girls with microarray data available had newly diagnosed TS, and that only 62% of girls with idiopathic short stature ever had a karyotype performed. In addition to algorithm-driven electronic health record searches, deep learning/artificial intelligence searches have been successful in finding undiagnosed patients with genetic conditions.

1.3.3 Convincing governments to increase diagnostic measures
Many children throughout the world receive their health care from government-funded programs. These often may not provide coverage for genetic testing. Anecdotal data and our personal practice expertise have shown the importance of early diagnosis and monitoring and prevention of complications such as cardiac events and hearing loss. However, additional studies gathering data to document these benefits is crucial to gaining government support for diagnostic testing.

1.4 New developments in genomics
Over the past decade, new methods and approaches for understanding the genomic nature of TS have become increasingly available, which have contributed to an advanced and refined picture of the genomics, a highly complex picture, with many layers, pathways, and interactions we do not yet fully understand. The current model indicates that subtle changes in the genome, transcriptome and proteome play in concert, rather than a single gene model explaining all specific phenotypic traits. In addition, gene association studies and pharmacogenetic studies have started to emerge, proposing genetic variants related to specific phenotypic traits and treatment response. In this section, we will highlight recent advances in the genomic field.
1.4.1 The methylome, transcriptome and proteome in TS

Although there is currently no evidence to support methylation and transcription analysis in TS for the purpose of clinical management, these studies are informative in understanding the biology of TS and its phenotypes. There is evidence of a unique and tissue-specific genome-wide methylation and transcription landscape in TS extending to both the X chromosome and the autosomes. In general, an overall hypomethylation and gene downregulation is seen in TS across tissues, and integrative analysis of the methylome and transcriptome have demonstrated several genes with a complementary pattern being both differentially methylated and differentially expressed. There is also evidence that sex chromosome dosage sensitive genes on the X chromosome regulate specific networks of autosomal genes, indicating an organized regulatory gene network of genes on the X chromosome and autosomes. ZFX and KDM6A have been highlighted as possible key regulators in these networks as have AKAP17A, CD99, DHR3X, EIF2S3, GTPBP6, JPX, PP2R3B, PUDP, SLC25A6, TSIX, XIST, ZBED1, BDNF. Enrichment analysis of the differentially expressed genes has revealed enrichment for terms related to the phenotype seen in TS (e.g., immune system, coagulation, otologic disorders, liver disease, bone differentiation, glucose metabolism, gonadal and neural development), highlighting these genomic changes’ involvement in the phenotype of TS. Several candidate genes for different phenotypic traits have been suggested, but conclusive evidence is still missing, except for SHOX, known to be associated with the decreased height in TS (for review see Gravholt et al. 2023).

The expression of noncoding ribonucleic acid (RNA), including micro RNAs, circular RNAs and long noncoding RNAs, have been found to be affected in TS. A relation between specific microRNAs and congenital heart defects, aortic deformation and arterial distensibility may exist. Further studies are needed to elucidate a possible impact of noncoding RNAs in the phenotype of TS.
1.4.2 Gene association studies and pharmacogenetics

Over the past 15 years, efforts have been made to identify genetic variants (single-nucleotide polymorphisms, indels, copy number variations, haplotypes) involved in the phenotypic variability seen in TS. Genetic variants associated with traits such as low BMD\(^{121,122}\), thyroiditis\(^{121}\), heart\(^{121,123-125}\) and renal\(^{121}\) malformations, autoimmunity\(^{126}\), obesity\(^{127}\), insulin resistance\(^{128}\) and thrombophilia\(^{129}\) have been reported in single studies. Much larger sample sizes are required both from single center and multicenter studies to validate and replicate these findings.

In addition to the above-mentioned studies, a few studies have also emerged with the aim of identifying genetic markers related to growth response to recombinant human GH (rhGH) therapy, as the growth response varies significantly across individuals. Deletion of exon 3 (d3) in GHR (encoding the GH receptor) has been proposed as a genetic marker for predicting response to rhGH. However, the results from studies of girls with TS are contradictory with some finding a significant effect on height velocity, total gain in height and adult height in girls with TS carrying one or two d3 alleles\(^{130-132}\). Other studies did not find an effect\(^{133-135}\). Recently, a large prospective multicenter study assessing the association between genomic markers and short- and long-term rhGH responsiveness identified potential genetic markers and expression profiles for rhGH-induced growth response in children with TS\(^{136}\). However, these findings need to be validated in other larger cohorts of children with TS before being applied in clinical practice.
2. Growth disorders and their management

2.1 Spontaneous growth and the etiology of growth disturbances
Short stature is a common feature and often the presenting concern leading to the diagnosis of TS. Growth failure in TS begins early, often in utero, characterized by mild intrauterine growth restriction, and with lower placental weight, resulting in average birth weight ~300-1000 grams and length 1-2 cm below mean values for healthy infants of similar gestational age and country of birth. The decline in growth rate, resulting in downward trend across percentiles, is particularly rapid during the first 2 years of life, with an established height deficit by 3 years of age. Linear growth remains suboptimal in childhood and the estrogen-mediated pubertal growth spurt is minimal or absent, resulting in an average adult height ranging from 138 to 147 cm, depending on the country; this represents a deficit of ~20 cm compared with population means for many countries. Country-specific reference standards for growth curves have been compiled for TS (Table S6).

Absence of the short stature homeobox-containing (SHOX) gene in the pseudo-autosomal regions of the X chromosome is primarily responsible for the short stature and skeletal dysplasia in TS. However, perturbations in GH and insulin-like growth factor-I (IGF-I) physiology, including resistance to IGF-I and estrogen deficiency, may also contribute to impaired linear growth. Short stature in TS affects the limbs more significantly than the trunk, resulting in disproportionate growth, with a longer trunk than legs (increased sitting height to height ratio). TS is also associated with increased prevalence of skeletal anomalies, including scoliosis, kyphosis, cubitus valgus, genu valgum, Madelung deformity of the wrist and short 4th and 5th metacarpals and metatarsals.

2.2 Growth hormone treatment

We recommend offering growth hormone (GH) treatment early, because growth failure in TS starts before birth and is rapid during the first years of life, and early GH treatment can prevent further loss of height potential. Treatment may be offered from as young as 2 years of age in the following circumstances: evidence of growth failure (rate of growth below normal or declining), short
The purpose of growth-promoting therapy in TS is to prevent progressive growth failure, facilitate the attainment of height during childhood that allows puberty to begin at a similar age to peers, and to result in adult height that minimizes physical and potential psychosocial barriers. GH, the primary therapeutic agent, increases height velocity and results in modest increases in adult height for most patients. Furthermore, as most girls with TS will require estrogen therapy to either initiate or complete puberty prior to completion of linear growth, the estrogen route, dose, and tempo of dose escalation will have an impact on pubertal growth and, therefore, on AH. While GH may be continued until adult height is attained, treatment may be individualized with the option to discontinue GH if the individual is satisfied with her height or attains a height within the normal range for the adult female population.

Although GH treatment is considered standard, growth promotion itself, or early treatment initiation, may not be appropriate for every child. We therefore recommend that the initiation of GH be individualized, and the potential advantages, disadvantages and burdens of treatment be discussed to allow shared decision-making. GH is available in many countries around the world (Table S7).

2.2.1 Effectiveness of GH treatment

Despite numerous studies of GH treatment in TS, only 6 randomized, controlled trials (RCTs) have compared GH treatment with a concurrent non-treatment or placebo control for at least one year and only 2 of these trials have followed non-GH-treated participants to adult height. Based on 3 studies published between 1998 and 2005, a 2007 Cochrane Center review concluded that girls treated with GH grew 3 cm/year more than untreated
girls in the first 12-18 months of therapy; after 2 years of treatment height velocity was ~2 cm/year greater for treated than untreated girls in the study that continued the control arm 
long-term 158. Since publication of the Cochrane review, a double-blind, placebo-controlled trial to adult height 160 and a 2-year RCT evaluating the impact of GH initiation before age 4 years 162 followed by a 10-year extension study to adult height 163 have been published. Individuals with TS treated to (near-) adult height had average gains compared with randomized concurrent non-treatment 164 or placebo 160, baseline predicted 165, 166 or projected height 159, 164, 167*1, or historical controls 167, ranging from ~5 to 8 cm over periods of 5.5 to 7.6 years 159, 160, 164, 167. A subsequent meta-analysis concluded a similar effect of GH therapy, reporting mean adult height gain of 7.2 cm 168, based on data from the two RCTs that followed non-GH-treated subjects to adult height 158, 160. Two European studies using high GH doses at young ages have demonstrated much more dramatic gains of 15–17 cm (mean) vs baseline projected adult height 169-171. Although there is marked variability in response to treatment, in aggregate, there appears to be approximately 1 cm of gain in height for every year of GH treatment. In the two clinical trials that maintained long-term untreated/placebo controls, adult height was within the normal range for 40-50% of treated individuals vs. 4-16% percent of non-GH treated individuals 158, 160. Results from large observational studies have confirmed similar short term growth improvement (average height SDS increase of 0.8 ± 0.7 after an average of 3.2 ± 2y of treatment) 172 and adult height gain (median near adult height gain +1.07 SDS over baseline height SDS) 173 but with significant individual variability.
In summary, if catch-up growth brings height within the normal range within the first two years of treatment, and height velocity subsequently is maintained close to the mean for age, adult height is likely to fall within the lower normal range for most GH-treated individuals 163, 174. Caution should be exercised interpreting height SDS changes during the typical time for

---

*1 [**Baseline predicted adult height** is typically calculated using the patient's baseline height, age, and bone age (for e.g., according to the methods of Bayley and Pinneau). **Baseline projected adult height** is calculated by extrapolating the patient's baseline Turner-specific height SDS to adult height SDS using the same Turner standard.]
puberty, as absent or minimal pubertal growth spurt often results in partial loss of the relative
pre-pubertal height SDS gain \(^{174}\).

2.2.1.1 Factors influencing the effectiveness of GH treatment

Various factors are associated with long-term height outcomes following GH treatment,
including intrinsic (nonmodifiable) factors, and extrinsic aspects of treatment that may be
subject to management decisions. Overall, factors predictive of taller adult height include taller
baseline height prior to GH initiation, tall parental heights (i.e., mid-parental height), younger
age at initiation of therapy, longer duration of treatment (especially pre-pubertal treatment
duration) and higher GH dose \(^{162, 171, 175, 176}\). Because of the wide variability of adult height
outcomes following GH treatment, mathematical prediction models have been developed with
the goal of providing accurate information for long-term outcomes (height gained and height
attained) \(^{177}\). However, the complexity of these models has impeded their use in clinical
practice. Additional intrinsic genetic variations \(^{132, 178}\) are also associated with GH
responsiveness in TS but such detailed genetic analyses are not currently available for routine
clinical use. Characteristics such as the patient’s baseline height and mid-parental height, while
not modifiable, may provide useful information to facilitate realistic expectations of treatment
outcomes. Modifiable factors that impact GH treatment outcomes include age at initiation of
treatment, GH dosing strategies and management of pubertal induction with low-dose
estrogen.

2.2.1.2 Age at GH initiation

Younger age at treatment initiation \(^{158, 162, 163}\), including at least 4 years of treatment prior to
puberty \(^{175, 179, 180}\), is associated with greater GH treatment effect. Early GH treatment in TS
prevents further growth failure \(^{162, 163, 180}\) and provides the opportunity to maintain height
within the age-appropriate normal range. In the long-term extension of the Toddler Turner
Study, the early-treated girls were taller at all key childhood timepoints and at puberty \(^{163}\). Early
treatment (around 2–6 years of age) is likely to result in greater height gains during childhood
and facilitate pubertal induction at an age closer to that of typical female puberty \(^{181}\), such that
the goals for both greater adult stature and near-normal timing of puberty can both be achieved. Although early GH treatment is optimal, late initiation of GH therapy may nevertheless result in meaningful height gains for individuals whose diagnosis is delayed, particularly in those with delayed bone age. However, such gains were at the expense of markedly late puberty, and the height gain was negatively correlated with age at GH initiation.

2.2.1.3 GH dose

We recommend a starting GH dose of 45–50 µg/kg/day or (1.3–1.5 mg/m2/day) in most instances, increasing up to a maximum of 68 µg/kg/day (2.0 mg/m2/day) if response is suboptimal and/or adult height potential remains substantially compromised.

GH therapy for TS is generally recommended to be initiated at a dose of 45–50 µg/kg/day or (1.3–1.5 mg/m2/day) administered daily, although there are regional variations in GH regimens for TS guided by regulatory limitations. Higher GH doses are not routinely recommended, but following careful discussion of potential risks and benefits, such as possible mild, reversible dose-dependent higher insulin concentration with normal glucose, an increase in GH dose up to 68 µg/kg/day (within the authority-approved dose range) may be considered in individuals with very poor height prognosis, or inadequate response to standard GH dosage. Optimal GH dosing is important, especially during the first year of therapy when the most rapid catch-up growth response occurs. Despite initial catch-up growth, the overall height gain is gradual and incremental, and it is important to set realistic expectations of adult height outcomes. Families should also be advised of the importance of treatment adherence. Observational data show reduced efficacy when prescribed doses are lower than recommended doses. Similarly, titration of GH dose based on IGF-I values may result in a suboptimal weight-based dosing of GH, with reduced height gain and adult height outcomes. Poor adherence to prescribed doses and early treatment discontinuation may also result in lower height gain.
2.2.2 Safety of GH treatment

Data on safety of GH treatment in TS in long-term prospective clinical and observational trials have generally been reassuring with respect to blood pressure and risk factors for cardiovascular disease, carbohydrate and lipid metabolism, body composition, bone mineralization, body proportions, and prevalence of otitis media and hearing loss relative to cohorts of non-GH treated individuals with TS. However, it is important to recognize that clinical trials are not powered for safety endpoints, hence caution should be exercised in their interpretation. Large observational studies that have adequate patient numbers to detect rare adverse outcomes provide more robust assessment of the longer-term safety of GH. However, the interpretation of safety data is complicated by use of varying comparator groups (concurrent TS, historical TS, other GH-treated non-TS, general population) and statistical methodologies.

2.2.2.1 Intracranial hypertension and skeletal issues

Individuals with TS appear to be at increased risk of intracranial hypertension and slipped capital femoral epiphysis as well as scoliosis during GH treatment compared with children with idiopathic GH deficiency or idiopathic short stature. Scoliosis is common in TS regardless of GH therapy, and may be exacerbated by the rapid increase in linear growth stimulated by GH, but two studies demonstrated no increased risk of developing scoliosis or worsening existing scoliosis with GH therapy in TS. Improvement of skeletal disproportion in some individuals with TS was reported with GH therapy in one study.

2.2.2.2 Lymphedema

In one retrospective study, a higher prevalence of lymphedema was seen in individuals with TS treated with GH compared to untreated individuals, likely reflecting a more severe phenotype in those treated, but no data were provided on the impact of GH therapy on prevalence or acute worsening of lymphedema.

2.2.2.3 Neoplasia

Although neoplasia has been reported rarely in GH-treated and non-GH-treated individuals with TS, data from GH registries provide no evidence of an increase in risk of neoplasia with
Although there is no reported evidence for an effect of GH treatment on risk for development or progression of nevi in girls with TS, the product labeling for somatropin (GH) in the USA advises that patients should be monitored for increased growth or potential malignant changes of pre-existing nevi.

2.2.2.4 Mortality

No overall increase in mortality due to GH relative to other GH-treated pediatric populations has been reported in individuals with TS followed in the GH registries \(^{173, 197, 208, 225}\). Although one multinational European registry study (SAGhE consortium) described an increase in standardized mortality ratio for moderate risk group of GH-treated children (which included patients with TS along with other genetic syndromes like Prader Willi syndrome, Noonan syndrome, multiple pituitary hormone deficiencies, Cushing syndrome, benign pituitary tumors, severe craniofacial malformations, and severe chronic pediatric diseases), these patient groups were compared to the general population instead of untreated controls, and there was no association with daily or cumulative GH dose, suggesting that the excess mortality may not be related to a GH treatment effect \(^{211}\).

2.2.2.5 Carbohydrate metabolism

Patients with TS are inherently at increased risk of disorders of carbohydrate metabolism \(^{226, 227}\) and have a specific defect in glucose-stimulated insulin secretion \(^{227, 228}\). Although alterations of glucose/insulin metabolism have been reported during or following GH treatment in TS \(^{169, 184}\), no permanent negative effects of GH treatment on insulin sensitivity or beta-cell secretory capacity have been observed \(^{229, 230}\). One observational study reported an increase in type 2 diabetes compared with rates in the general population \(^{231}\), but no increases were reported in analyses from other observational databases \(^{173, 199, 208, 210}\). Furthermore, no increase in the prevalence \(^{210}\) or incidence \(^{216}\) of type 1 or insulin-requiring diabetes has been reported. Improvements in body composition, abdominal adiposity, lipid profile and blood pressure resulting from GH therapy may have a beneficial effect on cardiometabolic status \(^{216}\).
2.2.2.6 Aortic disease

The risk of aortic dissection in TS is increased in those with increased aortic diameter. Studies examining the effect of GH exposure on aortic diameter have yielded conflicting results and their clinical implications remain unclear. This is an area that warrants further investigation. Presently there is insufficient evidence that GH treatment increases the risk for aortic disease or dissection in TS.

2.2.3 IGF-I: physiology in TS and role in monitoring GH treatment

R 2.4 We recommend monitoring the response to growth-promoting treatment by measurement of height approximately every 6 months and plotting on a standard (reference female population) and/or TS-specific height chart. Maintenance of height percentile equivalent to, or greater than, the pre-treatment height percentile on a female population-based growth chart or increasing percentile on a TS-specific height chart, provides evidence of treatment effect (☆☆☆).

R 2.5 We recommend monitoring GH therapy by measurement of IGF-I at least annually. We suggest generally maintaining IGF-I within the normal range for age, pubertal stage, and sex. GH dose reduction may be warranted for persistently high IGF-I values (☆☆☆☆).

Published guidelines by professional societies have recommended monitoring IGF-I and adjusting GH therapy to keep IGF-I concentrations generally within the normal ranges for age and sex in children with various growth disorders. However, the evidence for this approach in TS is questionable, both from an efficacy perspective and a safety standpoint. IGF-I values in non-GH-treated girls with TS are generally in the low-normal range and multiple lines of evidence have demonstrated relative IGF-I resistance in girls with TS. IGF-I values more than 2 SD above the mean for age and sex are common during GH treatment suggesting that these patients likely require supranormal circulating IGF-I concentrations to elicit an adequate growth response to GH treatment. Modest correlations between growth response and GH-treated IGF-I values have been reported in some studies but not others. In addition to the variability of IGF-I responses to GH in TS, and significant intra-individual variation in IGF-I values, there are methodological challenges associated with measurement of...
IGF-I in general \(^{240-242}\) and significant disparity among IGF-I assays, particularly at the upper end of the IGF-I concentration range \(^{243}\). These challenges raise questions regarding the validity of assigning an IGF-I value of +2 or +3 SDS as a flag for GH dosage reduction and warrant further study in TS. To mitigate the impact of intra-individual and inter-laboratory variation, IGF-I should preferably be measured consistently at the same reference laboratory, and attention should be paid to factors that may increase IGF-I variability, such as time of day, pubertal stage, nutritional status or obesity, and presence of intercurrent illness \(^{240}\).

Although concerns have been raised regarding associations between elevated IGF-I and neoplasia in epidemiologic studies of adult populations \(^{244}\), there is no evidence for such an association in TS. Nevertheless, because the potential long-term risk remains unresolved, we suggest a cautious approach by monitoring IGF-I approximately annually and considering dosage adjustment for values persistently above the normal range for age when measured under consistent conditions, with individualization of treatment goals.

### 2.3 Concomitant treatment with the anabolic steroid oxandrolone

Addition of oxandrolone, which has been used off-label for decades, produces synergistic increases in growth response during GH treatment \(^{245-249}\), and systematic reviews \(^{250,251}\) confirm a positive effect on adult height gain (2-4 cm). To minimize unwanted effects of delayed breast development and dose-dependent virilization \(^{245}\), previous guidelines recommended adding oxandrolone for those TS patients with a poor height prognosis or suboptimal response to GH alone, only around the age of 10 years, initiated at a dose of 0.03 mg/kg/day and maintained at no greater than 0.05 mg/kg/day. Oxandrolone therapy was associated with a lower HDL cholesterol \(^{252}\), but no negative impact on body composition, skeletal disproportion \(^{252}\), hearing \(^{253}\) or neurocognition \(^{247}\). However, oxandrolone has been unavailable in many countries, and the US Food and Drug Administration (FDA) withdrew marketing approval for oxandrolone in 2023 based on adverse event reporting (https://www.federalregister.gov/documents/2023/06/28/2023-13733/gemini-laboratories-llc-et-al-withdrawal-of-approval-of-one-new-drug-application-for-oxandrin [federalregister.gov]).
Although there is no information indicating whether these adverse event issues were related to
the use of oxandrolone in girls with TS, based on the position taken by the FDA, the Guidelines
Committee no longer recommends the use of oxandrolone in TS at this time. However,
physicians who choose to prescribe this medication in jurisdictions outside the USA may do so
according to local guidelines, with discussion of efficacy and safety, and with full disclosure of
the benefits and risks.

2.4 Concomitant treatment with prepubertal ultra-low dose estrogen

R 2.6 We suggest not to routinely add very low-dose estrogen supplementation in the prepubertal
years to further promote growth (ThetaThetaThetaTheta).

One double-blind, placebo-controlled trial using ultra-low-dose oral ethinyl estradiol as a
growth-promoting agent during the prepubertal period combined with GH, followed by a
standardized incremental pubertal induction regimen, demonstrated a modest synergistic
increase in adult height, normalization of the timing of thelarche for about one-quarter of the
girls, and modest improvements in cognition and memory within specific developmental
windows. An additional RCT that used a similar regimen but with higher ethinyl
estradiol doses found no long-term growth benefit from prepubertal estrogen treatment.
The formulation, route, and dosing of childhood estrogen have not been optimized. Hence,
until further studies are undertaken, the addition of prepubertal very-low-dose estrogen
replacement as a growth-promoting therapy is currently not recommended.

2.5 Other growth promoting therapies

Long-acting GH preparations have been approved for the treatment of GH deficiency and
several trials in children with TS are underway. A single 2-year retrospective study showed that pegylated GH was comparable to daily GH injections in terms
of growth promotion, without unexpected serious adverse effects. Though encouraging,
these preliminary, non-randomized data are insufficient to recommend long-acting GH for the
treatment of short stature in girls with TS, and data from registration studies are not yet
available.
Limited studies 258, 259 have shown that limb-lengthening procedures (distraction osteogenesis)
can result in substantial height increase in women with TS. However, the complication rates for
these procedures are still unacceptably high 258 and therefore this treatment is not
recommended.

2.6 Short stature and quality of life
Height is only one of many factors that affect QoL in TS. The methodology to assess impact of
GH treatment on QoL in TS is not robust and the data are inconsistent or inconclusive 260-262.
Hence the decision to offer GH treatment for a child with TS should involve a candid discussion
of the advantages and disadvantages, risks and benefits, knowns and unknowns of GH therapy
and incorporate the patient’s and family’s values and preferences to facilitate shared decision-
making.

3. Puberty and sex hormone treatment
3.1 Introduction
TS is usually accompanied by hypergonadotropic hypogonadism due to gonadal dysgenesis and
ensuing primary or secondary amenorrhea. The risk and timing of premature ovarian
insufficiency in TS varies. More than one third of girls with TS develop signs of puberty, in non-
45,X patients this is twice as common. Only one in five girls has spontaneous menarche, and the
chance for spontaneous pregnancy is about 10%, again more common in women with mosaic
karyotype 11, 263-267. This means that most girls and women with TS require or will require
hormonal replacement therapy (HRT) at various times and for various reasons.
Literature review and expert opinion of current knowledge about puberty and approaches to
HRT in TS are presented. A summary of the issues discussed, and questions raised are presented
in Figure 1.
3.2 Laboratory and ultrasound markers of ovarian function

**R 3.1** We recommend measuring Luteinizing hormone (LH), follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) at 8-9 years and yearly until 11-12 years to enable timely referral for fertility preservation if appropriate († † † †).

LH and FSH are basic markers in the assessment of ovarian function. Circulating concentrations of both FSH and LH present a biphasic pattern in TS individuals with hypogonadism: elevated after birth, declining to values similar to girls with normal ovarian function during mid-childhood, and rising again in the peripubertal years, or at the time of loss of ovarian function. We recommend measuring FSH and LH at 8–9 years old to have time to track changes and allow timely referral for fertility preservation if appropriate. If gonadotropins are normal for age, we recommend continued observation for spontaneous puberty, with future replacement therapy if gonadal failure occurs. FSH values > 6.7 IU/L in 6-10-year-old girls have been reported to reflect a higher rate of ovarian insufficiency.

Low AMH and undetectable inhibin B can also be used to predict ovarian insufficiency in TS, and we recommend measuring AMH along with FSH and LH during assessments. Measurable AMH concentration are positively associated with spontaneous breast development and spontaneous menarche. AMH < 4 pmol/L has been shown to suggest absence of puberty.

A higher frequency of primary amenorrhea is more common in individuals with 45,X than compared to those with 45,X/46,XX. Despite this evidence, it is also true that the correlation between karyotype and phenotype is highly variable as evidenced by cases of repeated pregnancies in multiple patients with 45,X.

The results of pelvic ultrasound in girls with TS have not yet proven useful as a marker of spontaneous puberty. Both ultrasound ovarian visualization and uterine volume in comparison to prepubertal controls did not help predict spontaneous puberty. Because very low concentrations of serum E2 in healthy prepubertal girls seem to have minimal impact on
uterine growth, this suggests that ultra-low-dose E2 may also not be beneficial to uterine growth during the prepubertal period in girls with TS.

### 3.3 Estrogen replacement therapy (ERT)

**R 3.2** We recommend initiation of low dose estrogen replacement between 11 and 12 years of age, if FSH is elevated on at least 2 sequential measurements. Estrogen dosage should be increased slowly to adult replacement dosage over 2-4 years (ΘΘΘΘ). 

**R 3.3** In individuals with a later diagnosis (>12 years) with short stature and continued growth potential, we suggest initiating treatment with low dose 17β-estradiol (E2) simultaneously with GH (ΘΟΟΟΟ).

Most girls and women with TS will require ERT for initiation or progression of puberty and/or maintaining the female endocrine milieu. The goal of pharmacologic puberty induction in TS should be to mimic physiology as closely as possible to support longitudinal growth and to gradually induce physiologic estrogen-dependent development at an age and at a tempo within normal range for girls without TS. Continuous information and guidance adapted to the girl/woman’s needs should be given by the health care provider(s). If gonadotropins (FSH in particular) in repeated samples (two or more) measured yearly from age 8-9 years are clearly elevated without any pubertal signs on physical exam, the girl with TS will need estrogen replacement therapy. Information and discussion on ‘how’ and ‘when’ can preferably start at age 10 years, anticipating actual E2 start will not take place for another 1-2 years. Being well prepared and informed contributes to the sense of security and confidence in girls with TS and their caregivers. Pubertal induction should start between 11 – 12 years old if there is evidence of gonadal failure based on repeatedly elevated FSH and no spontaneous thelarche. Pubertal induction should
start with very low doses of E2 to allow continued linear growth, followed by increasing doses
at a tempo mimicking serum E2 values in girls without TS\textsuperscript{278}. In addition to the psychosocial
advantage of reaching puberty concurrently with peers, using physiological age as a guide to
the initiation of ERT supports normal bone mineral accrual (discussed below). Recommended
dosing and schema for tempo of increasing dosage are discussed below.

Some girls with TS are not diagnosed until they fail to enter puberty or have secondary
amenorrhea. In these situations, if there is still linear growth potential and open epiphyses, GH
treatment can be initiated at the same time as low dose estrogen treatment. This
recommendation can be theoretically justified but has not yet been scientifically evaluated in
this age group. Caution is needed to not give too high an estrogen dose and thereby cause too
rapid bone maturation hampering remaining growth potential. For girls with TS who are
diagnosed later and have completed their growth, estrogen dosing does not have to start as
low and can increase more quickly.

### 3.4 Type, dose, and route of estrogen(s) administration for ERT

**R 3.4** We suggest E2 transdermal (TD) route when possible, with oral E2 as second choice. Ethinyl
estradiol has more risks but is better than no treatment (◯◯◯◯).  

**3.4.1 Type of estrogen**

17β-estradiol (E2) is the natural physiological form of estrogen and is the preferred option. It
has been shown to be effective in maintaining and improving BMD, increasing uterine size and
has some beneficial effects on endpoints relating to cardiovascular outcomes. In addition, it
tends to lower BP, improve liver function tests, and increase HDL cholesterol in women with TS
\textsuperscript{279-281}. Estradiol valerate may also be used because it is quickly converted to E2 in the gut and
liver and provides stable serum E2 concentrations \textsuperscript{282}.

Other estrogens include ethinyl estradiol and conjugated equine estrogens. Conjugated equine
estrogens are no longer recommended because they increase the risk of venous
thromboembolism, they are a non-standardized mixture of many different estrogens and metabolites, and there are more physiological alternatives. Ethinyl estradiol is a potent synthetic E2 analogue, widely used in the combined oral contraceptive pill and, historically, has been used as HRT in women with premature ovarian insufficiency including those with TS. It is long-acting; therefore, it cannot mimic the typical diurnal variation seen in early puberty, and serum concentration of E2 cannot be measured meaningfully while on ethinyl estradiol. It also has an adverse cardiovascular and metabolic profile and, pertinent for women with TS, it tends to increase blood pressure and is linked with an increased risk of venous thromboembolism.

Nevertheless, the combined oral contraceptive pill may be more attractive to younger women needing HRT because it is peer-friendly and user-friendly, inexpensive, accessible, gives good cycle control and provides contraception for those with residual ovarian function who wish to avoid pregnancy. If contraception is required, combined oral contraceptive pills containing estradiol valerate are now available. An example is Qlaira® (estradiol valerate 3mg →1mg + dienogest). Theoretically, this should provide good estrogen replacement as well as contraception.

3.4.2 Route of administration
There have been few studies comparing the efficacy of oral and transdermal (TD) E2 and minimal evidence to guide choice of formulation. E2 is available for both transdermal and oral use. The transdermal route is the most physiological form and is recommended for replacement therapy, based on the risk of potentially harmful liver metabolites when the oral route is used. A RCT comparing the metabolic impact of oral E2 versus TD E2, found that oral administration resulted in a disproportionate, significant accumulation of genotoxic estrogens compared with TD administration. Genotoxic estrogens are mutagenic metabolites which have been linked to breast carcinogenesis in post-menopausal women. Additionally, the TD route resulted in E2, estrone, and bioestrogen concentrations closer to normal compared to oral ERT. However, TD patches may fail to adhere well in girls with skin conditions such as eczema and they may also cause skin irritation, both limiting their use. This can be alleviated by replacing a patch on a new site (see options under “Dose of estrogen” below). Distribution
problems from the drug companies have been a recent problem. Patch doses have primarily
been adapted to postmenopausal women, making off-label use necessary even though cutting
matrix patches into smaller pieces has been shown to work nicely\textsuperscript{287, 288}. The oral route has long been used and reports on satisfying development of secondary sex
characteristics and growth are available\textsuperscript{289, 290}. However, a drawback is that tablets are
available in fixed doses, and it is difficult to divide into smaller doses. The lowest dose available
is 0.5 mg but is only available in a few countries. Even though the transdermal route is
theoretically attractive, it has not been shown scientifically whether any route is superior to the
other in a lifelong replacement situation in TS or in any other hypogonadal group. An initiative
to gather and share data from TS girls worldwide through an ESPE supported registry is in
process\textsuperscript{291}. A large recent review showed the effect of E2 was superior to ethinyl estradiol and
conjugated equine estrogens for BMD without difference according to route of administration.
However, oral E2 gave rise to a greater increase in HDL cholesterol than TD E2 indicating a
potential cardioprotective effect, but this would need to be balanced against the pro-
thrombotic effects in a large-scale long term prospective trial\textsuperscript{280}. Taken together, there is not strong evidence against oral E2 and perhaps some benefit to HDL
cholesterol but based on the more physiologic route of TD E2 and the potential for lower dosing
during puberty, we continue to suggest preference for the TD route and encourage ongoing
longer term prospective studies. However, we also stress the importance of patient preference
in the decision to increase adherence to treatment. We acknowledge that different
formulations may not be available in all countries.

3.4.3 \textit{Dose of estrogen}

The challenge for pubertal induction with both routes is to start with a low enough E2 dose. For
girls without spontaneous puberty, initial dosing needs to be low and dose increments can be
individually increased over 2-2.5 years to a serum concentration corresponding to reference
range for an adult woman\textsuperscript{292}. A physiological tempo is the goal, which can be more rapid in an
older girl to support her psychological and social wellbeing.
In early puberty there is a diurnal variation with E2 serum concentrations increasing first during
night-time and very early morning. In mid-puberty, the diurnal variation ceases, and serum E2
concentrations increase until menarche followed by the estradiol-progesterone cyclic variation
of the adult fertile woman. Several schemes for dosing have been published over the last few
years to mimic this diurnal variation and require multiple dose changes and patch applications
\textsuperscript{291-293}.

Low dose is important for two reasons. First, to mimic typical pubertal progression. Second, to
allow adequate time for linear growth because estrogen has a dual effect on the growth plate:
initially stimulatory but also leading to physeal fusion at higher concentrations. Even ethinyl
estradiol, generally not recommended for puberty induction, but used in ultra-low doses and
gradually increased, resulted in favorable adult height \textsuperscript{160, 181, 294}.

While no rigorous long-term prospective study to adult height has been performed comparing
E2 preparations (oral vs. TD), using doses that reach the same plasma concentrations of E2, one
observational cross-sectional analysis suggested that the impact on adult height of these E2
regimens used for pubertal induction was comparable \textsuperscript{295}. Additional studies are needed to
evaluate the optimal routes and dosages of estrogen replacement for pubertal induction in TS.

For girls with arrested pubertal maturation, E2 replacement starting dose should mimic a serum
concentration corresponding to her spontaneous puberty stage \textsuperscript{287}. Even if a physiological
tempo is the goal, in an older girl a higher dose increment tempo may support her psychological
and social wellbeing.

Ethinyl estradiol is not recommended for pubertal induction. For estrogen replacement after
attainment of pubertal induction, ethinyl estradiol has been shown to be inferior to E2 for bone
health, and therefore higher doses may be beneficial. In healthy older adolescents taking the
combined oral contraceptive pill for contraception, a dose of >20mcg ethinyl estradiol is
advised to allow ongoing bone mass accrual \textsuperscript{296}. This means that combined oral contraceptive
pill containing 30mcg ethinyl estradiol is advised, at least until peak bone mass has been
achieved. It is useful to remember that a standard oral contraceptive pill is taken for 21/28 days
and that a woman with TS will therefore be hypoestrogenic during the pause. It is possible that
modern extended regimens, without a pause, would be more effective for BMD. Following this, the dose will depend on other outcomes and variables such as blood pressure and lipid profile. Based on the literature and expert opinion, to mimic physiology, to individualize the approach, and be familiar with different situations and dose availability worldwide, we recommend the following E2-dose escalation protocol for puberty induction in girls with TS (Table 4). It is practically important to integrate each of the variables in Table 7 to optimize decisions about treatment. Note that if a patch falls off or is removed from the skin prior to the previously prescribed dosing interval, it can be replaced as soon as possible/practical as an effect is only present while patch is in place. If skin problems occur, patch can be removed before the prescribed interval and a new patch is attached on another site. Dose delivery is dependent on contact time and more frequent changes of patch does not result in an increased dose. Additionally, some patches are designed to be applied twice weekly and some weekly. It is important to check patient knowledge of regimen and product provided to ensure the estrogen delivery is as desired.

3.5 Progesterone replacement therapy

**R 3.5** We recommend adding cyclic progesterone once breakthrough bleeding occurs (mostly this will be after about 18 – 24 months of unopposed estrogen exposure but this can occur later based on pubertal stage, serum E2 and uterine growth, endometrial thickness, and estrogen dose). The preferred option is micronized progesterone 200 mg for 10-12 days per month (☆☆☆).

**R 3.6** We suggest combined sequential E2 and progesterone dosing in young women since they are more likely to experience abnormal uterine bleeding. A combined continuous regimen is an option when the endometrium is more stable (☆〇〇〇〇).
Progesterone or a synthetic progestin is added towards the end of pubertal induction. The primary indication for adding progesterone is endometrial protection. This allows the proliferative endometrium, stimulated by estrogen, to become secretory, avoiding hyperplasia, a forerunner of endometrial carcinoma\(^{297}\). Secondly, the addition of progesterone administered in a cyclic regimen with estrogen allows regular, controlled, predictable episodes of withdrawal bleeding or “periods”. Progesterone has other effects being crucially important for the implantation of the fertilized ovum, the maintenance of pregnancy\(^{298}\), and some psychopharmacological actions including anxiolytic, antidepressant and analgesic effects.

3.5.1 Type of progesterone and synthetic progestins

Progesterone itself has its major effects on the progesterone receptor (PR) with negligible effects on the glucocorticoid receptor (GR), androgen receptor (AR), and it is an antagonist of the mineralocorticoid receptor (MR)\(^{298, 299}\). All synthetic progestins bind to the PR effectively but differ in their binding affinities and effects on the GR, AR & MR giving rise to different profiles of actions and side effects\(^{298}\). Natural progesterone has poor oral bioavailability but this can be greatly improved by micronizing\(^{298}\). Micronized progesterone confers adequate endometrial protection when administered as part of a cyclic combined regimen (200 mg daily for 12 days each month) or as a continuous combined regimen of 100 mg per day. In postmenopausal women, this dose seems to be devoid of adverse effects on BP, lipid profile, breast cancer risk and thrombotic risk\(^{300}\).

Medroxyprogesterone acetate has been widely used in HRT because its bioavailability orally is >90%, it has high potency and its half-life is 24 hours, allowing for daily dosing\(^{298}\). It is effective at providing endometrial protection. However, although it primarily acts on the PR, it also acts on the GR giving rise to potential glucocorticoid-like adverse effects, not shared with natural progesterone, including an increased risk for breast cancer in non-TS populations and stroke in postmenopausal women. Other progestins are listed in Table 5 with notes regarding use.
3.5.2 Route of administration of progesterone and progestins

Oral administration is generally attractive to young women but progesterone and progestins vary in their oral bioavailability. Although E2 is well absorbed via the TD route, only norethisterone acetate (NET) and levonorgestrel are available TD as part of a combined hormone regimen. Progesterone can be administered vaginally and exerts good endometrial protective effects at low serum concentrations, although there is limited evidence assessing the efficacy and optimal regimen. The levonorgestrel intra-uterine device (LNG-IUS S2) is licensed for endometrial protection and contraception. It has minimal side effects and lasts for 5 years. Women who have never been sexually active may need brief general anesthesia for insertion.

3.5.3 Which one to choose?

Based on available data, theoretical concerns, and expert opinion, we recommend oral natural micronized progesterone (MP) or dydrogesterone, being a stereoisomer of natural progesterone, as first line therapy since these provide the most physiological replacement, allow regular withdrawal bleeding, and have lower risk for adverse health effects. The availability of different preparations differs widely between countries.

3.5.4 Dosing of progesterone and progestins

Because the main function of progesterone is to prevent endometrial hyperplasia caused by unopposed estrogen, it is prudent to note that evidence shows a consistent association between level of risk and duration and strength of the estrogen dose. Many young women with TS benefit from a higher dose of estrogen than their older peers, that is, exceeding 2 mg E2 orally or 50 mcg TD. This is particularly important for achieving maximal uterine growth and development as options for fertility treatment increase. As the dose of estrogen increases, a higher dose of progesterone is needed to balance this. Dosing schedules are clear for micronized progesterone and medroxyprogesterone acetate but there is a lack of evidence for other progestins. It is agreed that the duration of the average...
1 luteal phase should be matched, providing physiological replacement, so that progesterone
2 should be given for 12 days each month as part of a sequential combined regimen 304. In
3 general, endometrial protection is better in those women using a continuous combined
4 regimen 305. However, such a regimen is designed to avoid withdrawal bleeding which may not
5 be attractive to young women and may also give rise to erratic vaginal bleeding, especially in
6 those women using TD preparations. A continuous combined regimen gives rise to an atrophic
7 endometrium, and it is unclear whether this is a disadvantage in the short- or medium-term in
8 women planning an oocyte-donated pregnancy.
9 Micronized progesterone confers adequate endometrial protection when administered as part
10 of a cyclic combined regimen (200 mg daily for 12 days each month) or as a continuous
11 combined regimen of 100 mg per day. Higher doses of estrogen need higher doses of
12 micronized progesterone (300 mg daily for 12 days per month or 200 mg daily) 305. It is
13 important not to underdose progesterone as that leads to more abnormal uterine bleeding. It is
14 also important to remember that as the dose of estrogen increases, the dose of progesterone
15 may need to increase (Table 6). Recommended doses for progestins are given in Table 5 300.
16
17 3.5.5 When to add progesterone during pubertal induction
18 Progesterone is unnecessary until uterine growth and development is approaching maturity. In
19 girls undergoing pubertal induction, it is likely that progesterone will be needed after about 1.5-
20 3 years of unopposed estrogen administration or after the first episode of vaginal bleeding.
21 However, inter-individual variability in response to estrogen means that it is good practice to
22 ensure that starting progesterone is appropriate by carrying out pubertal staging and, if
23 possible, performing a pelvic US to review uterine dimensions and the presence of an
24 endometrial stripe > 4-8 mm 306, 307. In cases where the uterus is relatively small and the
25 endometrium is thin, progesterone treatment should be deferred, and more time or increased
26 estrogen dose considered. This ensures maximum time for uterine and breast development
27 with unopposed estrogen 308. Initial vaginal bleeding may be spotting only from an immature
28 endometrium and does not necessarily indicate timing to start progesterone. Recent data
suggest that girls with TS who initiate progesterone closer to 18 months into estrogen treatment may have less abnormal uterine bleeding. There are very few good quality studies of progesterone/progestins in pubertal induction or HRT in adolescents and women with TS. This means that the results of studies in women with premature ovarian insufficiency are extrapolated to support decision making in patients with TS. In practice, studies of premature ovarian insufficiency tend to include many subjects with TS and so this approach has some credence. Studies and trials describing the adverse effects of HRT invariably involve post-menopausal women. In these cases, extrapolation of results to young women with TS is much more dubious and results should be regarded with great caution. There are also very few studies addressing compliance with and acceptability of HRT medication. The most important factor when prescribing regular long-term medication is whether the patient is truly satisfied with taking it.

Results from recent literature search regarding TS and progesterone/progestins
There was only one study concerning progestins as hormone replacement in TS. This was a cross-sectional, non-controlled retrospective cohort study of 111 patients with TS who started estrogen at 15.8 years old. It was found that the prolonged use of medroxyprogesterone acetate, levonorgestrel or micronized progesterone showed no metabolic change (BP, lipid profile, fasting blood glucose, TSH, renal function) except for weight gain. The percentage of annual BMI increment was positive for all progestins used in TS women, but levonorgestrel seemed to best prevent weight gain over time.

3.6 Note about world-wide availability of estrogens and progestins
The availability of estrogen and progesterone preparations varies greatly world-wide as determined by an online survey conducted by ESPE between May 2020 and October 2022 (unpublished data submitted to Hormone Research in Paediatrics). TD E2 was the most widely available preparation (90%) and was the preferred option for pubertal induction in 69% of respondents. Although oral E2 preparations were widely available (82% of respondents), the lower doses of 1mg and 0.5mg tablets were only available in 40% and <10% of centers,
respectively. Low dose ethinyl estradiol (2mcg tablets) was available in nearly 50% of centers but was the preferred preparation in only 2.8%.

In almost all countries, oral preparations of progesterone and progestins were available (95.9%). Dydrogesterone (67%) and/or medroxyprogesterone acetate (67%) were generally available with TD progestins in 25% of centers. Availability in the Arab region has recently been published and showed that the most commonly available forms of estrogen were conjugated estrogen (29% of centers) followed by ethinyl estradiol (26%). The combined oral contraceptive pill was available in 32% centers. In the UK, it was recognized that access and availability to all treatment options was an important factor for shared decision making which can improve medication adherence. Social deprivation was a key influence on the availability of HRT treatment options but the reasons for this inequity are not understood. There are great disparities regarding the availability of HRT preparations between different countries/regions and even within countries. The availability of suitable low dose estrogen preparations for pubertal induction is extremely poor worldwide.

3.7 Monitoring during estrogen treatment

R 3.7 To optimize uterine growth during puberty and bone health in adulthood, we suggest multiple assessments of treatment effect, to include: breast development, height, uterine ultrasound, bone density, serum E2 concentrations, with the goal to achieve E2 concentrations of 100-150 pg/mL (350-500 pmol/L) at full adult replacement (◯◯◯◯◯).

R 3.8 We suggest using measurements of endometrial thickness and serum E2 concentrations in adolescents or women experiencing abnormal uterine bleeding to inform adjustments to E2 and/or progesterone doses (◯◯◯◯◯).

We suggest multiple assessments for monitoring, all of which are based on limited data but years of expert experience and common pathophysiology. No rigorous studies have looked at all variables together to assess outcomes. We suggest measuring E2 concentrations when a highly sensitive assay is available. E2 values in typical menstruating women depend on phase of...
cycle with great variability between women and between cycles; with follicular and luteal mean E2 values around 183 and 521 pmol/L (50 and 142 pg/mL), respectively. More detailed data coming from healthy adult women confirmed it as well: 100-181-730 pmol/L (27-49-199 pg/mL) for early-mid-late-follicular phase and 386-599-395 pmol/l (105-163-108 pg/mL) for early-mid-late-luteal phase, respectively but with wide variability with some women showing values as high as 2500 pmol/L. Both untreated girls with TS with confirmed hypogonadism and post-menopausal women have E2 concentrations around 18 pmol/L (5 pg/mL). Viuff et al. reported that E2 concentrations during HRT in TS were comparable to controls only at early follicular phase suggesting that the current regimen does not fully normalize E2 concentrations in TS. References from women without TS can be used for guidance. A suggested adult target is an E2 concentration of 350-500 pmol/l (100-150 pg/mL). The wide individual variability leads to our suggestion to use multiple variables for assessment of treatment including: breast development, uterine ultrasound, serum E2, LH, FSH, and DXA with further adjustments for patient satisfaction. Serum concentrations may be used to monitor E2 dose at the start of treatment to ensure target concentrations are reached but, in the medium- to long- term, effects of HRT on specific outcomes such as BMD and uterine growth assume greater importance. In contrast, in a study of 145 women with premature ovarian insufficiency, long term TD E2 100 mcg daily restored mean BMD to normal ranges and there was no benefit of increasing the dose to 150 mcg. A study with TD E2 compared with oral E2 showed that a higher dose corresponded to higher concentration of E2, however without linear correlation. TD E2 led to more effective feminization after 2 years compared with oral conjugated equine estrogen. Very sensitive radioimmunoassays or mass spectrometry assays for E2 may be used with care taken to note differences in concentrations based on assay chosen. These assays may not be commercially available or not supported by insurance. Taken together, we suggest a goal of adult serum E2 as mentioned above once pubertal progression is complete, with caution that E2 concentrations vary by assay used. There is also variability in the metabolic clearance of E2 between women, which supports the importance of monitoring serum E2 concentrations during treatment and making decisions based on more than just one measurement.
Uterine growth observed after the first 6-12 months of estrogen therapy induction suggested that uterine volume measurement may be a useful monitoring marker for ERT efficacy. E2 dosage affects uterine volume initially but not in the long term. It is important to note that uterine volume and endometrial assessments by ultrasound are operator dependent and more difficult to standardize, while MRI is superior in determining uterine volume, yet more expensive. Uterine size during induction of puberty can be a proxy for sufficient estrogen exposure and therefore valuable in addition to serum E2, or when serum E2 cannot be assessed.

Clinical assessment, patient satisfaction, patient age and often residual growth potential are the primary determinants for the timing of E2 dose increase. If potential for taller stature is still possible, girls may remain on lower estrogen doses longer. In older girls at initiation, the duration of time until adult dosing may be shortened. Serum concentrations may be used to monitor E2 dose - but, in the medium- to long-term, outcomes such as BMD, uterine growth, QoL, neurocognition and sexuality are of greater importance.

As E2 sensitivity is variable within and between individuals, monitoring serum E2 is valuable, but following the biomarker(s) of individual estrogenization seems paramount. Table 7 provides guidelines for markers of treatment effect.

### 3.8 Hormone replacement therapy in adults with Turner syndrome

**R 3.9** We recommend continuing cyclic estrogen and progesterone treatment until the usual age of menopause (approximately 50-55 years old) and then re-evaluate for possible continued lower dose of E2 and progesterone (/values).

**R 3.10** We recommend individualized E2 + progesterone replacement, taking account of patient preference, to aid adherence with their management plans (/values).
After completing pubertal induction, maintenance HRT is continued until the expected age of natural menopause, about 50-55 years, but lower in some populations, aiming for a period of at least 42 years of exogenous estrogen exposure mimicking normal physiology of endogenous estrogen exposure. During adulthood the aim is to restore the physiological hormonal environment as closely as possible and HRT is important for continuing bone mass accrual to reach peak bone mass during the third decade and for further uterine growth and development. HRT may also help to improve QoL and to avoid the effects of estrogen deprivation including vasomotor symptoms, urogenital effects, low BMD with increased risk of fracture, cardiovascular disease with increased risk of ischemic heart disease and stroke and, finally, possible neurocognitive effects.

Both duration of HRT as well as E2 dose are important for uterine volume and BMD increase. To date, no studies have rigorously defined the effect of dose on BMI, height, weight, or lipids. There is a very low risk of breast cancer in TS patients with no significant increase in those treated with standard doses of HRT. In women with urogenital symptoms such as vaginal dryness, vaginal estrogen is available in creams or pessaries. Vaginal E2 is not believed to carry a risk of endometrial hyperplasia based on data in older menopausal women.

Based on these data, suggested adult doses of E2 are given in Table 8. There is very little information about the bioequivalence of preparations. Estimated daily dose equivalence from the literature (depending on assays and clinical endpoints) are 50/100µg TD = 2mg oral E2 = 20µg ethinyl estradiol.

As previously discussed, it is not feasible to mimic the physiological cyclic variations of the adult woman with intact ovarian function so all risks and benefits of options need to be considered. There are reports where up to 37% of women less than 51 years old stop their ERT prematurely. Even though endocrinologists discuss E2 form, administration route and dose, the most important challenge is probably to individualize treatment in such a way that the hypogonadal woman can accept and adhere to her lifelong ERT. Therefore, a diversity of ERT possibilities is very valuable. Fear of side effects and financial constraints are among the reasons, even when evidence is given regarding poorer outcome for those without treatment.
The need for individualized HRT, taking full account of patient preference is crucially important and patient involvement in decisions about care are known to improve adherence. Estrogen effects on other outcomes are presented in Table 9.

Regular follow-up, about once a year, preferably in a dedicated clinic for adults with TS, is recommended. It is important to discuss compliance, patient satisfaction, side effects and the possible need for change of regimen or route of administration.

Measurement of BMD with DXA scan, ensuring adjustment of results for height and bone size, should be considered when pubertal induction has been completed. Following this, the frequency of repeat BMD assessment should be guided by the findings from the initial assessment, the patient’s risk factors and their compliance with HRT.

3.9 Testosterone and Oxandrolone
Viuff et al. showed that androgen concentrations are 30-50% lower in women with TS than in controls. One pilot study by Zuckerman-Levin et al. has looked at testosterone replacement in adolescents/young women with TS and confirmed that androgen replacement therapy (ART), as compared with placebo, reduced total cholesterol, triglycerides, but also HDL cholesterol. Moreover, it improved BMD, increased lean body mass, and decreased fat mass. Androgen replacement therapy improved attention, reaction time, and verbal memory, but had no effect on executive functions and spatial cognition. Their patients reported improved QoL, including general health, coping with stress, and sexual desire.

Oxandrolone use in TS to promote growth is well-described. However, its use is not considered standard of care and was reserved for very short girls. Of note, as of 2023, it is no longer available in the US (see section on Growth in TS). Further studies of androgen use in women with TS are needed.

3.10 Practical Guidelines Summary
For pubertal induction in girls with TS it is important to mimic physiology as closely as possible to support linear growth and gradually induce puberty at an age and tempo within the normal
range for peers. This is important for psychosocial well-being, bone health, uterine growth, pregnancy outcomes and possible neurocognitive benefits.

For girls who do not enter spontaneous puberty, as determined by elevated FSH on multiple checks between 8 – 11 years old, plan low dose E2 initiation between 11 – 12 years old. For girls with spontaneous thelarche, withhold treatment until any signs of ovarian insufficiency by FSH measurement. We recommend a starting dose of 7 mcg TD E2 or 0.25 mg oral E2, and increasing the dosing every 6 – 12 months. Breast stage and serum E2 concentrations can guide progression of dosing. Anticipation to reach adult dosing by year 4 of treatment with serum E2 concentrations close to 100-150 pg/mL (367-550 pmol/L). For girls who have spontaneous puberty and then develop ovarian insufficiency, E2 dosing should be parallel to their pubertal stage. For example, a girl who has reached breast stage 3 (or mid-puberty) can start treatment at 25 mcg TD E2 or 1 mg oral E2. Once linear growth is complete, if ethinyl estradiol is preferred, we recommend dosing with 30 mcg per day.

Progesterone should be added once spontaneous bleeding occurs if it is at least 18 – 24 months into estrogen treatment. If bleeding occurs sooner, then progesterone can be added if endometrial stripe on ultrasound is at least 4 – 8 mm. If endometrium is less than 4 mm, we recommend checking serum E2 concentrations and increasing E2 dose prior to adding progesterone to allow further development of the endometrium. When available, micronized progesterone at 200 mg for 12 days per month is the preferred progestin, with dydrogesterone at 10 mg for 12 days as second choice. It is important not to underdose progesterone to prevent abnormal uterine bleeding. Patients requiring higher E2 doses may also require higher progesterone doses. We advise a sequential regimen of E2 and progesterone to allow cyclical endometrial development and avoid abnormal uterine bleeding in younger women (Table 8).

Older women may prefer a combined continuous regimen and avoid menstruation.

GH treatment can continue in any girl with continued growth potential even as estrogen treatment is initiated.

In adult women with TS, it is very important to individually adapt dosing and route options to improve adherence. Patient choice is the most important determinant of adherence. Treatment
is recommended until typical menopausal age around 50 - 55 years. At that time assessment of
value of ongoing lower E2 dosing is possible.
We do not recommend ultrasound of the uterus prior to E2 initiation as it is not a good
predictor of spontaneous puberty nor changes the decision about when to start E2 treatment.
We recommend ultrasound of uterus at first bleeding if there has been E2 treatment for less
than 2 years or if breast development has not reached stage 3. Once adult height is reached
with full E2 dosing, if the uterus is still small on ultrasound, higher E2 dosing is recommended to
stimulate further uterine growth for possible future fertility options.
DXA and peripheral quantitative computed tomography estimation of bone mass will be low
until adult E2 dosing is reached. This is a good time to assess bone mass to aid in assessing
adequate E2 dosing. There is little data on when women with TS reach peak bone mass, so
repeat DXA and pQCT is suggested around 21 years of age. Table 10 lists areas for important
future research in relation to estrogen therapy.
4. Cardiovascular health

4.1 Introduction

Individuals with TS frequently cope with a lifelong burden of congenital and acquired cardiovascular diseases, which are primarily responsible for the increased mortality of adults with TS. CHD occurs in approximately half of individuals with TS, including BAV, aortic coarctation, and an arteriopathy that can lead to rare but often fatal aortic dissections. The lifetime prevalence of thoracic aortic aneurysms is approximately 25%. However, acquired cardiovascular conditions such as systemic hypertension, ischemic heart disease, and stroke are the major factors that reduce the lifespan. This consensus statement proposes guidance for decision-making about diagnosis, treatment, and monitoring of congenital and acquired cardiovascular diseases in TS. Clinical care guidelines for management of CHD also apply to individuals with TS with a few special considerations that are discussed.

4.2 Recommendations for cardiovascular surveillance

Early diagnosis and routine surveillance are essential for prevention and timely therapy of cardiovascular disease in TS. Even in the most experienced hands, prenatal or neonatal TTE may not definitively exclude BAV, anomalous pulmonary venous return, or variant aortic arch anatomy. Repeating images later in childhood and maintaining a low threshold for cardiovascular consultation may improve diagnostic sensitivity for congenital heart lesions (Figure 3). Establishing a routine of lifelong cardiovascular care is a key issue for young people with TS.

4.3 Congenital heart disease

R 4.1 We recommend that if TS is highly suspected or has been confirmed prenatally, a fetal echocardiogram should be performed.

R 4.2 We recommend that diagnosis of left-sided congenital heart disease (CHD) in a female fetus or child should prompt a genetic evaluation that includes testing for TS.
R 4.3 We recommend that a pediatric cardiologist should be included in the multidisciplinary care team when CHD is detected prenatally in a fetus with TS to provide counseling regarding the anatomy and physiology of the specific defect, the recommended site and mode of delivery, and postnatal cardiovascular management (⨁⨁◯◯).

R 4.4 We recommend that a newborn with prenatally diagnosed or suspected TS be examined with TTE at day 2 to 3 of life, sooner if CHD is suspected, even if the fetal echocardiogram or postnatal clinical examination was normal (⨁◯◯◯).

R 4.5 In settings where postnatal TTE prior to discharge after birth are not available, we recommend clinical cardiac evaluation with 4-extremity blood pressure, pulse oximetry, palpation of femoral pulses, cardiac auscultation, and ECG prior to discharge followed by outpatient TTE within the first weeks of life (⨁⨁⨁◯).

R 4.6 We recommend that visualization of the origin and proximal course of coronary arteries to identify potential coronary anomalies should be included in the cardiovascular assessment of all individuals with TS (⨁⨁◯◯).

R 4.7 We recommend that transthoracic echocardiography (TTE) should be performed at the time of diagnosis in all children and adults with TS, even when a fetal echocardiogram or postnatal clinical examination was normal (⨁⨁◯◯).

4.3.1 Prevalence of congenital heart lesions

Depending on the age and the imaging technique used, the prevalence of CHD in TS ranges from 40-60%, most commonly left-sided obstructive lesions such as BAV and coarctation (Table 11)\(^3,339-343\). The prevalence is higher in individuals with 45,X karyotypes compared to individuals with X mosaicism or other X structural abnormalities \(^344-345\). Neck webbing and an increased anterior-posterior thoracic diameter are strong predictors of arterial and venous anomalies in
TS $^{345, 347, 348}$. At least 13% of newborn girls with aortic coarctation have TS, and coarctation should be viewed as an independent marker of TS $^{349}$. Vascular anomalies, including partial anomalous pulmonary venous return, left superior vena cava, elongated transverse arch, and dilation of the brachiocephalic arteries, often remain undetected unless advanced imaging modalities are used $^{342, 350}$. Congenital coronary artery anomalies appear relatively common in TS, but their effect on mortality risk is unknown $^{351}$. However, there is no evidence that sudden cardiac death related to malignant anomalies such as origin from the opposite sinus is increased in TS $^{352}$. The cardiovascular surgeon needs to be aware of unusual coronary anatomy because it may necessitate modifications to the operative approach and can lead to adverse surgical outcomes in individuals with undetected coronary anomalies $^{353}$.

4.3.2 Prenatal and neonatal cardiac evaluation

With advances in fetal echocardiography, prenatal detection of CHD is becoming increasingly common, allowing opportunity for parental counseling and time for planning of perinatal management based on predicted risk of hemodynamic compromise after birth. Therefore, all fetuses diagnosed with TS or suspected to have TS should undergo a prenatal cardiac evaluation with fetal echocardiography, regardless of karyotype $^{354}$. If any CHD is detected prenatally, prompt evaluation by a pediatric cardiologist is recommended to determine the site and mode of delivery and postnatal management plans based on the CHD lesion detected $^{355}$. When CHD is detected in a fetus with a 45,X karyotype, the risk of cesarean section, adverse neonatal outcomes, and neonatal death is predicted to be higher than in non-TS fetuses with similar lesions $^{356}$. Therefore, prenatal counseling and planning for the perinatal management of such fetuses should include a multidisciplinary team that involves, at a minimum, pediatric cardiology, neonatology, and maternal-fetal medicine.

For fetuses with known or suspected TS but normal fetal echocardiographic findings, counseling should include recognition that not all CHDs can be easily detected prenatally. Ultrasound image resolution is insufficient to distinguish small fetal cardiac structures such as the morphology of the aortic valve. In addition, there are unique features of the fetal circulation...
due to fetal shunts, such as patent foramen ovale and ductus arteriosus, that make prenatal detection of aortic coarctation difficult on the fetal echocardiogram. Therefore, it is not surprising that fetal echocardiographic studies detected CHD in only 13% to 16% of fetuses with TS, as compared to the 50% prevalence of CHD on postnatal images. A postnatal TTE is recommended for all newborns with TS, even if the fetal echocardiogram was normal, because fetal echocardiography may not detect all CHD lesions. For TS newborns that are clinically stable with normal newborn pulse oximetry and reassuring femoral pulses on physical examination, the post-natal TTE should be planned on day 2 or 3 of life, based on the anticipated time of discharge. Postnatal development of aortic coarctation can only be completely ruled out once ductal closure is completed, which typically happens by 2 to 3 days of age. If the newborn displays any signs or symptoms concerning CHD, the TTE should be obtained sooner. Findings on the postnatal TTE should guide the timing of outpatient cardiac follow up evaluation and subsequent management. If resources are not available for postnatal echocardiography prior to discharge for a newborn that is clinically stable and with reassuring 4-extremity blood pressure, pulse oximetry, femoral pulses, cardiac auscultation, and ECG, it is reasonable to plan for TTE within four weeks of age.

4.3.3 Bicuspid aortic valve

BAV is detected in more than 25% of individuals with TS, or 50 times the rate in the general population. The prevalence of type 1 BAV morphology may be increased in individuals with TS. BAV is frequently associated with thoracic aortic dilation, coronary anomalies, coarctation, and other left-sided congenital lesions, which should be actively screened for if BAV is identified. Continuous surveillance is necessary for individuals with BAV to address these related issues and avert potential complications. Although BAV is a common feature of TS, isolated BAV is also common in the general population with a prevalence of 1-2%. Therefore, the diagnosis of BAV should prompt a genetic evaluation for TS only if additional clinical features of TS are present.
4.3.4 Management of CHD in Turner syndrome

Structural heart lesions such as shunts or coronary anomalies, which are prevalent in TS, can present as chest pain, dyspnea, or syncope in children or young adults. New cardiovascular symptoms in young people with TS should prompt an evaluation by a cardiologist (Figure 3). For individuals with TS and CHD, recommendations for cardiac surveillance, medical therapies, and surgical approaches are similar to non-TS patients, as outlined in clinical care guidelines for CHD management of the fetus, child, or adult with CHD. Treatment of valve dysfunction should be consistent with current guidelines for valvular heart disease.

Operative management can be more challenging given the medical complexity of TS. Median postoperative hospital stays, reoperation rates, and mortality are increased compared to non-TS patients. Percutaneous treatment of aortic coarctation, although effective, may be associated with significant morbidity and mortality due to increased risk for aortic dissection with a percutaneous approach. These risks suggest that alternative treatment options should be carefully weighed against percutaneous strategies while considering individual risk factors.

4.4 Imaging

**R 4.8** We recommend that in the absence of significant cardiovascular disease (hypoplastic left heart syndrome, Shone’s complex, aortic coarctation, bicuspid aortic valve (BAV), aortic dilation, or cardiac shunt) at the initial comprehensive screening, TTE should be performed at age 9-11 years, after growth completion or at transition to adult care, and at least every 5-10 years in adults. (⊚⊚◯◯).

**R 4.9** If the heart and aorta are completely visualized and are normal in an infant or child with no symptoms that could be attributable to cardiovascular disease, an initial cardiovascular magnetic resonance (CMR) scan is still recommended but can be delayed until it can be performed without general anesthesia (⊚⊚◯◯).

**R 4.10** CMR should be performed, in addition to or instead of initial screening echocardiography, in all adolescents and adults newly diagnosed with TS. Imaging should ideally be completed within 12
months, with the exact interval based on initial echocardiography findings (if echocardiography completed first), presence of additional risk factors, and clinician judgement (⊕⊕◯◯).

**R 4.11** Computed tomography (CT) is a reasonable alternative when CMR is not tolerated or available. Both CT and CMR scans should include electrocardiogram (ECG)-gated or ECG-triggered assessment of the thoracic aorta (⊕⊕◯◯).

**R 4.12** We recommend that individuals with TS, especially with aortic dilation or BAV, should be counseled to seek prompt evaluation if they experience acute symptoms consistent with aortic dissection, such as chest, neck, shoulder, back, or flank discomfort, particularly if it is sudden in onset and severe (⊕⊕◯◯).

Non-invasive imaging is an essential part of cardiovascular screening and surveillance across the life span of individuals with TS, but imaging remains underutilized and not systematically applied. The principal non-invasive imaging modalities are TTE, CMR, and CT. TTE is valuable for the diagnosis and surveillance of CHD and aortic dilation, but may be limited by poor acoustic windows, especially in older children and adults. Acoustic shadowing tends to be more pronounced in TS and may significantly limit the sensitivity of TTE to detect potentially outcome-determining lesions. CMR is not constrained by anatomic factors and is thus more sensitive for extra-cardiac lesions such as partial anomalous pulmonary venous return. CMR is also superior to TTE for the diagnosis of BAV, aortic dilation and aortic arch anomalies while also providing important data on shunt fractions and ventricular volumes that may inform clinical management. CMR is radiation-free and can be acquired without intravenous contrast medium and is, therefore, especially useful during pregnancy and in younger individuals. However, CMR is less widely available compared to TTE and requires more extensive patient cooperation. Young children will therefore need a general anesthetic to undergo CMR. CT is a reasonable alternative to CMR when CMR access is limited or if the individual cannot tolerate an awake CMR. CT provides anatomical information of comparable quality to CMR during a much more rapid acquisition. However, CT involves radiation exposure,
which is increased when ECG gating is used to obtain accurate aortic measurements. Therefore, CT is less suitable for serial surveillance.

4.5 Aortic dilation and dissection

**R 4.13** Individuals with TS require lifelong cardiovascular surveillance at a frequency that should be determined by their risk factors for aortic dissection (✔️◯◯◯).

**R 4.14** For children < 15 years old, aortic dilation may be categorized by calculating the TS-specific Z-score (Z). For adults and adolescents > 15 years old, aortic dilation may be categorized by calculating the aortic height index (AHI), the aortic size index (ASI), the TS-specific Z-score, or the general population Z-score (Z).

**R 4.15** For adults with TS, we recommend informed, individualized decision-making about the timing of elective aortic surgery, considering risk factors for aortic dissection, including moderate aortic dilation (AHI > 23 mm/m, ASI > 2.3 cm/m², or Z > 3.5) with at least one additional risk factor: BAV, aortic coarctation, hypertension, or a rapid increase in aortic diameter (> 3 mm/year). Dissection risk probably increases if more than one additional risk factor is present. Severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) as a single risk factor should prompt an evaluation for elective aortic surgery (✔️◯◯◯).

**R 4.16** For children with TS, the risk of aortic dissection is much lower than in adults. We recommend informed, individualized decision-making about the timing of elective aortic surgery, considering risk factors for aortic dissection including moderate aortic dilation (age < 15 years: Z > 3.5; age ≥ 15 years: AHI > 23 mm/m, ASI > 2.3 cm/m², or Z > 3.5) and hypertension, aortic coarctation, BAV, or a rapid increase in aortic diameter (> 3 mm/year or > 1 Z/year) (✔️◯◯◯).

**R 4.17** We recommend annual assessment of blood pressure, preferably using ambulatory blood pressure monitoring (ABPM), and initiation of medical therapies if hypertension is confirmed, for all individuals with TS. (✔️✔️◯◯).
The incidence of aortic dissection in TS is approximately 164 per 100,000 person-years, compared to 6 per 100,000 person-years in the general population. Seventy percent of aortic dissections originate in the ascending aorta (Type A), and 30% of dissections originate in the descending thoracic aorta (Type B). Dissections occur at a relatively young age in TS (mean 30-35 years), like other genetically triggered aortopathies. Dilation of the aorta, brachiocephalic and carotid arteries may be present even in the absence of structural heart disease, consistent with an underlying generalized arteriopathy. It is also important to note that aortic dissections occur at smaller absolute aortic diameters in TS than in other genetically triggered aortopathies. The proximal aorta may dilate more rapidly in individuals with TS if BAV is present, but there is no evidence that overall aortic dilation rates in TS are accelerated compared to matched controls without TS.

Many individuals with TS are significantly smaller than age and sex matched controls in the general population. In this context, applying the current absolute diameter thresholds for aortic dilation (> 4.0 cm) or aneurysm (> 4.5 cm) to adults with TS would almost certainly lead to delayed recognition of aortic disease. To correct for this size difference, we recommend indexing the ascending aortic diameter to body size. The most frequently used indexing methods are the Z-score (Z, dimensionless unit indicating the number of standard deviations from the population mean), the aortic height index (AHI, aortic diameter in millimeters divided by body length in meters), and the aortic size index (ASI, aortic diameter in centimeters divided by body surface area (BSA) per square meters) (Table 12). It is important to note that these indexing methods only apply to the ascending aorta, and ASI or Z-scores should only be used to guide medical decisions for adults who fall within 1-2 standard deviations around the mean BSA of 1.7-1.9 m² for all adult women. In practice, AHI is easiest to use and in one study showed greater predictive value compared to the absolute diameter, Z-score, or ASI. This is probably due to the prevalence of obesity, which can deflate the ASI or Z-score (Table 13). There is currently insufficient evidence to recommend one indexing method over another. For surgical decision-making, it may be useful to compare more than one indexing
method. Confirmatory studies are needed to clarify which indexing method may be optimal for TS individuals.

The prevalence of hypertension, aortic coarctation, and BAV is higher in individuals with TS who developed aortic dissections. Therefore, these diagnoses are viewed as additional risk factors for aortic dissection. A rapid rate of aortic dilation (> 3 mm/year) may also be a risk factor for dissection, but this has not been validated in TS. Individuals with one or more of these factors may require more frequent aortic surveillance or more intensive medical therapies to prevent aortic dissection (Figures 4 and 5).

We recommend a pragmatic approach to managing individuals with aortic dilation, recognizing the absence of clinical trials in TS cohorts that might provide guidance. Therefore, medical therapy of aortic disease in TS should be based on current clinical guidelines for aortic disease. As in other aortopathies, cystic medial degeneration has been documented in resected aortic tissues, suggesting that a similar medical management strategy is reasonable. As hypertension is common, maintenance of normal blood pressure may reduce the risk for aortic events. Because dissections can occur at relatively normal absolute aortic diameters, it is reasonable to begin prophylactic medical therapies as soon as aortic dilation is recognized, especially if hypertension is also present.

In general, technical concepts and perioperative care are not different for patients with TS compared to other patients with thoracic aortic aneurysms. When considering elective aortic surgery, an individualized shared decision between the patient and provider should be undertaken in consultation with an experienced team. In two studies, ASI > 2.5 cm/m², corresponding to AHI > 25 mm/m or Z > 4, was identified as an independent risk factor for aortic dissection in TS. However, other factors in addition to aortic dilation, such as a rapid increase in the absolute aortic diameter (> 3 mm/year), hypertension, aortic coarctation, or BAV, may increase dissection risk and should be considered when counseling patients about an elective preventative aortic procedure.
4.6 Hypertension

R 4.18 We recommend treatment with a beta-blocker, an angiotensin receptor blocker, or both for individuals with TS who have hypertension and have a dilated aorta (age < 15 years: Z ≥ 2.5; age ≥ 15 years: AHI ≥ 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5) (Θ□□□□).

R 4.19 We suggest that treatment with a beta-blocker, an angiotensin receptor blocker, or both should be considered for individuals with TS who have a dilated aorta (age < 15 years: Z ≥ 2.5; age ≥ 15 years: AHI ≥ 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5), even if they are not hypertensive (Θ□□□□).

R 4.20 We recommend that medical treatment of hypertension for all individuals with TS who do not have a dilated aorta (age < 15 years: Z < 2.5; age ≥ 15 years: AHI < 20 mm/m, ASI < 2.0 cm/m², or Z < 2.5) should be based on the appropriate pediatric or adult guidelines for medical management of hypertension (Θ□□□□).

4.6.1 Prevalence of hypertension

Hypertension is 3-4 times more prevalent in individuals with TS than in matched controls and does not vary significantly by karyotype. The prevalence of hypertension is as high as 20–40% in children and up to 60% in adults with TS. Systemic hypertension appears at early ages and progresses in frequency and severity throughout adulthood.

Hypertension is more frequent in individuals with dysmorphism, coarctation, or renal anomalies but may also be idiopathic. Hypertension can persist after coarctation repair, even in those without residual descending aortic pressure gradients. The intrinsic shape of the aorta in individuals with TS who do not have coarctation may also contribute to the etiology of hypertension and can become more accentuated over time as the aorta elongates. Therefore, lifelong monitoring and follow up of hypertension is essential for individuals with TS.
4.6.2 Screening for hypertension

For everyone with TS, frequent screening to identify hypertension is recommended, beginning in childhood \(^{401,413,414}\). Left ventricular hypertrophy and increased ventricular mass are commonly observed in TS, even in those who do not have a diagnosis of hypertension \(^{415,416}\). This could be an end-organ effect of hypertension, altered aortic biomechanics, or loss of diurnal blood pressure variation that is masked during clinic blood pressure measurement \(^{409}\).

Proximal aortic stiffness is frequently increased in TS, even if the aorta is not dilated and the aortic valve is tricuspid \(^{417-420}\). Ambulatory blood pressure monitoring (ABPM) may be useful to confirm suspected hypertension and document impaired nocturnal dipping, which has been linked to other evidence of autonomic dysfunction in TS \(^{327,421,422}\). Non-dipping or nocturnal hypertension is found in up to 50% of TS patients starting from a young age \(^{423}\). Diagnosis of nocturnal hypertension can only be made by ABPM. We therefore advise ABPM for surveillance of hypertension for adults and for children beginning around age 10 years. Other methods to screen for hypertension, such as patient-reported home blood pressure monitoring or submaximal exercise testing, are reasonable if ABPM is not available \(^{424,425}\). While hypertension is correlated with the presence of aortic dilation in TS, no studies have demonstrated that antihypertensive therapies slow or prevent aortic dilation \(^{401,411,413}\). Nevertheless, the presence of hypertension is an additional argument to start medical treatment if aortic dilation is present.

4.6.3 Management of hypertension

Several guidelines for assessment of systemic hypertension in children and adolescents \(^{426}\) or adults \(^{427}\) are available, but none specifically addresses hypertension in individuals with TS. Therefore, we propose an algorithm for assessment and treatment of hypertension in TS that is derived from current guidelines (Figure 6). Hypertension in adults is defined as a mean systolic blood pressure > 130 mm Hg or a mean diastolic blood pressure > 80 mmHg over at least two measurements \(^{427}\). For children, diagnosis of hypertension is dependent on normative values based on age, sex, and height that may vary between regional guidelines \(^{426,428}\). For all individuals with TS who have hypertension, it is essential to diagnose and treat secondary
causes of hypertension such as renal anomalies, obstructive uropathy, or coarctation. Both non-
medical and medical treatments should be considered if hypertension is present. In all cases,
the therapeutic approach to hypertension should begin with assessment and treatment of risk
factors such as obesity, dietary counseling, and encouragement of healthy lifestyle choices such
as regular aerobic exercise.

If aortic disease is present (BAV, dilation, defined as Z > 2.5, AHI > 20 mm/m, or ASI > 2.0
cm/m², or aortic dissection), initial treatment targets and antihypertensive medications should
be selected according to the 2022 ACC/AHA Guideline for the Diagnosis and Management of
Aortic Disease 394. Medical therapy of hypertension for individuals with TS and aortic dilation
should preferably include a beta-blocker, angiotensin receptor blocker (ARB), or both, which
have been shown to prevent aortic dilation and aortic dissections in individuals with other
aortopathy conditions 394. The choice between a beta-blocker and ARB should be based on
shared decision making with the patient and family, taking into consideration resting heart rate,
ECG abnormalities, and side effects such as fatigue. If aortic disease is absent (TAV and Z < 2.5,
AHI < 20 mm/m, or ASI < 2.0 cm/m², no dissection), initial treatment targets and
antihypertensive medications should be based on current guidelines for hypertension, which
recommend an angiotensin converting enzyme inhibitor or ARB as first-line therapy for adults
and children, depending on co-existing conditions such as diabetes 426-428.

4.6.4 Estrogen supplementation and hypertension
There is inconclusive evidence about the effect of estrogen supplementation on blood pressure.
A recent randomized clinical trial found no difference in the rate of increase in blood pressure
over 5 years in young participants with TS (23 ± 2 years) who were assigned to 2 mg or 4 mg of
oral E2 supplementation 327. A crossover study found that arterial stiffness and central blood
pressures decreased in older individuals with TS (29 ± 9 years) after they stopped taking 2 mg
oral E2 429. Another study showed that blood pressure decreased during treatment with E2
(either oral or TD) for 6 months compared with no treatment for 4 months 408. There is some
evidence that blood pressure may be substantially lower with TD E2 preparations compared to
oral ethinyl E2, but this has not been tested specifically in TS 430.
4.7 Coagulation and thrombosis

**R 4.21** We do not recommend routine screening for blood clotting disorders before initiation of female sex hormone replacement therapy (HRT). The diagnosis, surveillance, and treatment of blood clotting disorders in TS should be based on the appropriate pediatric or adult clinical guidelines for the general population (◯◯◯◯).

Coagulation is generally normal when evaluated in large TS cohorts, and in general TS does not seem to be an independent risk factor for venous thrombosis. While increased levels of procoagulant factors and reduced protein C and S were reported in some individuals with TS, most studies have reported normal levels of clotting factors, fibrinolytic factors, and clotting times. In addition, no evidence supports the concept that HRT increases risks for deep venous thrombosis.

Outcome data about venous thrombosis are rare in TS, and a common underlying cause of thrombotic events has not yet been identified. Because no consistent abnormalities in venous thrombosis have been described, there is no evidence-based consensus about when to assess the coagulation system in individuals with TS. However, raising awareness about thromboembolic disease can help to identify the relatively few individuals with TS who present due to coagulation issues.

While venous anomalies (anomalous pulmonary veins, left superior vena cava) are more common in TS, the question remains if malformations of the inferior vena cava or pelvic veins increase the risk for deep venous thrombosis of the lower extremities. Venous obstruction should be considered if an individual with TS develops unprovoked venous thrombosis.

4.8 Hyperlipidemia

**R 4.22** We recommend that an initial lipid profile should be obtained no later than the age of initial screening recommended by country-specific guidelines or at transition and repeated every 3 years.
The diagnosis and treatment of hyperlipidemia in TS should be based on the appropriate pediatric or adult clinical guidelines for the general population.

Hypercholesterolemia is prevalent in TS and is influenced by numerous intrinsic factors, including obesity, metabolic syndrome, and type 1 or 2 diabetes. Individuals with TS and comorbidities often exhibit higher total cholesterol, LDL cholesterol, and triglycerides compared to controls, although severe elevations are infrequently reported. There does not seem to be a specific dyslipidemia associated with TS.

Although there is evidence suggesting that estrogen treatment can affect lipid concentrations, the impact does not seem to be clinically significant. Additionally, the type or method of estrogen administration does not appear to modify cardiovascular risk. Therefore, there is no rationale for routine assessment of lipids prior to initiation of HRT. There is no international consensus on when to begin lipid monitoring in individuals with TS. A small study showed marginally increased plasma lipids in children and adolescents with TS. However, the individuals in that study also had significantly higher waist circumference, impaired glucose tolerance, and higher blood pressures. This means that the healthy and normal weight individual with TS may not have an increased risk of dyslipidemia per se.

If hyperlipidemia is detected, it is important to investigate potential secondary causes such as hypothyroidism, familial hypercholesterolemia, or primary hypertriglyceridemia. Treatment should then align with the recommendations for the general population that feature dietary changes, weight loss, and physical activity in the initial strategy. Statin exposure possibly exacerbates the risk to develop diabetes in individuals with TS, who are already at high risk for metabolic derangement. We acknowledge that this area requires additional research to clarify regional differences in when to assess and intervene.

4.9 Coronary artery disease

We recommend that new onset chest pain, regardless of age, should be assessed by a cardiologist. The diagnosis, surveillance, and treatment of coronary artery disease in TS should be...
Ischemic heart disease is a major cause of morbidity and mortality in TS\textsuperscript{27,29}. Studies that rely on death certificates to determine causes of death found that the standardized mortality ratio for ischemic heart disease is elevated in TS, with most deaths due to coronary artery disease occurring after age 45\textsuperscript{27}. The major risk factors for ischemic heart disease in TS are hypertension, diabetes, and the metabolic syndrome\textsuperscript{438}. There is no evidence that TS predisposes to coronary artery disease independently of traditional cardiovascular risk factors, such as hypertension, type 2 diabetes, obesity, or smoking (Funck, et al. 2021; Schoepp, et al. 2017). Two studies reached conflicting conclusions about this issue using coronary CT\textsuperscript{439,440}. However, the presence of CHD may increase the likelihood of developing coronary artery disease in later life\textsuperscript{441}. In the absence of evidence for a specific cause related to TS, management of coronary artery disease should be based on the appropriate clinical guidelines. Routine screening for coronary artery disease in asymptomatic individuals has not been beneficial and should not be considered in TS\textsuperscript{442}. However, if an adult with TS who has cardiovascular risk factors experiences chest pain, the first imperative should be to rule out coronary artery disease. With the broad use of CT angiography in different clinical settings, non-obstructive coronary plaques are likely to be observed coincidentally in individuals with TS. This could prompt a more thorough assessment of hypertension, glucose, and lipid status but should not lead to primary preventative therapy with aspirin due to the low probability of benefit and the high risk of bleeding\textsuperscript{443}.

4.10 Electrocardiographic abnormalities and arrhythmias

\textbf{R4.24} We recommend that a resting ECG should be performed at the time of diagnosis to assess for findings consistent with CHD, an arrhythmia, or conduction abnormality. Follow up ECGs should be obtained and reviewed by a cardiologist at intervals deemed appropriate based on baseline findings, underlying CHD, and clinical course (⊕ ⊗ ⊗ ⊗).
**R 4.25** We suggest, given prior concern for QTc prolongation in persons with TS, that the QTc should be routinely calculated, ideally using Hodges formula, whenever an ECG is performed on a patient with TS. However, newer research suggests that QTc prolongation is not more prevalent in persons with TS compared to the general population when defining prolongation as QTc > 450 ms in girls (up to 15 years old) and > 460 ms in women and when using Hodges formula (◯◯◯◯).

**R 4.26** We recommend that standard guidelines for the general population should apply to individuals with TS if QTc prolongation > 480 ms by Hodges formula has been detected on at least 2 serial ECGs. In those circumstances, consultation with a cardiologist, possibly an electrophysiologist, should be completed (◯◯◯◯).
should be determined by baseline ECG characteristics and the clinical course (i.e., discovery of CHD, development of hypertension, development of arrhythmia, new symptoms of concern, use of certain medications). For individuals with CHD, hypertension, or a history of arrhythmia, ECGs should be performed at intervals deemed appropriate by the cardiologist based on the specific diagnosis and indications. For individuals with TS who do not have existing diagnoses as above or new symptoms or medications of concern, it is reasonable to perform an ECG at each recommended imaging interval and associated visit (Figure 2).

We propose that cutoffs for QTc prolongation and thresholds for further work up, referral, activity restrictions, and medication restrictions should be consistent with existing societal guidelines and expert recommendations 449, 452.

4.11 Exercise and activity

**R 4.27** We recommend regular aerobic physical activities as part of a heart healthy lifestyle for all individuals with TS (⨉◯◯◯).

**R 4.28** We recommend that the function of the aortic valve, the presence of any other congenital heart lesions, and hypertension should be considered in determining athletic participation recommendations for the individuals with TS and aortic dilation (⨉◯◯◯).

**R 4.29** We suggest that for individuals with normal aortic size (age < 15 years: Z < 2.5; age ≥ 15 years: AHI < 20 mm/m, ASI < 2.0 cm/m^2, or Z < 2.5), it is reasonable to participate in all sports (⨉◯◯◯).

**R 4.30** We suggest that for individuals with a mild to moderately dilated aorta (age < 15 years: Z 2.5–3.5; age ≥ 15 years: AHI 20–23 mm/m, ASI 2.0–2.3 cm/m^2, or Z 2.5-3.5), participation in low and moderate static and dynamic competitive sports may be acceptable but intense weight-training should be avoided (⨉◯◯◯).
We suggest that individuals with a moderately to severely dilated aorta (age < 15 years: $Z > 3.5$; age ≥ 15 years: $\text{AHI} > 23 \text{ mm/m}$, $\text{ASI} > 2.3 \text{ cm/m}^2$, or $Z > 3.5$) should be advised not to participate in any competitive sports, intense weight-training, or physical activities with risk of contact injury to the chest ($\bigcirc\bigcirc\bigcirc$).

In most individuals with TS, the benefits of exercise outweigh the very low risk of exercise-induced aortic dissection. Therefore, exercise should be promoted as a general component of a healthy lifestyle.

In recent surveys, a sedentary lifestyle was reported by more than half of children and adults with TS and was associated with arterial hypertension $^{453-455}$. There is no evidence that exercise capacity is intrinsically lower in TS $^{456,457}$. Given the propensity for obesity and the metabolic syndrome in TS, health care professionals should be mindful of the significant benefits of having a ‘heart-healthy’ lifestyle in light of the low risk of aortic dissection in TS (about 40:100,000 patient-years), the rare occurrence of aortic dissection related to exercise, and growing evidence that supervised exercise is safe for individuals with thoracic aortic aneurysms or dissections $^{458-460}$. While there is no published data about the effects of exercise on vascular disease in TS, aerobic exercise was shown to decrease aortic growth rates in a mouse model of Marfan syndrome and may also be protective in humans $^{461,462}$. Therefore, consideration of aortic dissection risk should be tempered by the importance of encouraging individualized levels of physical activity. Current recommendations include at least 150 minutes of weekly moderate intensity, primarily aerobic physical activities for adults and at least 60 minutes of daily moderate to vigorous activities for children $^{463}$. Before anyone with TS starts an exercise program, it is important to evaluate and treat any congenital or acquired cardiovascular lesions that may increase exertional risk, such as BAV, thoracic aortic dilation, hypertension, or coronary heart disease, in consultation with a cardiologist.

Provided that these risks are addressed and treated, most individuals with mild to moderate aortic dilation ($Z \leq 3.5$, $\text{AHI} \leq 23 \text{ mm/m}$, or $\text{ASI} \leq 2.3 \text{ cm/m}^2$) can safely engage in low to moderate intensity recreational activities. High-intensity, competitive, and contact sports or physical activities are generally prohibited for anyone with TS who has a dilated aorta ($\text{AHI} \geq 20$.
mm/m, ASI ≥ 2.0 cm/m² or Z ≥ 2.5)\textsuperscript{464}. Practical guidance on the type, frequency, and intensity of exercise should be based on the 2020 European Society for Cardiology guidelines on sports cardiology and exercise in patients with cardiovascular disease \textsuperscript{465}. For individuals with TS who do not have congenital or acquired cardiovascular disease, the current evidence is insufficient to make specific recommendations about competitive athletics.

### 4.12 Cardiovascular management during pregnancy

**R 4.32** We recommend that cardiovascular imaging, ideally CMR or CT, should be performed at least within two years before planned pregnancy or assisted reproductive methods and repeated closer to pregnancy if recommended by a cardiovascular specialist (Θ⊕◯◯).  

**R 4.33** In the presence of aortic dilation (AHI > 20 mm/m, ASI > 2.0 cm/m², or Z > 2.5) or at least one other risk factor for dissection (BAV, aortic coarctation, hypertension, rapid aortic diameter increase), we recommend informed, individualized peripartum cardiovascular care by a multidisciplinary team that ideally should include a maternal–fetal medicine specialist and a cardiologist with expertise in managing women with TS, preferably in a center with expertise in aortic surgery and TS (Θ⊕◯◯).  

**R 4.34** In the presence of severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) and especially when other risk factors for aortic dissection are present (previous aortic surgery, previous aortic dissection, or rapid aortic diameter increase (> 3 mm/year), BAV, hypertension, or aortic coarctation), we suggest that assisted reproductive technologies or spontaneous conception should be avoided (Θ◯◯◯).  

**R 4.35** We recommend tight blood pressure control to a target of less than 130/80 mm Hg during the peripartum period. Antihypertensive therapies and low dose aspirin for the prevention of adverse pregnancy outcomes due to preeclampsia and related hypertensive disorders should be administered according to current clinical practice guidelines (Θ⊕◯◯).
R 4.36 We recommend obtaining a TTE at least once during pregnancies in low-risk women (AHI < 20 mm/m, Z < 2.5, ASI < 2.0 cm/m$^2$ and no BAV, aortic coarctation, hypertension, or rapid aortic diameter increase), ideally around 20 weeks of gestation ( célibataire ⚫ ⚫ ⚫ ⚫).

R 4.37 In the presence of aortic dilation (AHI > 20 mm/m, ASI > 2.0 cm/m$^2$, or Z > 2.5) or at least one other risk factor (BAV, aortic coarctation, hypertension, rapid aortic diameter increase), we suggest TTE at least once every 12 weeks during pregnancy, or more frequently on an individualized basis. Consideration of an additional imaging study in the early third trimester is reasonable and is strongly encouraged if there is any concerning change noted on the second trimester TTE ( célibataire ⚫ ⚫ ⚫ ⚫ ⚫).

R 4.38 We recommend that CMR (without contrast medium) should be performed during pregnancy when TTE raises suspicion of rapid aortic dilation. If aortic segments previously known to be dilated cannot be adequately visualized, or if new dilation is suspected, CMR should be used for confirmation ( célibataire ⚫ ⚫ ⚫ ⚫ ⚫).

R 4.39 We suggest that rapid aortic diameter increase (> 3 mm compared to pre-conception imaging) should lead to renewed risk assessment and discussion in an expert center with a multidisciplinary team to determine potential modifications of maternal risk factors for aortic dissection, delivery, and postpartum planning, including consideration of prophylactic aortic replacement ( célibataire ⚫ ⚫ ⚫ ⚫ ⚫).

R 4.40 We recommend the mode of infant delivery should be based on the safest method to prevent aortic and obstetric complications, individual preferences, and local professional expertise. Preventive measures (epidural anesthesia, expedited second stage of labor) that reduce the risk of aortic dissection should be considered, but are especially recommended in the presence of aortic dilation (AHI > 20 mm/m, ASI > 2.0 cm/m$^2$, or Z > 2.5) or additional risk factors for aortic dissection (BAV, aortic coarctation, hypertension, rapid aortic diameter...
increase). Cesarean section is preferred for individuals with severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) or a history of aortic dissection (usaha).

R 4.41 We recommend postpartum cardiac imaging and cardiology consultation due to the continued risk of aortic dissection. For individuals with severe aortic dilation (AHI > 25 mm/m, ASI > 2.5 cm/m², or Z > 4) or a history of aortic dissection, the initial post-partum visit should occur 2-6 weeks after delivery with at least one additional follow up cardiology visit. For individuals with less severe aortic disease, one post-partum visit 4-6 months after delivery may be sufficient before resuming routine follow up intervals (usaha).

R 4.42 We recommend that individuals who can become pregnant and have left-sided obstructive lesions (subaortic stenosis, aortic valve stenosis, or coarctation) should have regular aortic imaging and cardiovascular follow up with consideration for intervention before pregnancy (usaha).

R 4.43 We recommend that individuals with severe subaortic or aortic valve stenosis or significant valve disease and reduced cardiac function should be advised against pregnancy (usaha).

4.12.1 Aortic dilation and dissection

In 2003, the first reports of serious cardiac complications and deaths of pregnant women with TS were published [466]. Initial estimates of maternal deaths due to aortic dissections during pregnancy were much higher than in more recent studies, probably because pre-pregnancy cardiac evaluations were performed less frequently in older cohorts [467-470]. There is no evidence that multiple gestations are a significant risk factor for aortic complications, although multiple pregnancies and multiple embryo transfers does lead to an increased risk of hypertension, which might contribute to dissection risk [471]. Cardiovascular demands of pregnancy are high due to increased cardiac output, stroke volume, heart rate, and plasma volume. The risk of
Aortic dissections may be increased during the peripartum period in TS 472-474. Assisted reproductive technologies were proposed to be a risk factor for aortic dilation or dissection, but recent studies did not show any difference in aortic complications 467. Several studies have shown that aortic dimensions do not change significantly during pregnancy 468, 469. In TS cases when the aorta is dilated, there are no studies that consider the advisability of elective aortic surgery before pregnancy. After proximal aortic repair, women with TS are still considered to be at high risk for aortic dissections.

4.12.2 Other cardiovascular conditions
Apart from the risk for aortic dissection, women with TS may have other cardiovascular abnormalities such as aortic valve stenosis or coarctation of the aorta that can impact the management of pregnancy and delivery. The hemodynamic consequences of stenotic BAVs, subaortic obstruction, and coarctation can be exacerbated by increased cardiac output during pregnancy. It is important to conduct a comprehensive evaluation before a patient becomes pregnant to identify potential risks and provide guidance for pre-pregnancy valve interventions, coarctation repair, or other necessary measures. It is also important to compare the potential risks associated with interventions, such as mechanical valve replacement necessitating warfarin therapy during pregnancy, to the risks of pregnancy without intervention. Although there is limited data on TS, a Registry of Pregnancy and Cardiac Disease (ROPAC) study clearly demonstrated that women with moderate to severe aortic stenosis can complete successful pregnancies without fatalities. However, some experienced heart failure and required medical interventions 475. The hemodynamic challenges during pregnancy are similar for those with subaortic stenosis 476. Pregnancy is generally well tolerated by women who have undergone aortic coarctation repair 497. However, individuals with unrepaired coarctation or those who have undergone repair and have hypertension, residual coarctation, or aortic dilation, have an increased risk for complications, including aortic dissection 478. Therefore, pre-pregnancy assessment and counseling should include complete aortic imaging and blood pressure control. Balloon dilation
of coarctation during pregnancy should be avoided in TS due to complication risks\textsuperscript{372}. Current guidelines recommend counseling against pregnancy only for symptomatic patients with severe aortic stenosis or asymptomatic patients with impaired left ventricular function or an abnormal exercise test\textsuperscript{478}. Otherwise, pregnancy appears to be well tolerated. The guidelines for care are similar to those for women with cardiovascular disease without TS\textsuperscript{478}.

4.12.3 Hypertension during pregnancy

Women with TS are at increased risk for hypertensive disorders of pregnancy, including pre-eclampsia\textsuperscript{479-481}. Pre-eclampsia in the general pregnant population is associated with several risk factors, including a family history of pre-eclampsia, nulliparity, older age, elevated BMI, pre-existing diabetes mellitus, chronic renal disease, antiphospholipid antibodies, multiple gestations, and pre-existing hypertension\textsuperscript{482}. Hypertension is more common in women with TS throughout the lifespan, which may contribute to the higher incidence of hypertensive complications during pregnancy.

Medical treatment to reduce cardiovascular risks comprises anti-hypertensive medications and prophylactic medications to prevent aortic dilation. Anti-hypertensive treatment recommendations do not differ from those for pregnant women who do not have TS. There is no clear evidence for prophylactic medication during pregnancy in women with TS who have aortic dilation and no support for a specific type of anti-hypertensive medication. Beta-blockers may be considered during pregnancy for women with aortic dilation (extrapolated from data for women with Marfan syndrome) and do not cause fetal abnormalities. However, decreased fetal birth weight may be associated with peripartum use of beta-blockers and fetal growth should be monitored\textsuperscript{483, 484}.

To prevent hypertensive disorders of pregnancy, it is recommended to start 75-81 mg aspirin daily beginning at 12 weeks of gestation until delivery. This recommendation is based on evidence that aspirin use may be beneficial to individuals who have two or more moderate risk factors for adverse pregnancy health outcomes, such as a first pregnancy, chronic hypertension, or kidney disease\textsuperscript{485}. While oocyte donation is not seen as a specific risk factor, it does confer a
2-3 fold risk of preeclampsia \(^{486}\) and aspirin should also be considered for TS pregnancies that result from oocyte donation \(^{487}\).

### 4.12.4 Delivery plan

A delivery plan should be made by a multidisciplinary team consisting of at least an obstetrician, cardiologist, and anesthesiologist with expertise in pregnancy in the context of maternal heart disease or arteriopathy. Vaginal delivery is the preferred mode of delivery in most women, based on the available literature. In ROPAC data, cesarean section was not superior to a vaginal delivery in terms of maternal outcomes, but an increase in adverse fetal events was observed \(^{484}\). Based on expert opinion, in women with a dilated aorta, a cesarean section is reasonable, although it also leads to hemodynamic changes. Aortic dissection during pregnancy is a life-threatening complication that requires emergent cardiovascular specialist care. If the dissection happens in early pregnancy without a viable fetus, emergency aortic surgery is recommended. If the fetus is viable, it is recommended to perform a cesarean section followed by emergency aortic surgery.

**GRADE Question 3: What are the effects of blood pressure treatment on clinical outcomes in TS?**

TS is often accompanied by hypertension, which has been linked to the development of aortic dilation or dissection, which are both observed with strikingly increased frequency in TS. Some experts have advocated for stricter blood pressure control in TS individuals. Therefore, two questions were formulated:

1. At what blood pressure threshold should hypertension in TS be treated?
2. What anti-hypertensive treatment is most effective in TS?
We searched for studies comparing different blood pressure targets and different blood pressure treatments. Randomized and non-randomized studies were considered; cohort studies without a control arm and case series were ineligible. Two systematic reviews of hypertension in pediatric (127 full texts) and primarily adult (63 full texts) TS case series were published in 2022. No comparative studies of specific antihypertensive treatments or blood pressure targets were identified in either review. Therefore, there is currently insufficient evidence to answer the GRADE question.
5. Transition

5.1 Importance of intentional and defined transition pathway

Adolescents and young adults (AYA) with chronic health care needs have high rates of complications during the crucial years of transition. Structured transition in AYA with chronic health care needs is shown to be beneficial in a number of specific situations, though data are mixed. Measures of transition success have not been well-defined or applied, and longitudinal studies have not been conducted. Data specific to the impact of transition process in the TS population are sparse, though one study showed lower loss to follow up in AYA with TS with organized transition.

5.2 Transition pathway elements

White, et al., 2018 define six core elements of health care transition (Figure 1 in), outlining pediatric and adult contributions, with input from various members of the health care team. This guideline includes a specific focus on youth with medical complexity, and outlines responsibilities of various transition team members. The transition team may include physicians, social workers, nurses, clinic administrators, information technology staff, and home care clinicians. Applying the doctrines of this core structure allows adaptation of its principles to each setting and everyone. The process begins with an introduction of the transition plan, tracks the progress through transition, applies assessment(s) of transition readiness, defines specific steps towards transition, completion of transfer, and confirmation of transition completion/success (Figure 7). Through this process, concise and clear written clinical summaries and educational materials may be used to empower families and address gaps based on the type of clinician that is coordinating the care for a given individual with TS. Efforts for hospital systems and/or payors to support a care coordinator for individuals with TS are crucial to guide navigation of the various health care system and payors, and to...
ensure completion of referrals and visits. Transition checklists are available via various
societies/organizations to ensure completion of essential elements. Future efforts could include
a list of talking points and/or suggested questions for individuals with TS to bring to their new
provider. Efforts should also be made to connect individuals with TS and their family to
advocacy groups during healthcare transition \(^{405, 489}\). In Europe many pediatric caregivers have
access to adult TS health care teams, and the European Reference Network (https://endo-
ern.eu/) supports coordination and collaboration between health care centers also across
borders.

R 5.2 We suggest a formal assessment of transition readiness at multiple timepoints of the
individual and/or caregiver/support person to identify specific needs and barriers to
successful transition (⊕◯◯◯◯).

5.3 Transition readiness tools

Given the numerous challenges noted in healthcare transition for adolescents and young adults
with TS, tools have been developed for assessment and ongoing monitoring of transition
readiness \(^{405, 498}\). Several general (non-disease specific) transition readiness tools have been
created, with variable psychometric properties \(^{499}\). The Transition Readiness Assessment
Questionnaire 5.0 (TRAQ) is a 20-item validated measure which is used to examine knowledge
and health-related skills (e.g., appointment-keeping, managing medications and daily activities,
communicating with providers) \(^{500}\). Studies have shown adolescent and young adults with TS
have lower TRAQ scores than those without TS \(^{501, 502}\). Another tool that has been used in
clinical research but not yet validated is the TS-specific transition tool provided by the
Endocrine Society (Table S8), which includes 10 questions about health, 16 about using health
care, and 15 focused on social and emotional factors salient to TS \(^{503}\). In addition to these
assessment tools, various TS teams have described educational materials they use to facilitate
healthcare transition for their TS population \(^{495}\) (Supplement table S9).
5.4 Limitations to transition readiness tools

Despite the potential benefits of using these transition readiness assessment tools, many limitations exist. There is a paucity of research examining a broad spectrum of health outcomes, including developmental and biopsychosocial outcomes (e.g., adherence, self-efficacy, QoL) based on transition readiness scores and/or use of these tools in AYA with chronic conditions. Most transition-related research in AYA with TS and other endocrine conditions has focused mainly on the number of follow-up appointments and/or drop-out of care. Further, whereas these tools have been designed to assess progress towards transition readiness over time, longitudinal studies have not been conducted. Additionally, perspectives of transition readiness may differ across informants – specifically, research in TS and other conditions has shown conflicting readiness scores reported by patients versus caregivers, and it is not clear how clinicians should address these discrepancies.

Identifying implementation strategies for these tools is also critical, as research has shown transition discussions are inconsistent (particularly regarding reproductive, lifestyle, and psychosocial factors) and that transition tools are not routinely used in TS care.

5.5 Barriers to successful transition

The identification of barriers to successful transition is challenging due to a lack of consistent measures of what constitutes transition success. In a systematic review, the most important barriers to successful transition across chronic illness groups were in the "relationship domain" (e.g., difficulties in letting go of long-standing relationships with pediatric providers), "access to adult services," "knowledge" (regarding medication/illness), and "insurance issues." There are aspects of care in individuals with TS that pose barriers to transition that are unique from other chronic conditions, such as lower visuospatial processing and self-esteem, and difficulties with executive functioning. Moreover, although 80% of all TS adolescents were 100% accurate in reporting their personal medical history in a US single center study, this accuracy was not an adequate surrogate for transition readiness. Transition readiness and/or success in individuals with TS seems to differ from other chronic
conditions, with distinct requirements including, but not limited to, individualization of transition timing, and a longer period of caregiver support may be necessary.

Indeed, a survey showed most women with TS 18-25 years of age still relied on their parents for both care and finances, though independence increased with age. Additionally, perspectives of AYA with TS and their caregivers often differ regarding readiness for independence, with TS individuals reporting a much higher readiness than their caregivers. While full emancipation may be delayed, a gradual shift in responsibility (e.g., having the adolescent make appointments, answer questions during clinic visits, and call for medical refills) should be encouraged. General guidelines recommend that transition begin between 12 and 14 years of age, yet developmental age is likely more relevant than chronological age in individuals with TS given the increased neurocognitive and psychosocial differences.

Systematic barriers are also important to consider and address as AYA with TS reach adulthood and need to establish an adult medical home. Gaps in care among adult women with TS are in large part attributed to the lack of specialized adult TS providers/centers. Future efforts within societies and advocacy groups that support TS care and education should seek to improve early exposure of trainees in various specialties and promote outreach/networking between societies (e.g., joint conferences).

5.6 Studies related to transition

R 5.3 We suggest that developmentally-appropriate organ systems-based assessment and counseling occurs during transition, ensuring that these elements are documented upon transfer.

R 5.4 We suggest that pediatric health care teams transition individuals with TS to adult providers with expertise to manage TS comorbidities.

Studies on the impact of transition interventions have been undertaken in a range of clinical settings, in different age groups, and with differing endpoints, limiting comparisons across studies. There is also a lack of a unifying definition of a “successful transition.” Interventions to
improve transition show variable results, and data on transition outcomes in individuals with TS is limited.

Several studies have focused on the impact of transition interventions on loss to follow up. In one study, there was no impact on the consistency of follow up after meeting the specific adult provider with whom individuals with TS would eventually establish adult care. A separate study assessed data in French women with TS with and without organized transition. In this study, a significantly greater proportion of those without organized transition were lost to follow up. Organized transition was defined as having been referred directly from pediatric endocrinology care, while those without organized transition were individuals referred by their general practitioner, gynecologists, or self-referred. A survey study regarding priorities of adult women with TS showed that they prioritized flexibility in scheduling, followed by having one provider overseeing all aspects of care. One suggested transition strategy emphasized the need for multiple medical visits for AYA with TS over months to years dedicated to transition preparation within either the pediatric or adult setting, with joint visits (with both a pediatrician and adult endocrinologist), or with alternating visits. To this point, adolescents (not only TS individuals) have reported that it takes at least four to five visits before they trust a particular doctor.

The transition process is likely optimized with the inclusion of a transition coordinator as a member of the healthcare team. The tasks of the transition coordinator could include assessment of transition readiness at multiple time points to aid in identification of barriers specific to that individual, educating patients and caregivers on the transition process (including with handouts specifying the transition roadmap and providing a checklist), providing guidance regarding health care system navigation (e.g., appointments, insurance, pharmacies, social security systems), and assisting with communication between pediatric and adult team, including facilitating appointments. A transition coordinator could also be responsible for compiling the document detailing specifics of care for the individual to ensure the transfer of a medical summary to the adult provider. For many adolescents with TS (as with other
multidisciplinary clinics), the inclusion of a psychologist to develop individualized transition planning and assessing readiness may be valuable. Some authors have advised group sessions to prepare for transition and independence. In France, a one-day therapeutic small-group program for AYA with TS utilizing workshops focused on various aspects of health has been developed, but the impact of this program is unclear. An ongoing study in non-TS adolescents with prospective RCT has been set up to investigate the benefits of comprehensive transfer programs, but the results are not yet available. No studies were found investigating the benefit of structured transition pathways specifically in TS on the rate of loss to follow-up, QoL, or other health outcome measures.

Age-appropriate, individualized screening practices are covered in other sections of this guideline. However, we suggest that the pediatric provider confirm the completeness of this screening prior to transfer (Table 14). The period of transition to adulthood is particularly important given the high rates of loss to follow up, complications, and lack of health care access and affordability in adulthood in certain parts of the world. For example, in many areas of the US specific services are either not available or not covered by payors for adults. This includes, but is not limited to, neuropsychological and audiologic testing, and access to occupational and speech therapies. Table 14 emphasizes selected areas that warrant particular attention around the time of transfer. Additionally, there is a paucity of specialized adult providers with experience caring for individuals with TS, and quality of care and detection of comorbidities improves with adequate adult care.

An accurate summary of the individual’s medical history is essential to a successful transfer, and copies should be provided to the patient, their caregiver (as indicated), the primary care provider, the TS adult healthcare provider, and any relevant subspecialists. As previously mentioned, the assistance of a transition coordinator for this task would be invaluable. Often, this task falls upon the pediatric TS provider, with input from the various pediatric subspecialists.
Given that social skills are often, though not always, reported as a concern in TS, programs to foster these skills may be useful prior to transition. Wolstencroft et al. report on a feasibility study that adapted the Program for Education and Enrichment of Relational Skills (PEERS) to provide an intensive eight-week online course to female adolescents with TS, 17-20 years, blended with some face-to-face group meetings. Parents and adolescents typically report improvements in social skills after taking part in social skills interventions. However, expectancy bias may influence their reports as an independent evaluation of their social behavior by teachers did not agree. The biggest improvement noted was a gain in confidence. The PEERS program also has modules targeted towards career building skills. Whether this program has an impact on social and/or vocational relationships in TS remains to be determined. Social skill difficulties can also impact romantic relationships and sexual experiences. A study of first romantic and sexual experiences in the DSD Life Study showed that amongst all participants, those with TS showed the oldest debut age of sexual activity amongst individuals with DSD. Compared with individuals with premature ovarian insufficiency, individuals with TS showed a delay in median age at first relationship, irrespective of the age at start of estrogen treatment (below or above 14 years of age). Further, fewer women with TS had ever had sexual intercourse, and those who did were older at first intercourse. Thus, while all TS morbidities must be addressed prior to transfer, we suggest paying particular attention to guidance in sexual development and support in psychosexual wellbeing (see also Section 8).

Various healthcare transition models exist, ranging from adult and pediatric providers working within an integrated health care system, to completely separate settings/health systems and no structured hand-off process. While the availability of providers and resources often dictate transition, the type of physician consulted has been associated with adequacy of follow-up and screening. Endocrinologists are noted to complete more of the recommended testing than gynecologists or general practitioners. Notably, only 4% of adult women with TS undergo all recommended routine health care assessments.

Much of the transition literature highlights the need to identify local adult providers with expertise in TS to optimize care in adulthood. However, it is important to recognize that the
“optimal” healthcare transition plan is frequently not a reality. A recent national survey in the US showed that endocrinologists and cardiologists were the most frequently visited providers among adult women with TS, yet almost one-third stated they were not seeing an endocrinologist or cardiologist, more than half were not seeing a gynecologist, and less than a quarter were seeing a psychosocial provider. Transitioning care to an adult TS team may not be feasible in many centers and regions due to lack of access to specialists who have knowledge and training in TS care and/or inadequate funding to support streamlined transition processes and resources. In this context, it has been suggested that pediatric endocrinologists should take the lead in preparing adolescents with TS for healthcare transition in collaboration with gynecologists (with a focus on estrogen therapy and reproductive health). This team provides a structured “handoff” to a team to include an adult endocrinologist and a gynecologist. Additional adult specialists, such as cardiologists, should be involved, and the transfer details should include a summarized cardiac assessment for the adult cardiologist. Psychosocial counseling and support are critical to optimize QoL during the healthcare transition, though studies show that few individuals with TS report following with a psychosocial provider. Institutional/hospital boards should aim for the minimum standard of an adult endocrinologist and cardiologist as part of healthcare teams for care of adult TS women.

5.7 Cost-benefit analysis of not providing appropriate care during adulthood

Morbidity and mortality in adults with TS are well-described, with a life-long requirement for regular medical care and surveillance. Consistent screening and detection of comorbidities is inadequate in this population, and there is a high rate of inconsistent medication administration. The cost-benefit analysis of improving surveillance, and therefore diagnosis, of comorbidities in individuals with TS remains to be determined.
6. Fertility

R 6.1 We recommend developmentally appropriate disclosure of the potential for reduced fertility in individuals with TS. We recommend disclosing that the probability to conceive is primarily associated with the presence of a 46,XX cell line and spontaneous menarche, and that there is increased risk of maternal and fetal complications in pregnancy compared to the general population (◯◯◯). 

R 6.2 We recommend counselling by the primary care provider, pediatric endocrinologist or gynecologist as early as possible after diagnosis of TS, as appropriate, regarding family building options such as fertility preservation, foster care, adoption, surrogacy, egg or embryo donation or the choice to remain childless (◯◯◯). 

R 6.3 We recommend offering a referral to a fertility specialist with knowledge of TS-specific care to all individuals with TS (or their parents/guardians, when developmentally appropriate), at the time of diagnosis and intermittently over time (◯◯◯). 

R 6.4 We recommend offering AMH measurements to all individuals with TS from diagnosis. AMH should be monitored annually if fertility preservation is considered, along with pre- and post-test fertility counselling. Isolated AMH measurements are influenced by several factors, including age and pubertal stage, with known intra-individual variability and variation in test accuracy. The utility of AMH to predict ovarian reserve in younger age groups is uncertain (◯◯◯). 

6.1 Introduction 
Due to ovarian insufficiency, most individuals with TS are infertile, with spontaneous pregnancies occurring in about 10% 11, 468, 519-522. Many individuals with TS identify fertility concerns as among the most distressing aspects of living with TS, ahead of short stature, lack of sexual development during adolescence, and fear and uncertainty regarding the long-term effects of GH and HRT. Distress associated with infertility may persist even beyond typical
childbearing years, representing a lifelong challenge for individuals with TS. A range of potentially conflicting values and beliefs may affect TS individuals’ goals for fertility. For example, though many individuals with TS endorse a desire for biological children and pregnancy, concern about the negative impact of pregnancy on cardiovascular health may cause some individuals with TS to forgo fertility preservation options.

Infertility may also affect the psychological profile of individuals with TS, and has been associated with depressive symptoms in those with TS and premature ovarian insufficiency. Infertility may be a barrier to intimate relationships. Despite having normal sex drive/libido, individuals with TS are less likely to be married or in relationships as compared to women of the same age. The perception of being unable to participate in one of the primary functions of a long-term relationship – parenthood – may drive feelings of inadequacy among individuals with TS.

6.2 Fertility assessment, monitoring and counseling
Patients with TS are at risk of premature ovarian insufficiency due to rapid loss of ovarian follicles. As a result, discussions of options for fertility preservation for appropriate individuals should occur with parents of affected girls at early ages. Counseling about future options for family building should be provided by physicians experienced in caring for patients with TS, and should include fertility preservation, fertility treatment and alternative approaches to family planning, such as use of donor oocytes, adoption, fostering and the choice not to have children. Counseling should be revisited from time to time to optimize the chance of successful fertility preservation, when appropriate. To advance care and facilitate decision-making surrounding fertility preservation, we propose a set of critical information to guide the discussion (Table 15).

The risks and benefits of all options should be discussed thoroughly prior to pursuing fertility preservation to allow parents and patients make an informed decision. Physicians and caregivers must consider the ethical implications of fertility preservation or fertility treatment prior to initiating this care (see ethics section below).
The key predictive factors associated with the probability of spontaneous conception are a history of spontaneous menarche, and a 45,X/46,XX karyotype. Accurate characterization of even low-level chromosomal mosaicism by assessing two cell lines (lymphocytes and buccal cells) may help to more precisely estimate fertility potential.

Findings that may be associated with an increased likelihood of identifying follicles in the ovarian cortex include (1) mosaic karyotype with a 46,XX cell line, (2) spontaneous puberty, (3) measurable AMH or (4) FSH < 10 IU/L.

AMH reflects the primordial follicle pool and predicts the reproductive lifespan of women as a key biomarker of ovarian reserve. In individuals with TS, AMH is associated with clinical features of ovarian reserve and has the strongest positive correlation with the presence of follicles in ovarian cortex tissue. However, AMH concentrations can vary in the same patient due to inter-test and biological variability, and heterogeneity exists in available AMH assays and detection levels. Therefore, interpretation of AMH for counseling should be used with caution and in combination with other markers. Longitudinal AMH measurements on an annual basis or more frequently if indicated, provide a more accurate estimate of the ovarian reserve than individual values and may show a trend over time. AMH can be utilized to provide an assessment of individual risk of premature ovarian insufficiency regardless of karyotype or menarche status.

Following spontaneous conception, miscarriages are more frequent in individuals with TS compared with the background population: 29%-48% versus 15%. Pregnancies in individuals with TS are associated with a higher risk of maternal and fetal complications as are pregnancies after oocyte donation in both TS and non-TS individuals. Sex chromosome abnormalities may be more common in the pregnancies of individuals with TS.
Data are inconsistent regarding the risk of birth anomalies, which are reported in 0–24% of spontaneous TS pregnancies compared with ~3% in the background population \(^{11, 468, 519, 520, 544, 549}\). Reported anomalies include cerebral palsy, neuropsychological disorders, cleft lip and palate, coarctation of the aorta, ambiguous genitalia, hydrocephalus as well as trisomy 21 \(^{11, 520, 521}\). The odds of a preterm birth and small-for-gestational-age of infants born to individuals with TS compared with women in the general population are 3-fold and 5-fold greater, respectively \(^{550}\). Caesarean section rates in large TS cohorts are higher (35.6%) compared with the background population (12%) \(^{519, 549}\). The risk of developing preeclampsia is 6.3%–11% in TS vs. 3% in the general population \(^{468, 519, 549}\).

### 6.3 Fertility preservation

**R 6.5** We recommend thorough cardiac screening and appropriate counselling by a maternal–fetal medicine specialists and cardiologists with expertise in managing women with TS prior to planning a pregnancy, especially if oocyte or embryo donation is considered. (⁺⁺⁺⁺⁺)

**R 6.6** We recommend controlled ovarian stimulation and oocyte cryopreservation, in females with a fertility potential, as the primary fertility preservation option in post-menarche individuals of appropriate psychological maturity, in centres with sufficient expertise in managing women with TS and the availability of psychosocial support (⁺⁺⁺⁺⁺).

**R 6.7** We recommend that controlled ovarian stimulation and oocyte cryopreservation not be offered to premenarcheal children or individuals not mature enough to understand and undergo the procedure (⁺ₒₒₒ).

**R 6.8** We recommend in all TS, including minors who cannot make their own decision, that ovarian tissue cryopreservation only be offered in the context of an institutional/ethics board approved research study or with clinical ethics board approval (⁺ₒₒₒ).
The current options for fertility preservation in girls with TS are cryopreservation of oocytes retrieved following ovarian stimulation with exogenous gonadotrophin analogues, and ovarian tissue cryopreservation (OTC) retrieved following a laparoscopy. Cryopreservation of oocytes is preferentially offered to TS adolescents who experienced spontaneous menarche and are psychologically mature enough to understand and undergo the procedure of ovarian hyperstimulation and oocyte retrieval. This rules out around 85% of patients, because they face primary ovarian insufficiency before that time, leaving OTC as the only option for the majority. The success rate of pregnancy of using cryopreserved oocytes or OTC is unknown, because there is only one reported live birth after use of cryopreserved oocytes and one recorded pregnancies after OTC in TS.

6.3.1 Oocyte cryopreservation

Ovarian stimulation and oocyte cryopreservation is an established method of preserving fertility in adults, and oocyte cryopreservation is no longer considered experimental for adolescents and young adults undergoing gonadotoxic therapy. However, the utility of oocyte cryopreservation in individuals with TS who have underlying ovarian insufficiency is unknown. To date, published data regarding oocyte cryopreservation in individuals with TS entails 6 retrospective studies and 8 case reports comprising a total of 80 individuals ranging in age from 7 to 30 years. Individuals with mosaic TS are more likely to have spontaneous puberty, normal gonadotropin levels, a measurable AMH, and follicles in ovarian biopsies as compared to those who have monosomy X karyotype. While these factors have been proposed as predictors of successful oocyte cryopreservation, discrepancies remain. In one retrospective study to date Martel at al. found that age, karyotype and FSH had no correlation with the number of vitrified oocytes, while in the largest retrospective study to date Nadesapillai et al. reported that the percentage of 46, XX cells, FSH, AMH and antral follicle count had a significant correlation with...
the cumulative number of vitrified oocytes. While the successful cryopreservation of mature oocytes has been reported in a greater proportion of individuals with TS with mosaic karyotypes, there are also reports of oocyte vitrification in individuals with monosomy X, including cases with a decreased AMH. It is important to keep in mind that those with monosomy X could still be fertile enough to undergo ovarian stimulation successfully or become pregnant spontaneously, as a wide variation is seen between karyotype in peripheral cells and ovarian cells. Therefore, oocyte vitrification may also be considered in those with monosomy X and sufficient ovarian reserve. TS individuals who have sufficient ovarian reserve to store oocytes are also more likely to be able to conceive spontaneously. Recent publications describe oocyte preservation in minors; the youngest girl was 7 years old. Whether girls who are not competent to understand the physical and mental impact of the procedure should be exposed to such an intervention is debatable, especially if multiple treatment cycles are required for a higher number of oocytes. Because there are no data on the psychological impact of oocyte vitrification in prepubertal girls, mental well-being of this vulnerable group deserves special attention and responsibility from healthcare providers during counseling.

In individuals with threats to ovarian reserve such as oncological patients and those with endometriosis, cumulative live birth rate after oocyte cryopreservation is associated with the number of vitrified oocytes. In general, 10 to 20 oocytes are needed for one live birth in non-TS individuals less than 35 years old. In individuals with TS, the number of oocytes needed for one live birth is expected to be significantly higher due to the high aneuploidy rate in ovarian cells, the increased risk of miscarriage and chromosomal abnormalities in offspring. Therefore, care should be taken in counseling individuals with TS and their families as the optimal number of oocytes required for a successful live birth is still unknown.

6.3.2 Ovarian tissue cryopreservation

Although, OTC is an established procedure for women facing gonadotoxic therapy, little is known about its utility in conditions when a chromosomal abnormality that is associated with underlying ovarian dysgenesis such as TS is present. The current knowledge on OTC in TS...
consists of 4 cohort studies and 4 case reports, involving a total of 185 TS-patients with ages varying between 3 and 22 years \(^{263, 539, 542, 574}\). Borgström et al. performed laparoscopic ovarian biopsies in 57 patients; in 15/57 girls (26\%) follicles were observed. Nadesapillai et al. performed a unilateral ovariectomy in 93 patients; in 30/93 (32\%) follicles were found \(^{263, 542}\). Both prospective cohort studies did not exclude TS patients based on karyotype, hormone concentrations or age, since predictive parameters on finding follicles had not been established by larger prospective studies. Mamsen et al. studied retrospectively histology sections of 15 TS patients who underwent OTC and in 9/15 patients (60\%) follicles were found \(^{539}\). Patients with a mosaic karyotype have the highest prevalence of follicles, respectively 67-100\% \(^{263, 539, 542}\). Furthermore, in 3 of 4 case reports follicles were found in cases with a mosaic karyotype \(^{560, 575-577}\). The odds of finding follicles in patients with a structural X chromosome aberration or a 45,X/47,XXX karyotype is 23\%-44\% and with a 45, X karyotype 4\%-11\% \(^{263, 539, 542}\).

Spontaneous puberty has a significant positive correlation with the presence of follicles \(^{263, 539, 542, 578}\). Follicles were found in 58-86\% of girls with spontaneous thelarche, 62-86\% with spontaneous menarche and in 10\% without spontaneous onset of puberty. No correlation was observed between age and follicle density in the ovarian cortex tissue \(^{542}\). Ovarian reserve declines as women ages and it could be expected that the younger the girl, the higher the odds of having follicles. The fact that this correlation could not be observed, could be explained by the small sample sizes of the study.

An FSH <10 IU/L has a positive correlation with the presence of follicles. Follicles were present in 50-100 \% of TS girls with FSH < 10 IU/L (including prepubertal girls) \(^{263, 539, 542}\). However, FSH < 10 IU/L in prepubertal girls should be interpreted with caution, as this hormone is physiologically low at this age.

The mean follicle density in TS ovarian tissue is considerably lower than the density of age-matched controls \(^{570, 579}\). Additionally, an aberrant follicle morphology of up to 30-67\% was observed in TS ovaries \(^{539, 569}\). This means that only a part of the already limited follicular reserve in girls with TS is likely to be functional for fertility purposes.
Long-term follow-up will be required to assess outcomes of OTC in TS. However, in vitro studies in mosaic girls have been encouraging. They showed that most oocytes had a normal X chromosomal content, while granulosa and ovarian stromal cells were mainly aneuploid. The functional potential of cryopreserved ovarian tissue of girls with mosaic karyotype was evaluated in a murine xenograft model. Despite the presence of a large content of aneuploid granulosa and stromal cells, primordial follicles underwent normal follicular development until antral stages. The follicle density of xenografts from ovaries of prepubertal girls with TS was significantly higher than that of pubertal girls with TS and was comparable to that of age-matched controls. This supports the theory that prepubertal girls with mosaic TS could have a more promising outcome after ovarian tissue transplantation (OTT) than pubertal girls.

However, initial ovarian reserve in girls with TS is already limited, while the follicular loss after OTT is more than 50%, due to ischemia in in transplanted tissue during the first days after the procedure. In this light, it is questionable whether the follicle density after OTT in girls with TS would be sufficient to achieve pregnancy.

Based on these findings, OTC could be an option for TS patients with favorable predictive factors, such as mosaic karyotype, spontaneous puberty, and detectable AMH and / or FSH < 10 IU/L. Because data after OTC in TS are lacking, it remains an experimental procedure and should only be offered under research and clinical ethics board approval. Caution should be taken when counselling girls and their parents to avoid unrealistic expectations regarding the success rate of OTC and OTT. In the future, if options for in vitro maturation or rescue therapies of the initial accelerated follicular loss become available, OTC could become a more promising option for TS girls.

6.4 Non-autologous gametes (oocyte and embryo donation) and gestational carriers

Both oocyte and embryo donation, as well gestational carriers are alternatives in family planning for individuals with TS. All these treatments require a dedicated team with special expertise in TS, fertility and cardiological management before and during pregnancy and should not being offered in centers without this complex expertise. Single embryo transfer is strongly
recommended because of the higher risk of complications, particularly cardio-vascular complications during pregnancy. The maternal deaths reported in TS have been in oocyte donation pregnancies when IVF practitioners were unaware of TS implications. Pregnancy complications are more common after oocyte donation compared to autologous IVF or spontaneous pregnancies.

6.5 Ethical considerations

R 6.9 We suggest that clinical teams employ shared decision making when addressing fertility preservation and treatment for individuals with TS (Ungraded Good Practice Statement).

6.5.1 Beneficence

As discussed above, significant distress accompanies infertility for many individuals with TS and their parents/guardians. Individuals with TS may derive comfort from learning about fertility preservation options through consultation with knowledgeable providers and the associated sense of having explored all possible options for future fertility.

Early referral for fertility preservation - including for pre-adolescent or adolescent individuals with TS - might improve outcomes and allow time to consider goals/implications and the possibility of fertility preservation. Because timing of follicular atresia for any individual is difficult to predict, there are no standardized approaches to referral for fertility preservation among pediatric providers, beyond referring only those who have spontaneous puberty. While likely not eligible for oocyte cryopreservation, individuals without spontaneous puberty may benefit from expert counseling about the range of options for family planning, such as oocyte and embryo donation, use of gestational carrier, adoption, and the choice not to have children.

6.5.2 Nonmaleficence

For pediatric clinicians, reducing harm includes acknowledging unique barriers to utilizing fertility preservation procedures for children and adolescents. These include: the relative
dearth of physicians with expertise in pediatric fertility care; the difficulty of assessing future family building goals for younger patients; and concerns about pre-adolescent/adolescent patients’ ability to tolerate interventions such as ovarian stimulation or transvaginal oocyte retrieval. Before proceeding with treatment, adult and pediatric clinicians should communicate clearly about the difficulty of anticipating success and limited data on long-term outcomes of fertility preservation for patients with TS, as well as the possible health risks and complications with fertility treatment. Biochemical screening with AMH may allow physicians to set some expectations for the likelihood of successful oocyte retrieval prior to referral, avoiding “false hope” for patients and families. Patients interested in utilizing autologous oocytes should be counseled on the apparent increased risk of pregnancy loss or birth defects and of X chromosome abnormalities being transmitted to the fetus.

Patients should be counseled about the potential availability of prenatal genetic diagnosis and pre-implantation genetic diagnosis or screening, but that this approach may be limited by the number of oocytes received with ovarian hyperstimulation or if IVF is not successful. Whether conceiving with autologous or donated oocytes, patients must be counseled regarding increased pregnancy-associated morbidity and mortality including cardiac risks (see section on cardiovascular issues). A realistic estimate of pregnancy-associated health risks must be balanced with individual patient goals, given significant fears about health consequences of pregnancy among patients with TS. This counseling may result in grief and hardship. Behavioral health support through multidisciplinary teams may help patients manage emotional hardship associated with this counseling, undergo healthy mourning in processing infertility and provide support during fertility preservation or treatment if they are pursued.

6.5.3 Autonomy

Patients who are pre-adolescents or adolescents at the time of decisions about fertility preservation may be too young to discuss future goals for family building, to understand the impact of infertility or to give informed consent for fertility preservation procedures. Nevertheless, the child’s opinion - and assent - should be sought and due consideration given to
her concerns. In order to ensure that patients are as informed as possible, clinicians should focus on providing developmentally appropriate information on TS and ovarian function, information about fertility preservation procedures, assessing the patient’s understanding of the care and her willingness to accept it \textsuperscript{532, 588}.

Decisions about fertility preservation for pediatric patients may fall in the zone of parental discretion, in which parents attempt to act in the best interest of the child. The physician’s role is to ensure the patient’s needs are considered alongside parent/guardian priorities, and effort is made to encourage communication between patients and their families \textsuperscript{532, 583}. Clinicians should also be sensitive to socio-cultural or family norms that may inform the parents’ responses to the discussion as referenced earlier (Section 3.1).

6.5.4 Justice

Issues of justice arise because both fertility counseling and preservation consume health care resources. Patients and families should be counseled on the possibility of being unable to utilize cryopreserved oocytes and/or ovarian tissue because of health concerns related to pregnancy, or lack resources for storage or fertility treatment \textsuperscript{589}.

Fertility preservation/treatment may or may not be covered by health insurance or government-funded healthcare, which may mean that these services are prohibitively expensive to patients and families with limited financial resources. Evidence-based fertility preservation techniques should still ideally be made accessible to all patients who have a reasonable chance of benefiting from them, and decisions should be left to the family \textsuperscript{532, 583, 588}. 
7. Health surveillance for comorbidities throughout the lifespan

7.1 Newborn and infant care

R 7.1 We recommend delivery of a fetus with known or suspected TS occur in a facility equipped to provide neonatal care (◯◯◯◯).

R 7.2 We recommend a comprehensive physical examination with particular attention to hip stability and lymphedema, echocardiography, and renal ultrasonography be obtained regardless of prenatal imaging results, ideally prior to discharge (◯◯◯◯◯).

R 7.3 We recommend monitoring pre-feeding blood glucose levels in the first 48 hours of life and ensure that the infant is euglycemic prior to discharge. We suggest heightened awareness for symptoms of hypoglycemia in the early years of life (◯◯◯◯◯).

R 7.4 We recommend counseling on, and monitoring for, feeding difficulties and poor weight gain in the first year of life, with collaborative evaluation and treatment by the primary care provider and/or specialists based on the concern and available resources (◯◯◯◯◯).

R 7.5 We recommend expectant and new parents/caregivers be offered genetic counseling, referred to specialists in TS care, and be provided resources for local support and advocacy groups (◯◯◯◯◯).

7.1.1 Neonatal Morbidity and Mortality

Incidental prenatal identification of TS is increasing, necessitating consideration of perinatal recommendations. Rates of prematurity (birth <37 weeks’ gestation) are similar or only slightly higher than the general population (10-19%), with extreme prematurity uncommon 356, 590, 591. However, TS may be associated with a higher infant mortality, with studies reporting 10-16 times greater mortality infants with TS compared to the general population 356, 592. Similarly, several studies have reported 2-3-fold higher mortality in neonates with TS with hypoplastic left
heart (HLH) compared to all cases of HLH, suggesting an independent risk of TS to mortality \(^{593-595}\). In the absence of HLH, the 5-year survival of infants born with TS is \(\sim 95\%\) \(^{592,596}\). One study suggests that infants with TS were hospitalized more frequently in the first year of life than infants without TS \(^{592}\). Although more clarity is needed on the causes of neonatal morbidity and mortality, we suggest planning delivery of a fetus with prenatally identified TS in a facility equipped to provide appropriate care for neonates.

7.1.2 Postnatal Evaluation

Although many complex congenital anomalies can be identified through prenatal imaging, several conditions may not be apparent until after birth. Therefore, evaluation of the neonate with known or suspected TS should include a comprehensive physical examination, confirmatory chromosome analysis and echocardiogram ideally prior to discharge from hospital (see 4.9-4.10). Renal ultrasound and hearing screen should also be obtained in the neonatal period.

7.1.3 Feeding

Approximately one-third of infants with TS are born small for gestational age (SGA), though the degree of SGA is typically mild \(^{590,591}\), but can be up to 600-1000 grams lighter \(^{59}\). Inadequate weight gain is common, with estimates of up to half of all infants with TS experiencing failure to thrive \(^{1}\). High arched and narrow palate, hypotonia, poor coordination, and delay in oral-motor skills can all contribute to feeding and/or swallowing difficulties in infants with TS \(^{597}\). While there are no TS-specific treatment recommendations, anticipatory guidance and proactive intervention are desired \(^{597}\).

7.1.4 Hypoglycemia

Recently, an association between TS and hyperinsulinemic hypoglycemia has emerged \(^{598-602}\), postulated to be due to haploinsufficiency of the gene \(KDM6A\) \(^{601}\). In approximately half of the reported cases of hyperinsulinemic hypoglycemia, low blood glucose first presented within the
first 24 hours of life; however, the diagnosis was made as late as one year of age. In addition, many neonates with TS will have other risk factors for hypoglycemia including prematurity, SGA, poor feeding, and CHD. Neonates experiencing hypoglycemia may be asymptomatic or have subtle symptoms including irritability, jitteriness, lethargy, hypotonia, tachypnea, poor feeding, and apnea. Prompt recognition and treatment of neonatal hypoglycemia is critical to decrease the risk of adverse neurologic outcomes. Therefore, we recommend universal pre-feeding blood glucose monitoring during the first two days of life in all neonates with TS. If blood glucose (BG) is <2.8 mmol/L (50 mg/dL) between 24-48 hours of life or BG < 3.3 mmol/L (60 mg/dl) at or after 48 hours of life, evaluation and treatment of neonatal hypoglycemia should be pursued as recommended by relevant national guidelines in any infant with hypoglycemia. A high level of suspicion for hypoglycemia should be maintained in all young children with TS, particularly during periods of prolonged fasting or in settings of inadequate weight gain or poor oral coordination. Other symptoms that should raise concern for hypoglycemia include a history of episodic tremor, sweating, paresthesia, tingling, confusion, loss of consciousness, seizures, coma, and/or transient focal neurologic deficits.

7.1.5 Caregiver counseling
Expectant parents are faced with many unknowns when they receive prenatal genetic counseling about TS. Information and support needs before and after birth will be different. Resources including, but not limited to genetic counseling, consultation with medical specialists in TS, and TS support and advocacy contacts may help caregivers during this potentially vulnerable time.

7.2 Ophthalmologic health

R 7.6 We recommend a comprehensive ophthalmologic examination between 6 and 12 months of age, or at the time of diagnosis if older.

R 7.7 We recommend follow-up ophthalmologic examinations if the initial examination is...
abnormal or if new visual or ocular concerns arise (⊕⊕○○).

Strabismus occurs in up to 25% of individuals with TS, and refractive errors such as hyperopia, myopia, and astigmatism affect ~40% 604-607. Congenital and acquired glaucoma and cataracts are also more prevalent in TS than the general population, with risk ratio estimates ranging from 3-6 607. Ptosis is noted in 2-21%, epicanthal folds in 2-35% and congenital nystagmus in 2-9% 604-606. Color blindness has previously been reported to be similar to the prevalence in males (8%)604, however a more recent study found colorblindness in only 1% of all individuals with TS 605. Early identification and treatment of glaucoma, cataracts, strabismus, and refractive errors are important to prevent amblyopia and vision loss. These serious eye conditions can be easily missed on routine medical or vision assessments, therefore comprehensive ophthalmologic examination is warranted.

7.3 Otologic health

R 7.8 We recommend otoscopy evaluation for detection of middle ear disease, including effusion and cholesteatoma, annually in childhood and with symptoms (⊕⊕○○).

R 7.9 We recommend newborn hearing screening be completed, and if this is normal, age-appropriate behavioral audiometric evaluation be conducted every 2-3 years in childhood and adolescence starting as soon as developmentally able (1-2 years of age), every 5 years in adults, and any time decreased hearing is suspected (⊕⊕⊕○).

R 7.10 We recommend annual tympanometry up to 5 years of age where clinically available (⊕⊕○○).

R 7.11 We recommend antibiotic treatment should be administered for acute bacterial otitis media per local treatment guidelines (as for a high-risk population) and a repeat examination should be done to ensure resolution (⊕⊕○○).

R 7.12 We suggest placement of tympanostomy tubes at the early stages of chronic or
recurrent middle ear disease in childhood (as for a high-risk population) \( (\bigoplus \bigoplus) \).

**R 7.13** We recommend rapid intervention with tympanostomy tube insertion or hearing aids for conductive hearing loss due to middle ear disease in childhood \( (\bigoplus \bigoplus) \).

**R 7.14** We recommend rehabilitation with hearing aids or cochlear implantation for sensorineural hearing loss \( (\bigoplus \bigoplus) \).

**R 7.15** We recommend counseling on, and monitoring for, balance and vestibular problems in adults with sensorineural hearing loss, and referral to appropriate specialists for vestibular testing and compensatory training if concerns are identified \( (\bigoplus \bigoplus \bigoplus) \).

---

1. Hearing loss affects 36-84% of individuals with TS and negatively affects QoL and well-being \(^{261, 608, 609}\). TS is associated with both conductive and sensorineural hearing loss \(^{610, 611}\). While adults can often self-identify a decline in hearing ability, 75% of children with TS identified to have hearing loss reported no concerns prior to screening \(^{612}\). Craniofacial abnormalities, history of middle ear disease, aortic anomalies, metabolic syndrome, and age have all been associated with hearing loss severity and progression in TS \(^{607, 610, 613}\). Karyotypes 45,X, 45,X/46,iso(X), and ring X appear to be at the highest risk, however the incidence rate for ear and hearing diagnoses is 35-fold higher in all TS karyotypes combined compared to the general population \(^{590, 607}\).

2. Because of the high risk of hearing loss, universal behavioral audiometric evaluation (e.g. visual reinforcement audiometry, play conditioned audiometry, pure tone audiometry) should be performed throughout the lifespan, although low-risk adults with normal hearing evaluations and no hearing concerns may not require ongoing screening.

3. The pathophysiology of ear disease in TS is multifactorial. The *SHOX* gene is involved in the maturation of the pharyngeal arches into external ear, middle ear and pharyngeal structures.
The external ear malformations observed in 20–62% of individuals with TS, including low-set ears, cupped auricles or narrowing of the external ear canal can largely be explained by SHOX haploinsufficiency. Additionally, abnormal craniofacial development in TS leads to a less pronounced slope of the Eustachian tube, and muscular hypotonia impacts function of the soft palate and Eustachian tube opening. This negatively affects the drainage of the middle ear and facilitates intrusion of microorganisms from the nasopharynx, resulting in a higher risk of middle ear effusions and infections. In addition to these anatomical differences, reduced expression of the *UTX* gene is associated with impairment of the T-cell mediated immune response and chronic viral infections. Finally, estrogen deficiency may contribute to sensorineural hearing loss as supported by studies of inner ear pathology in estrogen receptor beta knockout mice, although evidence in humans is lacking. Neither estrogen nor GH therapy has been associated with ear disease or hearing loss in TS.

From early childhood through adolescence, persistent middle ear fluid and recurrent acute otitis media are common (24–48%) in TS. Recurrent otitis media in early childhood has been shown to be a strong predictor of future middle ear pathologies, including tympanic membrane perforations and scarring, retractions, and cholesteatoma. Furthermore, middle ear fluid is often accompanied with conductive hearing loss that is not clinically recognized, particularly in infants and young children. Even mild to moderate hearing loss can negatively affect language development as well as cognition, behavior, and QoL in at-risk children. Therefore, prompt identification and treatment of persistent middle ear fluid and recurrent acute otitis media in children with TS is needed. Otoscopy and tympanometry can identify middle ear disease with or without associated hearing loss. While not studied in TS specifically, pneumococcal vaccination, tympanostomy tubes and/or hearing aids may have to be considered at younger ages than in the general population, with the goal of normalizing hearing and preventing middle ear disease complications.

Sensorineural hearing loss affects around one third of all individuals with TS and can occur even in the absence of preexisting middle ear pathology. The prevalence of sensorineural hearing...
loss in TS increases with age, however children can also be affected. A mid-frequency dip is an early sign, followed by early onset presbycusis-like high frequency loss. This combination has a notable effect on hearing speech, therefore hearing aids are often beneficial. Progression to severe hearing loss is less common but does occur, in which case rehabilitation with cochlear implantation may be necessary. Sensorineural hearing loss is also known to be accompanied by decreased vestibular functioning, impacting balance, and increasing the risk for falls. Indeed, individuals with TS have been found to have poorer balance and fine motor skills related to hearing ability. Vestibular function testing should be considered in individuals with TS and significant sensorineural hearing loss, particularly if also accompanied by low BMD due to the higher risk of fractures.

7.4 Dental and orthodontic health

R 7.16 We recommend at least annual dental care from first tooth eruption throughout the lifespan, with particular attention to periodontal health (★★★★).

R 7.17 We suggest orthodontic evaluation after permanent tooth eruption for initial consultation and anticipatory management (★★★★★).

R 7.18 We suggest screening for obstructive sleep-disordered breathing through history and/or validated instruments throughout the lifespan (★★★★★).

Dental and periodontal problems in TS include reduced tooth crown height (predominant finding), alteration in tooth morphology and root size, bifurcated and supernumerary roots, increased root resorption, increased tooth mobility, early tooth loss, smaller primary and permanent teeth, thin hypoplastic enamel, abnormal dentin, variation in eruption patterns and periodontal disease. Dental maturity is often advanced because of shorter length of the roots and earlier root formation. Amelogenin, the gene encoding human enamel protein located on Xp22, is expressed on both sex chromosomes, explaining the thinner and hypoplastic
enamel observed in TS. While caries may be less prevalent, periodontal disease such as gingivitis appears to be more common\textsuperscript{624}.

Craniofacial anomalies are common in TS. Underdevelopment of several facial structures, an increased cranial base angle, a small and narrow mandible, maxillary hypoplasia and retrusion, high-arched and narrowed palate, micrognathia, malocclusion, bilateral crossbite and ectopic tooth eruption have all been described\textsuperscript{626, 627}. GH treatment has been shown to have a positive impact on craniofacial dimensions; however it does not correct the proportional and positional anomalies in TS\textsuperscript{628}. Dental extractions, palatal expanders and orthodontia are often indicated. In addition to contributing to feeding problems in infancy, these anatomic differences can result in a smaller pharyngeal airway space, predisposing individuals with TS to upper airway resistance, sleep disordered breathing, and obstructive sleep apnea\textsuperscript{629}. Observational studies suggest higher rates of sleep disorders in TS even in very young children\textsuperscript{369, 607, 630}. While there is insufficient evidence to recommend formal polysomnography for all individuals with TS, inquiry for symptoms and/or use of validated questionnaires to screen for sleep disorders is suggested\textsuperscript{631}. Individuals with symptoms of obstructive sleep disorders should undergo polysomnography and be treated aggressively if diagnosed. It is also worth noting that poor growth, neurodevelopmental delays, and behavioral disorders are associated with untreated obstructive sleep apnea\textsuperscript{632}.

7.5 Skin, nails, and lymphedema

**R 7.19** We recommend annual skin assessment to identify compromising lymphedema, dermatitis, infections, autoimmune skin conditions, and skin neoplasms, with appropriate evaluation and treatment by a dermatologist if indicated (⨁◯◯◯).

**R 7.20** We suggest use of compression garments, lymphatic massage, and referral to specialists in lymphedema care for any compromising lymphedema (⨁◯◯◯).
Clinically apparent lymphedema occurs in 12-27% of girls and women with TS. However, lympho-scintigraphy studies have demonstrated abnormal lymphatic valve and vessel development even in individuals without lymphedema on physical examination. Clinical lymphedema is often present at birth, frequently resolves or at least improves by age 2 years, and may have a relapsing and remitting course throughout life. Lymphedema is reported more often in association with a 45,X karyotype compared to other karyotypes.

Lymphedema may be managed supportively using techniques that encourage lymphatic drainage including compression garments and lymphatic massage. Though treatment typically leads to only temporary improvement, it may be useful in preventing further complications such as skin breakdown, ulceration, and infection. Referral to lymphatic specialists such as physical therapists, occupational therapists, and lymphatic massage therapists can be useful for patients with persistent lymphedema. Podiatrists can treat ingrown toenails and assist patients with selecting appropriate footwear. Currently, there are no recommended surgical or pharmaceutical therapies for treatment of lymphedema in the context of TS.

Fetal lymphedema may present as cystic hygroma and hydrops fetalis; both conditions conferring an increased risk for spontaneous fetal demise. Central lymphedema may contribute to the development of congenital heart anomalies in TS as well as webbed neck (pterygium colli). Webbed neck has been reported in 18-25% of individuals with TS, and patients with webbed neck have 3.3 (1.5-7.4) times the odds of coarctation of the aorta or BAV compared to those without webbed neck. While surgery may be done to correct webbed neck, there are no data to suggest superiority of one technique over another. Potential complications of surgical corrections that have been reported include hypertrophy of the surgical scar (keloid formation) and recurrence of the webbed neck. Meanwhile, peripheral lymphedema is thought to contribute to development of nail anomalies such as deeply set, narrow, and hyperconvex nails, affecting 19-73% of individuals with TS. Complications can include ingrown toenails and skin infections (IRR 23.7).
Common dermatologic conditions in TS include seborrheic dermatitis, atopic dermatitis, allergic contact dermatitis, and psoriasis. A specific mechanism underlying the immune dysfunction in TS leading to these skin conditions has not been elucidated. Other dermatological problems more often noted in girls and women with TS include keloid scarring, vitiligo, alopecia areata, and lichen sclerosis, though additional data are needed to determine the association between these conditions and TS.

The 45,X karyotype is associated with increased risk for benign skin neoplasms [HR 2.03 (1.42-2.9)] and non-melanomatous skin cancer [HR 5.38 (2.63-10.98)]. Large cohort studies disagree on whether there is an increased risk for melanoma.

### 7.6 Renal manifestations

**R 7.21** We recommend a renal ultrasound at time of diagnosis to identify congenital anomalies of the kidney and urinary tract (⊕⊕⊕⊕).

**R 7.22** We recommend performing additional laboratory testing or repeat imaging if there are new renal or urinary concerns, such as urinary tract infections and hypertension. Annual urinalysis for proteinuria is indicated in all individuals with renal agenesis, bilateral hypoplasia or horseshoe kidney (⊕⊕◯◯).

Congenital anomalies of the kidney and urinary tract are common in TS, with highly variable reported occurrence rates ranging between 18-60% 643-646. Horseshoe kidney and duplicated collecting system are the most common findings in TS, each occurring at a frequency of 15-20%. Other associated conditions include malrotation or positional rotation of the kidneys (5%), single kidney (<5%), and multi-cystic kidneys (<5%). Congenital anomalies of the kidney and urinary tract have been ascribed to a variety of genetic and environmental elements present at the time of renal development in utero that disrupt the fetal renal migration pattern, including possible lymphatic factors 647.
Structural renal anomalies may occasionally predispose to urinary tract infections or impaired renal function. In the general population, around half of individuals with congenital anomalies of the kidney and urinary tract develop chronic renal insufficiency, a precursor to end-stage kidney disease. In contrast, despite a wide range of abnormal renal morphology, long-term kidney function remains normal in most youth and young adults with TS, although there are few longitudinal studies. One pediatric study of 122 children with TS up to age 18 years showed normal estimated glomerular filtration rate (eGFR) over time, though there was a small decline in four girls. Another study reported no change in successive eGFR measurements over time in girls with or without renal anomalies. Notably, creatinine may not fully reflect renal function in TS because muscle mass may be decreased due to overall smaller body size. There is a paucity of data on kidney function in older adults with TS.

Renal ultrasound is useful to identify anatomical abnormalities; however, abnormalities may still be missed if not done by experienced technicians. Ultrasound yields low sensitivity for identifying duplex kidneys and axis/rotational differences, whereas bowel gas may obscure horseshoe kidney. Additional testing, e.g., measurement of serum creatinine and urine microalbumin, and/or further imaging, may be indicated if there are new renal or urinary concerns, such as urinary tract infections and hypertension. Yearly urinalysis for proteinuria is indicated in all individuals with renal agenesis or bilateral hypoplasia, or horseshoe kidney beginning at the time of diagnosis of the structural abnormality. Referral to a nephrologist is recommended in case of recurrent urinary tract infections, proteinuria and difficult to control hypertension in the setting of any structural kidney anomaly. Referral to a urologist is recommended if there is hydronephrosis or urinary tract infections in the setting of collecting-system anomalies.

### 7.6 Cardiometabolic disorders

**R 7.23** We recommend promotion of healthy lifestyles including exercise to address modifiable risk factors of cardiovascular disease (儦〇〇〇〇).
**R 7.24** We recommend screening for diabetes with measurement of hemoglobin A1c or fasting glucose every 1-2 years starting at age 10-12 years or sooner with symptoms of diabetes (⊕⊕◯◯).

**R 7.25** We recommend assessment of diabetes autoantibodies at diagnosis of diabetes in women with TS to determine the type of diabetes as it is not easy to differentiate Type 1 and Type 2 diabetes in this population (⊕⊕⊕⊕).

### 7.6.1 Overweight/obesity

Individuals with TS have a prevalence of overweight/obesity as high as 48% with some variation due to small samples sizes, age, definitions, and local prevalence of overweight/obesity 404, 653-657. Overweight/obesity increases from childhood to adulthood, with a cumulative incidence of 8 – 60% from age 10 to 30 years 590. Factors related to the increase in overweight/obesity have not been well elucidated, though fetal programming and small for gestational age (SGA) have been proposed as contributing factors 658. Resting energy expenditure (REE) does not seem to explain the difference as resting energy expenditure per fat-free mass is actually higher in girls with TS 659, and a study in adults found higher body fat, lower leptin concentrations, and no difference in resting energy expenditure per fat-free mass compared to controls 660.

Both visceral and total fat mass are elevated in adults with TS, while lean body mass and skeletal muscle mass are decreased 661. Youth with TS have higher waist circumference and visceral adiposity 434. Periaortic, epicardial and perihepatic fat thickness are positively correlated with cardiometabolic abnormalities in youth with TS 654, 662.

### 7.6.2 Dyslipidemia

A quarter of children and half of young adults with TS have dyslipidemia 404, 656, 657 and hyperlipidemia is present in about 30% of adults and is closely linked with BMI (Sandahl et al).
Age, BMI, and waist-to-height ratio correlate with adverse lipid profiles but account for only a minority of the variability. This leads to the question of how TS itself impacts lipid metabolism and what other variables contribute to this pathology. To date, there are no data directly linking cholesterol profiles to morbidity or mortality in TS, and there are no studies evaluating treatment of dyslipidemia in TS. Therefore, lipid profiles remain a biomarker of uncertain significance in this population.

7.6.3 Diabetes mellitus

Diabetes mellitus is common in TS, with studies reporting a 25-70% lifetime prevalence. Individuals with TS are at an increased risk for both type 1 and type 2 diabetes. Although the majority of diabetes in adult women is attributed to type 2 diabetes, there is accumulating data for a TS-specific type of diabetes. Several studies support that diabetes occurs at an earlier age and is less likely to involve the usual risk factors (BMI, body composition, and family history) in TS compared to the general population. Furthermore, multiple studies demonstrate impaired beta cell function as well as reduced insulin sensitivity are involved in the development of diabetes in TS, while one study found glucose intolerance despite apparently normal beta cell function. Genes on Xp related to beta-cell function and insulin signal transduction affect overall glucose metabolism and likely contribute to the risk of diabetes in TS, as illustrated by studies showing individuals with a 45,X karyotype or deletions of Xp to have a much higher incidence of diabetes compared to individuals with deletions isolated to Xq (17-23% vs 9%).

Several studies have demonstrated that fasting glucose and hemoglobin A1c can be normal even in the setting of impaired glucose tolerance in individuals with TS. Therefore, some authors suggest that oral glucose tolerance testing (OGTT) may be a better screening test for diabetes in TS. However, given the higher burden of OGTT, more evidence is needed. There are no TS-specific intervention studies to inform the best treatment modalities for diabetes (insulin, GLP-1 agonist, oral agents, etc.).
7.6.4 Predictors and modifiers of cardiometabolic risk

Some studies have found an association of metabolic abnormalities with monosomy X, ring X, isochromosome Xq, and Xp deletion, however findings are inconsistent and require more data before clinical interpretation 404, 590, 657, 663.

Despite the willingness of women and parents of individuals with TS to participate in research related to eating and/or nutrition 670, there is a paucity of research in this area. The available literature shows that girls and women with TS do not meet current general recommendations for physical activity 408, 410, 453-455, which is concerning because less physical activity has been associated with excess weight gain and hypertension in adults with TS. A mixed methods study in adolescents found individuals with TS may have unique factors, such as psychosocial complications, impacting physical activity engagement that warrant tailored approaches to achieve best outcomes 454. Another study found only 37% of TS adults had received nutrition counseling and only one fifth of these were adherent to the recommended Mediterranean diet which is believed to support cardiometabolic health 455. There is no information available on use of pharmacotherapy for the treatment of obesity in TS.

The effect of GH on cardiometabolic health is contradictory, though leans toward benefit 229, 338. BMI increases during the time that girls with TS are on GH therapy 671, although body composition in adults who had been treated with GH was not different from those who did not receive GH 672. GH increases insulin resistance; however, estrogen replacement appears to reverse this 673 and the insulin resistance reverses after completion of GH therapy. GH favorably affects the lipid profile by lowering total cholesterol and LDL and raising HDL. There is also evidence that GH is not associated with an increased risk of diabetes in TS 229, 338 and better heart health 674 in TS.

7.7 Liver disease

**R 7.26** We recommend measuring liver enzymes (alanine aminotransferase (ALT) at minimum) in childhood and every 1-2 years starting at the age of 10 and continuing throughout the lifespan. Aspartate aminotransferase (AST), gamma-glutamyl transferase...
(GGT) and alkaline Phosphatase (ALP) should be added in adults (✔️✔️〇〇).

**R 7.27** We suggest that if liver enzymes are elevated at least twice the upper limit of the normal, reassessment is recommended as fluctuation is common. Persistent liver function abnormalities (LFA) warrant further investigation including a liver ultrasound and referral to a gastroenterologist (✔️✔️✔️✔️).

**R 7.28** We suggest that in adults with LFA, the fibrosis-4 score (FIB-4 score) and/or liver elastography is useful for evaluating the severity of liver damage (✔️〇〇〇).

**R 7.29** We recommend that hormone replacement therapy should be continued in the presence of LFA (✔️✔️✔️✔️).

Liver function abnormalities defined as increased liver enzymes are present in 40% to 80% of patients with TS, with more recent studies on the high end of that estimate 675-679. Fluctuations of LFA are frequent in TS. Risk factors for liver function abnormalities are age, obesity, insulin resistance and Xq isochromosome, however even young children with TS without risk factors have a higher prevalence of LFA 675-679. In the presence of LFA, the risk of cirrhosis among TS is six times higher than in the general population 678, 680. Similarly, a British study showed a three-fold increased risk of liver disease-associated death in patients with TS 27. Therefore, assessment for LFA in TS is important.

The pathophysiological mechanisms underlying LFA in TS are poorly understood. Three main types of hepatic damage are described in TS: steatohepatitis, vascular damage mostly observed in regenerative nodular hyperplasia (RNH) and autoimmune disease 681. Metabolic-associated fatty liver disease (MAFLD), is the most common finding in patients with TS 682. In the presence of LFA (at least twice the upper limit of normal or persistent), alcohol abuse and medications with potential liver toxicity should be sought. Measuring ferritin and viral hepatitis B, C, and E serological status are useful to rule out hemochromatosis and infectious hepatitis, respectively. Screening for the presence of antinuclear, anti-smooth muscle, anti-liver cytosol antigen type 1
(LC1) and anti-microsome type 1 (LKM1) and anti-mitochondrial autoantibodies should be performed if the initial evaluation is negative or if the patient has other autoimmune conditions. Liver ultrasound plays a crucial role in the presence of LFA to exclude focal hepatic lesion(s), bile duct dilatation (obstructive cholestasis), or signs of portal hypertension. However, it should be noted that ultrasound does not reliably detect lower-level steatosis (<20%) and does not reliably detect steatosis in individuals with a BMI higher than 40 kg/m². Individuals with TS should be referred to a hepatologist when LFA persist to determine if a liver biopsy is indicated.

Simple non-invasive methods are available to assess the severity of liver damage in the presence of persistent LFA. One of the most sensitive surrogate markers of liver fibrosis in adult patients with chronic hepatitis is the FIB-4 score. It is based on a formula combining age, biological markers including aspartate aminotransferase (AST) and alanine aminotransferase (ALT), as well as the platelet count: \( \text{FIB-4} = \frac{\text{age} \times \text{AST}}{\text{platelet count} \times \sqrt{\text{ALT}}} \). A FIB-4 score below 1.45 indicates a low risk of fibrosis and a score above 3.25 is in favor of advanced liver fibrosis. Recent studies suggest that FIB-4 scores are lower than expected in patients with TS, possibly reflecting that liver diseases are mild in most cases. Vibration-controlled transient elastography (FibroScan) measures liver stiffness as a surrogate marker of liver fibrosis and is another non-invasive tool now widely available in routine clinical practice. However, its predictive value for liver diseases has not yet been tested in large cohorts of patients with TS. Acknowledging the utility of noninvasive markers has not been fully evaluated in TS, we recommend calculating the FIB-4 score in adults and considering elastography when LFA are present.

Several studies have shown that HRT is not deleterious to liver function in patients with TS and there may even be benefit. The deleterious role of hypogonadism on LFA has been emphasized in two review articles. A recent study has shown that there is no difference in the prevalence of LFA between women with TS who have endogenous ovarian function compared to those receiving HRT. Therefore, HRT should be initiated or continued in the presence of LFA. Close monitoring is required for patients with histologically proven liver vascular disease (RHN) or hepatic adenoma.
Management of LFA largely depends on the etiology. Addressing steatohepatitis should initially include lifestyle interventions, such as avoiding alcohol, reducing weight, and increasing exercise \(^{686, 687}\). No intervention studies targeting LFA in TS have been published.

### 7.8 Celiac disease

**R 7.30** We recommend screening for celiac disease by measuring tissue transglutaminase antibodies (TTG IgA with total IgA) in asymptomatic individuals starting at age 2 years, and subsequently every 2-5 years (◯◯◯◯).

**R 7.31** We recommend screening for celiac disease if there are gastrointestinal symptoms, poor growth, weight loss, osteoporosis, skin changes, anemia and/or other symptoms present at any age (◯◯◯◯).

The incidence of coeliac disease is increased in TS compared to the background female population consistent with other autoimmune diseases \(^{678}\), although the mechanism remains speculative. A single report demonstrated an increased incidence of the possible high-risk polymorphism \(MYO9B\) in individuals with TS \(^{688}\). A recent metaanalysis found approximately 1 in 22 individuals with TS have coeliac disease \(^{689}\), with minimal difference if serology (3.4%) or biopsy (4.8%) is used for diagnosis. The prevalence of coeliac disease increases with age \(^{690, 691}\) and is highest in 45,X, 45,X/iso q or ring chromosome karyotypes where up to 7.5% have positive coeliac antibodies \(^{26, 590}\). Coeliac disease may present with weight loss, poor growth, abdominal pain, diarrhea, anemia, and cutaneous stigmata, however symptoms can be very subtle and but no definitive associations have been shown in TS per se. Tissue transglutaminase IgA is 98% sensitive and specific for coeliac disease, however intestinal biopsy is recommended to confirm the diagnosis \(^{692}\). While HLA DQ2 and DQ8 are found in most patients with coeliac disease, routine HLA testing is not currently recommended in TS, although it may be helpful if the diagnosis is uncertain.
7.9 Anemia, inflammatory bowel disease, and intestinal bleeding

We suggest measurement of complete blood count to evaluate for anemia every 1-2 years in adolescents and adults (★★★★).

Emerging data indicate an increased risk of iron-deficiency anemia among TS populations. Anemia may be related to a variety of risk factors and mechanisms including autoimmune conditions, gastrointestinal bleeding, coagulopathy, or anti-coagulation medications.

Inflammatory bowel disease (IBD) is more common among individuals with TS than the general population. A 2023 meta-analysis found an increased expressivity of IBD in TS of 1.86% (95% CI 1.48-2.34%), congruent with the findings in a previous systematic review reporting a prevalence range between 0.67-4%. Unlike previous studies reporting higher rates of IBD among patients with isochromosome Xq karyotype, a systematic review of 25 cases in the literature found equal distribution between monosomy and structurally abnormal X chromosomes. IBD in TS may also present at a younger age (mean 17.8 +/- 2.3 years, range 3-41 years), be more severe, and/or have unique treatment complications, although there is likely reporting bias.

A study from the national Danish registry that compared 1,156 Turner women with age-matched controls identified increase incidence rate ratio (IRR) of gastrointestinal hemorrhage 3.4 (95% CI 1.8-6.2), anemia 3.2 (95% CI 2.0-5.0) and coagulation disorders 2.9 (95% CI 1.1-7.1). Interestingly anemia and gastrointestinal bleeding were not associated with IBD or celiac disease. Telangiectasias and dilated veins of the small bowel are reported as additional causes of GI bleeding among patients with TS, and in one case-report, bleeding from a vascular malformation in the gastrointestinal tract and resultant microcytic anemia improved with initiation of estrogen replacement therapy.
7.10 Bone health

R 7.33 We recommend that all individuals should be counseled on healthy lifestyle measures including dietary intake of calcium and vitamin D, weight-bearing activity, and the role of estrogen replacement for bone health (◯◯◯◯).

R 7.34 We recommend routine screening for vitamin D deficiency using a serum 25 (OH) vitamin D level concentration between 9-11 years of age and every 2-3 years ongoing and treating with inactive vitamin D supplement as necessary (◯◯◯◯).

R 7.35 We recommend obtaining a dual energy X-ray absorptiometry (DXA) scan after completion of growth but prior to 21 years of age and every 5-10 years throughout adulthood (◯◯◯◯).

R 7.36 We recommend using serial DXA scans to monitor BMD in high-risk women (fractures, inadequate hormone replacement, celiac disease and other comorbidities) and once reaching menopause or discontinuing estrogen therapy (simulating menopause) (◯◯◯◯).

It is estimated that 23.8% of adults with TS have osteoporosis and a 25% increase in fracture rate exists. Although karyotype per se is not predictive of BMD, the “dose effect” of the SHOX gene is associated with thinning of cortical bone and increased bone geometry at the distal radius.

Studies on the effect of GH on BMD have not shown a consistent effect in girls with TS. Evidence for positive effects of estrogens in bone health is multifold: (1) spontaneous puberty is protective for BMD in TS, BMD improves with estrogen supplementation. Later start of ERT is associated with lower BMD, and trabecular BMD is not affected in TS during prepubertal ages with an age-dependent decrease in BMD in peripubertal children in absence of spontaneous or medically-induced initiation of puberty. Trabecular bone is abnormal in TS and in other causes of premature ovarian insufficiency but improves...
with estrogen therapy. Current expert opinion suggests to start estrogen replacement at age 11-12 years (if FSH is elevated), gradually increase the dose to adult levels over several years, and to continue the treatment until the average age of menopause (mean age 51-53 years).

The risk of vitamin D deficiency in individuals with TS should parallel that in the general population with additional concern for those with other comorbidities affecting vitamin D status. Regional guidelines for both vitamin D intake as well as dietary calcium intake should be followed. The NHANES vitamin D study showed peak deficiency between ages 12-39 years in the general population. Autoimmune comorbidities add additional risk for low BMD, including celiac disease, inflammatory bowel disease, and type 1 diabetes mellitus. In addition, there are direct actions of thyroid hormone and thyrotropin (TSH) on bone such that both hyper- and hypothyroidism can decrease BMD but should recover in the euthyroid state.

Studies report decreased BMD in TS by DXA (g/cm2), but interpretation is confounded by the effect of short stature in this population. Research tools such as volumetric quantitative computed tomography (qCT) (g/cm3), can accommodate for short stature and delineate differences in cortical versus trabecular BMD as well as characterize bone geometry and microarchitecture in TS. However, DXA is widely accessible in clinical practice with low irradiation exposure. Consequently, attempts to adjust for height include BMD_HAZ height-for-age Z-score (https://zscore.research.chop.edu/calcpedbonedens.php) and bone mineral apparent density (BMAD) adjustment (https://courses.washington.edu/bonephys/opBMAD.html). These calculations are only available <21 years of age, therefore obtaining DXA prior to age 18-21 years is a helpful baseline from which to trend spine BMD over time.

Fracture risk in TS appears most related to timing of estrogen treatment and/or compliance. The most common site is the forearm, with peak incidence at childhood and then above 45 years. Fracture rate is increased in those with a hearing deficit. Fracture risk assessment in the general population relies on DXA-derived fracture risk assessment tool (FRAX) using BMD T-score to estimate risk of osteoporosis-related fracture over age 10 years.
Due to lack of height adjustment in T-score calculation, we do not recommend FRAX in women with TS due to risk of over-estimation of fracture risk and potential for inappropriate initiation of treatment. Back pain and worsening spine DXA may prompt assessment for vertebral compressions fractures \(^{728, 729}\).

### 7.11 Skeletal anomalies

**R 7.37** We recommend physical examination to identify scoliosis at diagnosis and then at least annually until skeletal maturation (◯◯◯◯).

**R 7.38** We suggest screening for orthopedic anomalies (such as scoliosis, genu valgum, Madelung deformity) which in severe cases, may lead to pain and improve with intervention (◯◯◯◯).

A high percentage of individuals with TS have skeletal anomalies, though the true prevalence is difficult to assess given that most studies are small, retrospective, completed at various stages of life, have poor definitions of anomalies and poorly documented inter- and intra-reliability (Table 16). SHOX is expressed in the developing bone with the strongest expression in the middle of the limb (e.g., elbow and knee) and may account for the skeletal phenotype associated with TS including disproportionate growth, genu valgum, cubitus valgus, and Madelung deformity \(^{730, 731}\). SHOX is also expressed in vertebral bodies, possibly playing a role in development of kyphosis and scoliosis \(^{732}\).

We recommend that girls and women with TS be evaluated by an orthopedist if there is back, wrist, elbow, knee, or ankle/foot pain. Idiopathic scoliosis is the most common form of scoliosis noted in individuals with TS though congenital scoliosis, thought to be due to abnormalities of vertebral bodies, also occurs \(^{215, 730}\). Research is varied on whether GH therapy leads directly or indirectly to progression of scoliosis with new data suggesting there is no clinically significant progression \(^{215, 733}\). As intervention for scoliosis has shown to decrease progression of the curve, we recommend screening for scoliosis through full skeletal maturation. Newborns and infants
should be examined for developmental dysplasia of the hip and screened with imaging per
guidelines in the setting of breech delivery, family history of dysplasia and abnormal
examination. Slipped capital femoral epiphyses is rare but can appear in girls with TS while
on GH therapy. Concern for slipped capital femoral epiphyses should lead to recommendations
for non-weight bearing and urgent orthopedic referral. A recent review outlines common
skeletal abnormalities in TS along with guidance on referral and treatment.

7.12 Neoplasia

**R 7.39** While there is no indication for general cancer surveillance in TS, we recommend
adhering to population screening guidelines (⩽⩾⩾⩾⩾).

**R 7.40** We recommend individualized decision-making about gonadectomy/salpingo-
oophorectomy in girls and women with TS and Y chromosome material identified on
standard karyotyping or FISH analysis. This also includes a discussion of the timing of the
procedure weighing risk of gonadoblastoma/dysgerminoma against the potential benefit of
gonadal function and fertility (⩽⩾⩾⩾⩾⩾).

Large population- and registry-based studies have shown that the overall risk of cancer is either
not increased in TS [Denmark: hazard ratio 1.04 (95% CI 0.80-1.36)\(^{331}\); Great-Britain: standard
incidence ratio 0.9 (95% CI 0.7-1.2)\(^{25}\) or only slightly increased [Sweden: standardized
incidence ratio 1.34 (95% CI 1.04 – 1.69)\(^{642}\) and Korea: hazard ratio 1.82 (95% CI 1.01-3.27)\(^{734}\)].
Increased risk for melanoma and central nervous system tumors (meningioma and
astrocytoma) were identified in two of the three series, while an increased risk for thyroid,
colon, rectal, and tongue cancer was reported in only a single study. There is a lack of
consistent prospective data and likely ascertainment bias in smaller studies; thus, no routine
screening protocol is currently recommended beyond awareness of possible incidental
abnormalities which should be investigated and managed as appropriate.
There is no current unifying pathogenesis to explain any increased risk of specific tumors in TS. Importantly, no relationship has been found between increased risk of development of neoplasms and HRT or GH treatment, including, for the latter, in multiple large post-marketing GH registries. Finally, a decreased risk of breast cancer has been reported in TS patients which may be due to lower lifetime estrogen exposure \(^{331, 332}\).

Gonadoblastoma with or without malignant transformation is associated with the presence of Y-chromosomal material. An increased prevalence of germ cell tumors such as gonadoblastoma and dysgerminoma among individuals with TS with Y chromosome material has been reported. However, there is a significant variation in the rates of gonadoblastoma, ranging from 0-100% in the different studies (for review see \(^{735}\)). An entire Y-chromosome is suggested as bringing a higher risk \(^{735}\). The risk of malignant transformation has been reported to be rather low (1-22%); it usually occurs after the second decade and metastasis is rare \(^{735-737}\), resulting in a relatively good prognosis. However, no reliable clinical markers or imaging for follow-up exist \(^{736, 737}\) and some patients may be at risk to loss of follow-up. Spontaneous puberty, menarche and pregnancies have been reported in TS individuals with 45,X and Y chromosome material, but information regarding residual ovarian function after puberty and fertility potential is still limited \(^{735-737}\). Early gonadectomy includes a surgical intervention prior to an age in which patient participation is possible and can therefore affect bodily autonomy. Thus, based on the current data, we recommend individualized decision-making about gonadectomy/salpingooophrectomy in TS girls and women with Y chromosome material identified on standard karyotyping or FISH analysis. This also includes a discussion of the timing of the procedure weighing risk of gonadoblastoma/dysgerminoma against the benefit of gonadal function and potential fertility.

7.13 Autoimmunity

R 7.41 We recommend screening for hypothyroidism with measurement of TSH every 1-2 years starting at 2 years of age and continuing through adulthood, and with new symptoms.
If TSH is elevated, we suggest testing for anti-thyroid antibodies (⨁◯◯◯).

**R 7.42** We recommend counseling on and screening for symptoms of other autoimmune conditions, such as vitamin B12 deficiency, celiac disease, psoriasis, vitiligo and inflammatory bowel diseases (⨁◯◯◯).

Women with TS are at increased risk of autoimmunity with a 61% lifetime prevalence and positive association with age. Hashimoto’s thyroiditis is the most prevalent autoimmune disease in TS followed by coeliac disease (4-7%) and vitamin B12 deficiency (5-12%). Yet many other autoimmune disorders have been reported including, though not limited to, type 1 diabetes, Addison’s disease, Grave’s disease, psoriasis, vitiligo, alopecia, lichen sclerosis, inflammatory bowel disease, gastritis, primary biliary cirrhosis, rheumatoid arthritis, ankylosing spondylitis, and idiopathic thrombocytopenic purpura. A recent study demonstrates increased incidence of vitamin B12 deficiency independent of malabsorption and associated with hypothyroidism in TS.

The reason for increased autoimmunity is multi-factorial. A lower ratio of CD4+/CD8+ lymphocytes and/or excess pro-inflammatory cytokines and decreased anti-inflammatory cytokines have been reported. However, they do not consistently relate to clinical findings of autoimmunity. Given that estrogen and androgens are involved with immune regulation, hormonal deficiencies due to primary ovarian insufficiency are potential contributors to immune dysregulation in TS. In addition, genetic causes have been described, such as absence of Xp (i.e., 45,X and 46, X,i(Xq))

Haploinsufficiency of X-linked genes or varied X inactivation may also be associated with autoimmunity in TS through differential expression of genes on the X chromosome. They include AR1, CD99, DSF2RA, IL3RA, AP1S2, TLR7, CD40L, FOXP3, XIC, KDM6A, and MECP2. The high-risk polymorphisms known to be associated with thyroid autoimmunity (PTPN22 and ZFAT) in the general population have not consistently been found in TS though the high-risk polymorphism for celiac (MYO9B) is more common in TS. Differentiated
methylation patterns have been found in TS including hypomethylation of KDM6A which is implicated in immune regulation.\textsuperscript{103, 106}

Screening with TSH, with or without free T4 is recommended every 1-2 years. It can be done more frequently if clinically indicated (i.e., constipation or growth failure more extensive than expected). Screening with thyroid antibodies is not recommended as treatment will not be altered and no prevention of hypothyroidism is available. Treatment of autoimmune disorders is the same as that for the general population and should follow local guidelines.

See section 7.8 for more information on coeliac disease and other GI and hepatic autoimmune disorders, section 7.9 for more information and section 7.6 for type 1 diabetes.

7.14 The Turner syndrome clinic

Clinical care in TS is complex and chronic. As evident herein, individuals with TS may need specialty care from a dozen or more different providers. Managing this care can be challenging for anyone, with added burdens for individuals with limited health literacy, access to care, and financial resources. The authors recognize that system- and patient-level factors will affect implementation of these proposed clinical practice guidelines. Furthermore, the phenotypic heterogeneity of TS and limited high-quality research demands individualization of care. In this section, we outline considerations to improve TS clinical care delivery and outcomes. In table 17 we present our suggestion for planned outpatient follow-up of TS.

Primary care providers (pediatricians, family practitioners, internists, generalists) are an essential part of the healthcare team, in collaboration with specialists, to deliver comprehensive and evidence-based care for individuals with TS. In a web-based survey on healthcare priorities of 543 adults with TS and 795 parents of a child with TS, respondents ranked having one provider who oversees all components of their healthcare needs as very important.\textsuperscript{508} Unfortunately, only 15-30% felt their primary care provider was very knowledgeable about TS. Given the prevalence of TS, the average primary care provider will
only have one patient with TS – therefore lack of knowledge and experience is expected. TS specialists should partner with primary care providers for their mutual patients. Creative approaches to support and educate primary care providers caring for individuals with TS, such as rare disease networks like the European Reference Network on Rare Endocrine Conditions (EndoERN) and the Endo-ERN registry ‘EuURRECA’ (www.eurreb.eu), Project ECHO (Extension for Community Healthcare Outcomes) and local care protocols disseminated throughout a region, may prove valuable in TS. Finally, advocacy groups can maintain lists of primary care providers with experience caring for individuals with TS that patients could reference.

Multidisciplinary clinics (MDC) are common for specific conditions necessitating care among many specialists. The last iteration of the TS clinical practice guidelines recommended individuals receive care within an integrated MDC. However, there is not a strict definition of what an MDC is, and there are minimal data supporting improved clinical outcomes with MDC care in TS to date. Small studies have reported patient satisfaction with MDC care, and retrospective studies have suggested better identification of comorbidities. At minimum, a TS MDC presumably involves providers who are knowledgeable in TS, and this may alone have measurable benefits given the knowledge gap of providers on TS care reported in several studies. Given the patient-identified importance of a “ringleader” in the healthcare priority survey, TS MDCs should strive to have a coordinator to integrate care recommendations and facilitate communication between the patient/family, primary care provider, and MDC team. The TS Global Alliance has developed a tiered system of designations for TS MDCs available on their website, although at present this is predominantly for pediatric clinics in the US.

Telemedicine may improve access and quality of care for individuals with TS, especially for those living in areas that are resource limited. In the healthcare priority survey, only ~5% of adults with TS stated they would be willing to travel >3 hours for TS care, but there are many individuals who live more than 3 hours away from TS experts. In addition, flexibility for appointments was their top priority. While there are minimal data on telemedicine in TS specifically, this has been studied in other chronic multisystemic conditions such as type 1
diabetes and cystic fibrosis. There is ample evidence that telemedicine can reduce barriers from social determinants of health. Telemedicine may also have unique benefits to the TS population, such as accommodations for those with hearing impairment. However, telemedicine does have important limitations, including incomplete physical examination, additional visit for laboratory or radiological studies, and legal or financial considerations in some healthcare systems.

TS support and advocacy organizations serve an important role in clinical care outcomes, and TS clinicians should identify and partner with such organizations. TS advocacy groups have taken a lead in providing peer networking forums for patients and families. Studies have demonstrated the effectiveness of peer support to enhance behavioral and social well-being for patients with chronic conditions. Peer support provides opportunities for fostering social interactions, shared experiences, and local resources, all of which may foster adherence to clinical care and recommendations. Advocacy organizations are an important avenue for patient education. Following the publication of the previous clinical practice guidelines, a family-friendly version was developed and disseminated by advocacy organizations with far-reaching effects. Finally, TS organizations can advocate for policies and system change aimed at improving clinical care access and delivery for the TS community on local, regional, and national levels.

**R 7.43** We recommend the clinical care recommendations herein be implemented on an individual basis with consideration of both patient- and system-level factors (Good Practice Statement).

**R 7.44** We recommend all individuals with TS receive care from specialists with expertise in genetics (and/or genetic counseling), cardiology, endocrinology, reproductive medicine, audiology/otolaryngology, ophthalmology, neurodevelopment, and mental health. Additional subspecialists should be involved as needed, such as dermatology, gastroenterology, nephrology, orthopedics, podiatry, nutrition, and speech/occupational/physical therapy.
R 7.45 We recommend that girls and women with TS attend specialist interdisciplinary or multidisciplinary clinics for health surveillance in addition to their primary care provider (◯◯◯◯).

R 7.46 We suggest that the TS care team provide resources for additional education, self-advocacy, and connecting with other affected individuals such as through TS support and advocacy organizations (◯◯◯◯).

R 7.47 We suggest telehealth may supplement medical and/or psychosocial care if it is available and improves access to TS specialists (◯◯◯◯).

TS Research Considerations

Although many advancements in TS care are being made, the collective effort to collate evidence to inform these clinical practice recommendations also highlighted many knowledge gaps that need to be filled. The clinical landscape is constantly evolving, as illustrated by the adoption of non-invasive prenatal screening (NIPS) in many countries that identifies TS not only prenatally but also in pregnant women, generating new clinical conundrums. Unfortunately, TS research faces similar challenges like many other rare disorders, including limited sample sizes, public awareness, and funding. Most of the recommendations included within are based on single-center studies conducted in affluent countries and encumbered by multiple biases. Overcoming these barriers requires innovation and collaboration. International collaboration efforts are underway, including the European Reference Network on Rare Endocrine Conditions (Endo-ERN) and more specifically to TS, the international registry for TS (iTS) (https://sdmregistries.org/). A national TS registry has been established within the US as well with multi-stakeholder commitment. These emerging resources will be important in studies.
best served with larger sample sizes and international generalizability. However, as both ancestry and sociodemographic factors influence the phenotypic variability in TS, more diverse populations will need to be included. Using and even combining secondary datasets may be another way to achieve larger, more diverse TS samples, but will need to establish computable phenotypes and common data elements appropriate for this population.

Personalized medicine presents a valuable opportunity for the TS community. Through incorporation of genetics, biomarkers, and environmental factors we can and should be able to risk stratify individuals with TS to provide individualized care rather than a global approach. Given the many TS karyotypes and the wide phenotypic heterogeneity, many studies have sought to risk stratify by karyotype; however most are far underpowered to do so. In addition, while some studies have concluded there are few undiagnosed cases of TS, we are still unsure of how prevalent 45,X mosaicism is and what (if any) clinical manifestations low-level mosaicism poses. Population-based genomic biobanks may elucidate novel observations for individuals with TS; however selection bias toward healthy participants, lack of deep phenotyping, and age-related X chromosome loss in peripheral blood present challenges in these studies as well.

Finally, integration of basic science into TS research is critical. Animal and cellular models of TS can further our understanding of pathophysiology, individual variability, and potential intervention targets. Ideally, clinical questions will inform basic science, followed by incorporation of basic science results through the translational research spectrum into clinical care. Integrated team science is particularly relevant for rare, multisystemic, lifelong conditions like TS in which a single perspective may neglect crucial details. Collaborative science along with innovation should be priorities for the TS research community.
8. Neurocognition, mental health and well-being

8.1 Introduction

Research on neurocognition and behavior in TS now spans decades of findings consistently demonstrating a correlated phenotype, which may often impact adaptive functioning and QoL. Genetic variations, including sex chromosome aneuploidies, are not entirely deterministic of a particular neurocognitive phenotype, i.e., individuals with the same karyotype may demonstrate significant interindividual variability in the expression of associated phenotypes. Nevertheless, the volume of evidence from studies in TS provides important insights into which neurocognitive features are linked to loss of an X chromosome. Accordingly, this knowledge has the potential to inform clinical management of neurocognitive function and behavior in individuals with TS and is typically a combination of anticipatory guidance, diligent screening/detection, and early intervention when symptoms arise, to mitigate potential impacts on an individual’s overall functioning.

To summarize prior literature, the overall neurocognitive profile associated with TS spans multiple stages of development, and affected domains can include attention, working memory, executive function/cognitive control, perceptual-motor and visual-spatial skills, visual memory, language, motor function, social cognition, and academic achievement. Approximately 90% of individuals with TS have overall intellectual abilities within the average range; however, significant discrepancies across domains have been documented with relative strengths in verbal reasoning compared to weaknesses in visual-spatial reasoning abilities. Further, certain karyotypes, such as having a ring X chromosome, have reportedly been associated with more pronounced cognitive impairments and heightened risk of psychoeducational problems, though there is conflicting evidence in this domain. Psychological and functional areas can also be affected, including social withdrawal, social-emotional well-being, anxiety, initiation and maintenance of peer relationships, and development of self-concept. Many of these underlying neurocognitive and behavioral domains map onto diagnostic criteria for common clinical conditions, including Attention-Deficit/Hyperactivity Disorder (ADHD), developmental coordination disorder, social (pragmatic) communication disorder, autism spectrum disorder, anxiety disorder, and specific learning disorder. Since the publication of the last clinical practice...
guidelines, there have been significant advances in our understanding of underlying mechanisms driving neurocognitive features in TS. These are centered around innovative findings in genetics and neuroimaging. Firstly, insights into the genetic link between abnormal X chromosome number, spanning monosomy, mosaicism, and more complex karyotypes in TS, have slowly progressed towards clearer delineation of mechanisms linking this genotype to known phenotypes, as well as identification of candidate genes differentially expressed in TS, potentially driving the neurobehavioral phenotype.

Research findings serve as important guideposts informing effective clinical management of individuals with TS as outlined in the first half of this section. The latter section summarizes recommended standards of care in clinical management of neurocognitive and behavioral features in TS. To better contextualize appropriate screening and intervention in clinical management most relevant to current understanding of each developmental stage, the present version of TS clinical guidelines in neurocognition and behavior have been structured within a developmental framework, spanning prenatal periods to adult life.

8.2 Developmental framework for neurocognition and behavior in Turner syndrome

8.2.1 Prenatal Period

It is currently unclear how the partial or complete loss of the second sex chromosome influences prenatal neurodevelopmental processes. A study of 117 midgestational fetuses with phenotypic TS reported no malformations of the CNS and brain weight was similar to controls of the same gestational age. A better understanding of fetal brain development in TS could be achieved through the application of advanced techniques for fetal MRI. In the future, these technologies may provide insight into a child’s anticipated psychosocial and educational needs, allowing earlier interventions. Another gap in research relates to the placenta and its potential role in neurodevelopment. Because the placenta is derived from fetal cells, with a contribution from the lining of the mother's uterus, the placenta in TS is genetically different from a 46,XX or 46,XY placenta. Given this organ's key role in maternal-fetal processes, future
research is needed to examine altered placental function as a potentially modifiable factor that could influence brain development in TS.

Clinical counseling, based on a prenatal diagnosis, should include psychoeducation that intelligence is typically within the normal ranges and educational achievement is like peers without TS. Expecting parents should also be informed about specific cognitive challenges and strengths that might occur in their child. Clinicians should be aware of how medical conditions associated with TS might influence prenatal brain development, such as prematurity and CHD. While no TS-specific neuroprotective strategies currently exist, parents and clinicians should be encouraged to implement strategies for supporting healthy brain development during pregnancy in general including appropriate nutrition, mental health support for parents, and attention to social drivers of health.

8.2.2 Infancy/Preschool (0-4 years)

While early reports suggested delayed development in a variety of areas, recent studies indicate that infants and toddlers with TS demonstrate similar developmental profiles compared with children without TS, with the potential exception of motor skills. These early investigations included a study in which parents reported late development of motor activity, fine motor control, speech, and language, as well as a very high rate of feeding problems, for which they desired greater support and advice. Feeding problems appeared to stem from both oral-motor dysfunction and dysmorphic features – notably high-arched palates. Delayed language development was reported by 15 of 122 individuals in a retrospective cohort study, which could be a consequence of increased rates of middle-ear disease and otitis media. More recent reports improve on the earlier literature by using a prospective cohort design with both clinic-based assessments and well-standardized caregiver-report measures. Pretzel et al. (2020) found that standardized measures of cognitive abilities, temperament, and adaptive function were largely within the average range for 12-month-old girls with TS and only the gross motor scale differed significantly between girls with TS and typical male and female individuals after controlling for key covariates. Motor skills also fell in the bottom quartile on a
caregiver rating form of adaptive skills (Vineland Adaptive Behavior Scales-II), confirming this is an area where infants and toddlers with TS may benefit from early screening and additional support. Finally, caregivers reported that girls with TS were more cautious in approaching new people and situations, which could contribute to social challenges sometimes observed in older children and adults with TS. Because individuals with TS are more likely than those without TS to meet diagnostic criteria for autism spectrum disorder (ASD), screening for ASD during routine well-child checkups is important and practitioners should keep in mind potential sex and gender-related differences in ASD presentation. Children with TS and comorbid ASD will benefit from early identification and early interventions like autistic children without TS. Reinhartsen et al. (2021) delved more deeply into language skills and discovered a positive neurodevelopmental profile. While clinical assessments of receptive language skills were significantly lower than expressive language skills at 12 and 24 months of age, both were within normal limits. Social and symbolic communication skills were also average and improved significantly from 12 to 24 months. Caregivers reported that use of gestures and production of speech sounds exceeded normative expectations. Interestingly, some aspects of the neuroanatomical phenotype described in older individuals with TS are already present at 12 months of age including volume reductions in primary visual cortex, while others, such as volume reductions in the cuneus and superior parietal lobule, are not. Thus, future research should evaluate early visual processing during this age range.

Overall differences between individuals with TS and their peers with typical chromosome complements are milder at this stage, but some children may benefit from early intervention to address motor delays, feeding difficulties, or social behavior. In addition, regular monitoring is important as children transition from early childhood into middle childhood, when the classic neuropsychological features of TS become more evident. It is also important to continue to monitor for ASD symptoms across later childhood and adolescence and consider ASD evaluation if concerns arise with increased social expectations.
8.2.3 School Age/Middle Childhood (5-11 years)

During middle childhood in individuals with TS, increased risk emerges for a constellation of cognitive vulnerabilities. Early research into the cognitive profile of individuals with TS revealed evidence of a lateralized profile, with relative strengths in verbal reasoning abilities compared to nonverbal/visual-spatial reasoning abilities (VIQ-PIQ discrepancy). A cognitive profile involving a significant discrepancy between verbal intellectual abilities and nonverbal/visual-spatial reasoning abilities has been documented in children with TS as young as 4 years of age. This classical cognitive profile tends to be more frequently associated with the 45,X karyotype. Continued vulnerabilities in motor skills noted during early childhood can result in weaknesses in fine motor domains, which affect a child’s early visual constructional skills, including handwriting and drawing. These vulnerabilities can be exacerbated by weaknesses in visual-spatial reasoning abilities that affect not only the perception of visual information, but also an individual’s ability to recreate visual designs or remember visual-spatial information.

In addition to fine motor and visual-spatial vulnerabilities, individuals with TS are at increased risk for specific learning difficulties in mathematics. Previous research has highlighted a connection between visual-spatial skills and math abilities. While some children exhibit vulnerabilities in understanding numeracy concepts early (e.g., the ability to count physical objects in order), weaknesses in math concepts may not arise under later childhood as academic topics become more abstract or include visual-spatial concepts (e.g., geometry). Prevalence rates for specific learning disabilities in mathematics vary significantly across studies, with rates ranging from 10-79% of the study sample. In contrast, individuals with TS tend to have age-appropriate verbal and language-based academic skills. Despite these relative strengths, there does appear to be an increased risk for weaknesses in understanding non-literal language (e.g., sarcasm). Difficulties with attention and aspects of executive functioning can begin to significantly interfere with academic success as a child progresses through elementary and middle school. There is a higher prevalence of ADHD in individuals with TS - 7 to 25% of the sample population - compared to unaffected same-aged peers. Of note, girls appear to be at greater risk of the hyperactive/impulsive presentation of ADHD during early childhood than other girls in the general population. Executive functioning skills
gradually develop over the course of an individual’s life with increasing development of the frontal lobes and other areas of the brain involved in mediation of executive functioning skills (e.g., planning, organization, task initiation). Weaknesses can also be observed in completion of speeded or timed tasks in individuals with TS and may underlie weaknesses observed on other measures (i.e., math)\(^787,793\).

In addition to the unique cognitive profile observed in school-aged individuals with TS, social-emotional difficulties may emerge or increase during this period for some children. Individuals with TS may experience difficulties with initiation and maintenance of peer relationships, secondary to vulnerabilities in social communication skills. Comorbid conditions such as ASD and ADHD also influence social-emotional function. While there are qualitative reports of increased symptoms of anxiety related to social interactions and medical procedures\(^794\), the prevalence rate of anxiety disorders and symptomatology has not been well-defined in early childhood and school-aged children and requires additional research. The interplay between cognitive and social-emotional vulnerabilities can affect an individual’s ability to successfully navigate social and academic settings, leading to reduced self-esteem. It is important to ensure that the child participates in screening and/or evaluation for potential cognitive and social-emotional concerns during early childhood. Some children may benefit from school-based accommodations, while others may require more significant academic interventions. Consideration of therapies to address motor and communication vulnerabilities, if present, are encouraged. Young children with TS may benefit in therapeutic interventions such as behavioral therapy or parent management training, as well as interventions such as Applied Behavioral Analysis (ABA) therapy if needed (https://www.bacb.com/about-behavior-analysis/).

8.2.4 Adolescence (12-17 years)
Adolescence marks a developmental epoch encompassing significant changes in social expectations, as well as dramatic biological changes typically triggered by puberty and associated circulating sex steroids. Together, these changes are tied to evolving interpersonal relationships with family members, peers, and potential romantic partners, and signal an emerging need for sophisticated approaches to navigating increasingly complex social and
academic environments. Relatively, adolescence is a particularly critical period in
neurodevelopment – since the last clinical practice guidelines, several studies, discussed
below, have examined how individuals with TS navigate this developmental period, including
examination of neurocognitive and brain outcomes. Particularly relevant to TS, there has also
been some examination of the impact of estrogen on these domains which is a putative primary
driver for many observed changes in typical puberty.

Regarding neurocognition, features from the neuropsychological profile observed in earlier
stages of TS appear to be similar in the adolescent period. This includes findings of persistent
visual-spatial differences, arithmetic abilities, and executive function, as components
underlying the characteristic and ongoing verbal IQ – performance IQ discrepancy. Recent
longitudinal studies in the adolescent period have examined these aspects within individuals
across several years, demonstrating stable neuropsychological profiles that progress in parallel
to trajectories observed in typically developing female peers in mathematics performance and
visual-spatial abilities, as well as executive functions and social cognition. In other words,
these new findings indicate that cognitive differences observed prior to adolescence continue
to develop through this period, and do so in parallel to typically developing peers, though the
difference in between-group domain scores persist throughout this developmental stage. These
neurocognitive findings are partly mirrored in longitudinal findings on MRI, which similarly
demonstrate global brain differences, such as smaller total surface area in girls with TS relative
to typically developing peers, persisting across ages 8-14 years. Similarly, within the context
of known maturational changes in typical puberty where white matter volume continues to
increase linearly while gray matter volume decreases under the context of pruning – global
cortical thickness differences emerged well into adolescence where individuals with TS appear
to demonstrate relatively greater cortical thickness volumes, putatively driven by a slowed rate
of thinning. Other specific regional differences that are often observed may arise in part
from the absence of expected pubertally related cortical thinning seen in typically developing
controls. The extent to which these emerging differences in mid-adolescence derive from
estrogen effects remains unclear given the design of existing studies. However, subjects
receiving estrogen supplementation were found to have expected maturational decreases in
surface area/volume in postcentral gyrus, middle temporal gyrus, parahippocampus, inferior parietal, as well as other regions, compared to individuals with TS who were not receiving estrogen. These estrogen-related findings should be interpreted with caution given that the underlying rationale for timing of estrogen replacement in subjects was not specifically controlled for in these investigations.

Regarding psychiatric symptoms, adolescence is a known developmental period associated with emergence of common mental health conditions. Evidence that rates of anxiety in TS during the adolescent period exceeds prevalence in the general population is mixed. Some studies have reported increased reports on anxiety screening, particularly based on parent reports, while others found no differences relative to age-matched peers. Specific to mood, while rates of depressive symptoms do not appear elevated in childhood, a recent systematic review indicates emerging depressive burden in adolescence and elevated rates in adulthood. Given the inconsistency of methods across several factors, rigorous assessment of anxiety and mood in TS across the lifespan, is needed in future research. Lastly, social skills continue to demonstrate significant deficiencies compared to unaffected adolescents. Recent work demonstrates social skills impairments extending from adolescence into young adulthood and increased rates of meeting diagnostic criteria for ASD both in sample-based findings, as well as large population-based cohorts.

8.2.5 Transitional Age/Adulthood (>18 years)

Neuropsychological and mental health concerns are elevated in young adults with TS. As individuals transition from adolescence to adulthood, it is crucial for healthcare systems to ensure that psychiatric symptoms do not go unnoticed during the change of caregivers as young adults move from pediatric to adult healthcare settings. While research on the neurocognitive function of adult women with TS is not as extensive as that on children and adolescents, it is evident that the cognitive profile remains consistent throughout life. However, how symptoms of neurocognitive and socioemotional deficits in TS are expressed over the lifespan may change. As an example, there seems to be a shift in the manifestation of ADHD symptoms in adult women with TS, with a greater emphasis on inattentive deficits.
as opposed to predominantly hyperactive/impulsive symptoms observed in children and adolescents \cite{790,803}, which parallels broader findings in ADHD.

The occurrence of neurodevelopmental and psychiatric disorders in adults with TS is also reportedly higher in individuals with TS than in the general population \cite{777,800}. As described above, evidence regarding prevalence of anxiety is mixed \cite{798,800}, while depression in TS may become more prevalent with age, with the highest risk in adulthood \cite{799}. It should be noted however, that significant variability exists in measurement methodologies \cite{799}, where obtaining a clinical diagnosis may require comprehensive assessment rather than self-report measures.

Attention deficits are also frequently seen among adult women with TS. There is a group of women who do not fully meet DSM-V criteria for ADHD but, to a milder degree, experience problems stemming from executive function, such as weaknesses in attention, regulation of emotions and behavior, and difficulties in organizing and planning. For these women, training and applications based on cognitive-behavior therapy and accommodations at work may demonstrate benefit \cite{804-807}; however research examining applications in TS is still needed. For effective healthcare navigation, appropriate recognition and diagnosis of symptoms is critical to facilitate appropriate treatment \cite{808}, and interventions should primarily be symptom-driven and consistently provided when necessary \cite{805}.

Studies on health-related quality of life (HRQoL) do not reveal conclusive outcomes. This may be related to the application of different measuring instruments with differences in outcome measures, groups sizes, and cultural context. A recent large population study revealed no differences in HRQoL between women with TS and the reference population \cite{261}. HRQoL was not associated with GH treatment, genotype, body composition, hypothyroidism, or the presence of cardiovascular malformations, but appeared to be negatively associated with age, age at diagnosis, hearing impairment, and unemployment/disability \cite{261}. However, dissatisfaction with body stature and positive evaluation of GH treatment has been observed in older studies \cite{260,809,810}. Several studies found that large percentages of women had a restricted social network, with increased reports of loneliness and difficulties in initiation and maintenance of social and intimate relationships \cite{809,811,812}. Also, women reported delays in achieving milestones of sexual development such as first romance, first serious partner-relationships, and sexual experiences.
Social communication challenges continue to be described in adult women who have TS. Reduced attention or difficulty interpreting non-verbal communication cues, as well as challenges in understanding ambiguous or non-literal language have been reported, as well as reported difficulties in new, unstructured, or ambiguous social situations. Adult women therefore may benefit from training programs to strengthen their social competence. Recent studies also indicate adult women with TS experience elevated stress and fatigue levels, which is attributed to the associated cognitive profile combined with heightened stress levels, potentially related to coping with a congenital disease or a chronic medical condition. In adulthood, optimal neuropsychological functioning, particularly executive functions and social communication, are pivotal for self-dependence and successful social engagement. Conversely, difficulties in these domains present significant functional challenges, which may require ongoing support or accommodations to reduce stress in daily life.

Vocational counseling, combined with neuropsychological evaluation, may sometimes provide valuable insights in individual profiles of strengths and challenges, to optimize social participation and well-being.

### 8.3 Clinical Recommendations

#### 8.3.1 Evaluation, screening, and surveillance

We recommend that cognitive/neuropsychological evaluations and behavioral/social/emotional screenings be integrated into the care of individuals with TS across the lifespan.

In response to increased life expectancy for individuals with a variety of complex medical conditions, there have been advances in understanding of related neurocognitive sequelae that affect developmental outcomes and QoL in affected individuals. As a result, there has been an increasing demand for comprehensive neuropsychological evaluations as part of clinical practice guidelines for complex medical conditions, and should be similarly pursued in clinical care for TS. Unfortunately, access for comprehensive neuropsychological evaluation can...
be limited due to availability of services in areas, long wait lists, or financial restrictions. In response, there has been increased interest in methods for screening or targeted evaluations for individuals at risk for neurocognitive impairments. These have included alternative methods of neuropsychological evaluations, including monitoring/surveillance, consultation, screening, and targeted evaluation to assist in triaging individuals who might most benefit from comprehensive evaluations. This tiered method of neuropsychological evaluations paired with collaborations with other providers who may be able to complete evaluations assessing cognitive, learning, attentional, or social-emotional vulnerabilities (e.g., school personnel, community practitioners), may help increase the availability of resources to individuals with TS who historically may not have been able to access a comprehensive neuropsychological evaluation (Figure 8, Table 18 and Supplemental Text 1).

R 8.2 We recommend surveillance of generic risk factors associated with chronic medical conditions that can threaten well-being and quality of life (QoL) (Ungraded Good Practice Statement).

The focus in clinical management in TS is, understandably, on condition-specific features to avoid or minimize the development of more serious medical problems. Less commonly highlighted are those circumstances and experiences shared by individuals affected by a wide range of chronic medical conditions (and their families). Such a “noncategorical approach” represents a balancing of treatment for specific medical conditions with the need to address related personal, social, and educational/vocational issues related more generally to having a chronic medical condition or caring for an affected child. Holistic strategies for intervention involve counseling and support of patients and families regarding predictable nonspecific experiences of pediatric chronic conditions.

Providers should be aware of caregiver challenges given the psychological strain which can accompany caring for any children with a chronic condition. For example, there are effects on caregivers such as psychological distress related to the diagnosis, negative emotional spill-over effects, and perceived child vulnerability and overprotectiveness. Chronic pediatric conditions can also exert variable financial and time burdens on caregivers relative to caregiving.
burdens for healthy children\textsuperscript{829}. Youth with chronic medical conditions have been shown to experience higher rates of missed school, peer victimization, academic challenges, and threats to body image and self-esteem\textsuperscript{830, 831}. More specifically, those with hearing loss tend to encounter social isolation, experience discomfort in interactions with peers, and exhibit signs of immaturity\textsuperscript{832-834}. Later pubertal onset, a feature of many pediatric chronic conditions\textsuperscript{835}, can perturb healthy psychosocial and psychosexual development\textsuperscript{714}. Chronic medical conditions are associated with delays or arrest in psychosexual milestones\textsuperscript{836, 837}. A final example of a noncategorical or generic factor that threatens positive psychosocial adaptation stems from the influence of chronic medical conditions on employment and career development\textsuperscript{838}. While there is widespread recognition of cross-condition factors that could jeopardize positive psychosocial adaptation, well-being, and the overall QoL of individuals and their families, these factors might sometimes be overlooked due to the prevailing focus on biomedical treatment advancements and the escalating specialization within the healthcare field. Nevertheless, there are brief screening tools available to assess patient and family risk and resilience at the time of diagnosis and periodically during ongoing care. As an illustration, consider the Psychosocial Assessment Tool\textsuperscript{TM} (PAT) (https://www.psychosocialassessmenttool.org/), which is rooted in the Pediatric Psychosocial Preventative Health Model\textsuperscript{839}. This tool offers a three-tier assessment of patient and family risk (Universal, Targeted, Clinical) based on the cumulative PAT score. It has been implemented across a diverse range of pediatric chronic conditions and is available in multiple languages. The PAT identifies patient and family areas of risk and resiliency across multiple domains (e.g., family structure and resources, family problems, social support, child problems, acute stress, sibling problems). Although it has not been validated in TS, the use of the PAT, or similar standardized tool, can be used to triage families to services based on need.

8.3.2 Evidence-based Treatment for Mental Health Conditions in TS

\textbf{R 8.3} We recommend that evidence-based interventions for cognitive or psychosocial problems in the
While several evidence-based therapies are universally available for symptoms of anxiety, depression and social skills challenges, data demonstrating efficacy of these psychosocial interventions specific to TS has been sorely lacking until recently. Social skills difficulties are among the most consistent challenges faced by girls and women with TS. As outlined above, differences in social interaction are present from childhood, and may become more conspicuous in adolescence, when the complexity of social interaction increases significantly for most girls. By adulthood, women with TS report feeling more socially isolated than their peers and fewer close relationships. Many of the social difficulties in TS are reminiscent of those experienced by girls with ASD. There is robust evidence from international randomized controlled trials that social skills training interventions, such as the Program for the Education and Enrichment of Relational Skills (PEERS), improve social ability in individuals with ASD, ADHD, anxiety and depression. PEERS is a manualized treatment program that can be delivered to preschoolers, adolescents, and young adults over 14 to 16 weeks. The group sessions are structured to provide didactic instruction as well as social skill rehearsal on topics such as conversational skills, developing friendship networks and finding sources of friends, entering and exiting group conversations, handling teasing and embarrassing feedback, and resolving arguments. The young adults program includes additional sessions on relationships and dating. In TS, a feasibility study found the PEERS adolescents program to be acceptable, feasible and showing promise in improving social outcomes. This supports the delivery of the PEERS family of interventions, with few adaptations, for girls and young women with TS with social skills challenges. Together with earlier studies examining cognitive training, these findings indicate psychosocial therapies should be actively pursued in TS whenever impairing symptoms are present, in line with broader clinical indications for management of social skills challenges, anxiety, depression, ADHD or learning difficulties. Literature examining mechanisms, efficacy, or treatment course for psychopharmacological interventions in TS is fundamentally lacking, despite the broad evidence for higher rates of psychiatric conditions whose treatment may indicate use of medications. One such example is...
treatment of ADHD – given the benefit of pharmacological management for ADHD in the
general population, psychostimulants, atomoxetine, and alpha-agonists are also frequently
utilized in routine management of individuals with TS. Several considerations are relevant given
the broader constellation of symptoms and potential comorbidities in TS when using these
classes of medication. This includes concerns that catecholaminergic effects in
psychostimulants (e.g., methylphenidate, mixed amphetamine salts, etc.), and atomoxetine,
may be associated with unintended adverse side effects of increased heart rate, hypertension,
and potential association with arrhythmia. Specific to TS, there is additional concern for
individuals with TS with known structural cardiac defects, particularly the aorta, or history of QT
prolongation. Given these considerations, it is recommended that individuals with TS be
referred for cardiac consultation and/or ECG prior to starting pharmacological treatment for
ADHD, which is also consistent with existing guidelines for ADHD management for individuals
with an increased cardiac risk profile.

However, it should also be noted that despite lack of TS-specific literature, expert clinical
opinion suggests that with appropriate screening and routine subsequent monitoring, effective
management of ADHD with traditional medications may have significant benefit for affected
individuals. Another alternative in management of ADHD includes treatment with alpha
agonists, such as long-acting clonidine or guanfacine, which may be associated with
hypotensive effects. While not a specific treatment target in ADHD management, this should
also be considered, in coordination with cardiological management. Another aspect of
psychostimulant management of ADHD includes recent data demonstrating potential overall
decrease in adult height in cohorts of youth with ADHD who consistently took stimulants over
an extended period. This potential adverse side effect should be considered with families to
develop shared decision-making treatment plans balancing goals for ADHD symptom
management and growth.

8.3.3 Collaboration with schools
**R 8.4** We recommend that a “support plan” be prepared by the patient’s specialist providers as a tool to empower individuals and their caregivers in advocating for all necessary supports, outside the medical environment (e.g., schools, community), to achieve optimal educational and socioemotional development (Ungraded Good Practice Statement).

For children and adolescents with TS, we recommend close communication and collaboration between the individuals’ specialist providers and the school system. This recommendation is in line with best practices for supporting children with health-related conditions (https://www.cdc.gov/healthyschools/chronic_conditions/pdfs/2017_02_15-how-schools-can-students-with-chc_final_508.pdf; https://www.gov.uk/government/publications/supporting-pupils-at-school-with-medical-conditions--3). Not all families live near a hospital with TS specialty providers, which limits how often the patient is able to visit the hospital or clinical setting for intervention/treatment sessions. However, all children spend a large majority of their time in the school setting. Therefore, school staff (e.g., teachers, school psychologists, social workers, school nurses) are in an ideal position to be able to support the educational and socioemotional needs of students with TS. Not all school staff, however, are familiar with the neurocognitive and psychosocial features of TS. We recommend that healthcare/specialist providers prepare a “support plan” in collaboration with the individual, the family, and relevant school staff to enhance communication and understanding regarding TS and associated features. Individualized health care plans are often used by the school system for children with chronic health conditions such as diabetes or epilepsy, but we propose that use of an adapted support plan, with increased emphasis on psychosocial support, may be highly beneficial for students with TS. This support plan should include psychoeducation about TS to inform school staff of the primary features and relevant implications. Additionally, the plan should outline the student’s needs in terms of medical and psychosocial care. For example, the plan may include information about a student’s hearing impairment, as well as describe difficulties with processing speed or social interactions. The plan might also outline a specific intervention that will be implemented with the student (e.g., social skills group) and identify goals and next steps. As individuals with TS transition into the workforce, this support plan can be adapted to meet
vocational needs and can be used as a tool for individuals to advocate for any necessary accommodations in the workplace. It is important to note that not all families will feel comfortable sharing details of their child’s diagnosis or features with their school. Therefore, the use of a support plan should only be considered after engaging the individual and their caregivers in shared decision making (example template of a support plan for students with TS is provided as supplemental text 2).

8.3.4 Psychoeducation and Health Literacy Across the Lifespan

R 8.5 We recommend counseling regarding TS that emphasizes personal understanding and meaning of the features associated with TS (Ungraded Good Practice Statement).

TS may have far-reaching consequences for psychosocial functioning and well-being. Psychoeducation on the neuropsychological and psychosocial consequences enables parents and individuals to anticipate potential neuropsychological and psychosocial needs and to initiate early intervention when indicated. Congenital and chronic conditions require coping and adaptation, however for most parents and affected individuals, role models for coping are often unavailable. Teaching the active use of coping strategies empowers patients’ abilities and improves psychosocial well-being. In the process of acceptance and adaptation, many parents or individuals often benefit from shared understanding of experiences and associated distress, and provision of support. Relatedly, to obtain required help, caregivers and individuals must be able to effectively communicate on the diagnosis and their neuropsychological or psychosocial problems.

There are strong reasons for emphasizing openness with girls with TS regarding all aspects of the medical condition and its varied implications. First, successful transition from pediatric to adult care is predicated on the person’s full understanding of their condition, its treatment, and its potential impact on their future. Additionally, developing skills in communication, decision-making, and self-advocacy is crucial to support their empowerment. Withholding details about aspects of their condition from girls with TS can only serve to impede a successful
transition process. In a recent survey including adults with TS (26 years and older), 86.4% self-reported they were independent in managing their healthcare, whereas only 63.5% of parents perceived their daughters of the same age as being independent. Similarly, only 59.0% of adults with TS and 47.6% of parents of adults were very confident in the woman’s ability to understand her healthcare providers' recommendations. Although gaps in understanding are multifactorial, lack of openness throughout development is a modifiable contributor that should be targeted (additional information in Section 5. Transition).

Another key reason for emphasizing openness in educating the child and teen with TS is the relationship between such communication and the person’s emerging self-image. The view of oneself (self-image) and the value ascribed to it (self-esteem) are key elements of the individual’s self-concept and significant contributors to emotional well-being. A positive self-concept can serve as a buffer against psychosocial stressors and mitigate emotional distress. Having a clear and well-defined self-concept, including a realistic understanding of one's strengths and weaknesses, fosters a positive self-image. Research has indicated that individuals with a well-developed self-concept tend to experience less uncertainty and often have greater self-confidence.

Secrecy about the child’s medical condition can threaten the development of a positive self-concept, yet reluctance to fully educate youth with chronic medical conditions is common. In the case of TS, barriers to educating the child include caregivers feeling ill-equipped to disclose the diagnosis, and desire to protect their daughter from potential emotional distress related to infertility. Secrecy surrounding a child’s medical condition can pose a risk to the development of a positive self-concept. It is important for caregivers and healthcare providers to consider how to provide developmentally appropriate information and support, considering the person’s emotional well-being as well as the benefits that can come from a better understanding of the condition and its potential implications. A tool for this purpose has recently been described. It is crucial to strike a balance between the child's right to privacy and the need for disclosure in certain situations, such as informing healthcare providers, teachers, or close family members who may be involved in the child's care and support.
Decisions about when and how to disclose a child's TS, or any chronic condition, should prioritize the child's well-being and best interests.

Narrative methods for chronic illness involve using storytelling and personal narratives as a means of understanding, coping with, and communicating the experience of living with a chronic health condition (Morioka and Nomura 2021). This approach recognizes the importance of individuals' unique stories and perspectives when it comes to a chronic condition. Key components of a narrative approach include storytelling, in which the individual is encouraged to share personal stories through writing or speaking; providing a more comprehensive understanding of the impact of the medical condition that goes beyond medical symptoms to consider the emotional, social, and psychological implications of the condition and associated medical experiences. Benefits of a narrative approach include empowerment that comes from sharing one’s story, making sense of one’s experiences, and gaining a sense of control over their lives. In the survey of adult women with TS and parents of adult daughters cited above, only 48.1% and 40.6%, respectively, felt “very confident” in the woman’s ability to explain her healthcare needs to friends and family members.

Narratives can serve as a coping mechanism by providing an outlet for expressing emotions, processing experiences, and developing resilience in facing the challenges stemming from the medical condition. Personal narratives can challenge stereotypes (e.g., all women choose to become pregnant) and reduce the stigma associated with a chronic condition (e.g., learning disabilities or problems with social communication). Sharing narratives within support groups or online communities can create a sense of belonging and support. Others facing similar challenges can relate to and learn from these stories. Engaging with one’s narrative can be a form of healing and self-care. It encourages self-reflection and self-compassion.

**R 8.6** We recommend that girls and women with TS receive counseling regarding sexual health and sexual well-being (Ungraded Good Practice Statement).

The World Health Organization defines *sexual health* as “…a state of physical, emotional, mental and social well-being in relation to sexuality; it is not merely the absence of disease,
dysfunction or infirmity” (https://www.who.int/health-topics/sexual-health#tab=tab_2). While the term “sexual health” encompasses both the public health and personal well-being aspects of sexuality, healthcare systems often prioritize areas such as fertility management, sexual violence prevention, and the prevention and treatment of sexually transmitted infections over the person’s subjective sexual experiences and contentment with their sexual life; factors such as enjoyment, comfort, and satisfaction.

It is a recurring finding that women with TS are delayed in psychosexual milestones and less likely to be sexually active or in a stable romantic/sexual relationship, compared to the general population or other comparison groups \(^{527, 529, 814, 859, 860}\). Simple accounts, such as specific genetic, hormonal, or other physical features of the syndrome, do not systematically account for these differences across studies \(^{527, 529, 814}\), but on-time puberty may have a salutary influence \(^{528, 814}\). An additional, non-syndromic factor investigated as contributing to poorer sexual well-being in women with TS is poorer self-concept and body image \(^{860, 861}\) and lower confidence as a sex partner \(^{814}\). A more consistent observation has been that women with TS who are in a stable relationship report typical levels of sexual satisfaction \(^{529, 859, 860}\).

Physical appearance and body contentment play a role in shaping self-perceptions and sexual behavior. A negative body image can lead to heightened self-consciousness during intimate encounters, difficulties in initiating sexual interactions, and a reduced likelihood of experiencing satisfying sexual encounters. Keeping in mind the deeply individual nature of sexual well-being and the role that clinical management can exert in the process. It is noteworthy that one study found that just over a slight majority of women with TS reported being satisfied with their breasts \(^{810}\). This level of satisfaction aligns with the results of other studies which have reported relatively low breast satisfaction in women with TS \(^{862, 863}\).

In response to these well-documented threats to sexual well-being, it is advised to start discussions related to sexual development during early adolescence. Topics covered include the importance of hormone-replacement therapy and the potential impact on sexual well-being. Parents can play a crucial role in initiating these discussions. They may introduce the topic, answer questions, or facilitate communication with healthcare providers and can provide important insights into the teen’s readiness and interest. Discussions about sexual well-being...
can be initiated during routine follow-up appointments with specialists. This can provide a structured and supportive context for these conversations. It is necessary to revisit and adapt these conversations over time as the person's needs and developmental stage evolve.

It is important to discuss the emotional aspects of sexual well-being, including self-esteem, body image, and relationships and to offer support and strategies for dealing with any emotional challenges related to TS. For those who are sexually active, concerns such as pain during intercourse should be addressed with information on treatments or strategies to manage these issues. Encourage participation in TS support groups or counseling services specializing in sexual well-being to connect with others facing similar challenges. Sexual health counselors are well-equipped to assist women with TS or anyone experiencing anxiety related to sexual health by applying a variety of evidence-based therapeutic approaches.

**R 8.7** We suggest that individuals with TS and their parents be encouraged to network with local/regional/national TS peer support organizations.

Peer support for those affected by medical conditions refers to a reciprocal and beneficial relationship in which individuals who have encountered or are confronting similar challenges share emotional, informational, and social support. In the case of chronic health conditions, support can be sought directly by the patient or by their caregivers. Peer support may be individual or group-based, in-person or online. Peer support has become a common feature of individual- and family-centered care because of its purported positive effects on various aspects of well-being and health outcomes. A recent systematic review of reviews on peer support for people (children and adults) with chronic conditions found methodological weaknesses across the underlying research literature and lack of consistent significant effects of peer support.

Similarly, a Cochrane systematic review of peer support interventions for caregivers of children with complex healthcare needs found no clear evidence of effects of peer support interventions on any parent outcome; however, the certainty of evidence was low to very low. Importantly, this review found no evidence of harm from participation. Despite these caveats, there is an abundance of qualitative data indicating that patients and parents value and find...
emotional support in peer networks. A recent survey involving individuals affiliated with major TS support organizations in the U.S. included items regarding peer support. Participants included adults with TS (>18 years), parents of adults with TS, and parents of girls with TS (<18 years). Notably, even though these participants were in some way connected to TS support organizations, only a minority (ranging from 25.1% to 38.6%) reported currently utilizing peer support. It is essential to recognize that the appeal and effectiveness of peer support can vary based on factors like the nature of the chronic illness, and the specific peer support program. To reduce the barrier to girls and women with TS benefiting from peer support, providers may need to facilitate early contacts to overcome hesitancy stemming from anxiety and social communication difficulties frequently observed in this population.

8.3.4 Principles of Shared Decision Making

Optimal clinical care for TS encompasses a variety of medical procedures and treatments that are not urgently required to address life-threatening or immediately critical medical situations. Elective medical interventions in TS include screening and diagnostic tests, GH therapy, timing of pubertal induction, cosmetic plastic surgery, gonadectomy in girls with Y chromosome material, and fertility treatments, among others.

Shared decision making (SDM), considered a core feature of patient-centered care, is a process that recognizes patients (or their caregiver proxies) as active participants in their healthcare, valuing their input and preferences. The principles of SDM are broadly endorsed by national and international medical societies and organizations. SDM holds particular importance in situations where evidence does not decisively favor one option or when a decision requires careful consideration of individual values.

SDM is characterized by three fundamental elements: first, providers acknowledge, and patients (or caregivers) recognize, the need for a decision; second, all parties involved gain an understanding of the best evidence related to the advantages and disadvantages of all reasonable treatment options, including those not preferred by the clinician; and third, the values and preferences of patients (and for minors, those of the child's parents) are integrated into the decision-making process. Beyond its ethical significance and alignment with clinical
guidelines and healthcare policies, SDM offers a range of benefits, including: equipping patients with a deeper understanding of their medical condition and available treatment alternatives; increasing patient satisfaction; enhancing adherence to treatment plans; ensuring a closer alignment between the chosen option and the patient's tailored needs, values, and context; diminishing uncertainty in decision making; and fostering a collaborative and trusting relationship between individuals and their healthcare providers. Notwithstanding its importance as an indicator of healthcare quality, evidence that SDM is routinely implemented in pediatric and adult healthcare is difficult to find, whereas reports of barriers and resistance to its application are plentiful.

Patient decision aids (PtDAs) have been introduced as tools or resources to increase the likelihood of adherence to the principles of SDM. These aids have been demonstrated to enhance knowledge, accuracy in understandings of risk, reduced decision-related uncertainty, and better alignment of personal values with the chosen course of action. PtDAs are designed to complement, rather than replace, counseling from a healthcare provider. Several recommendations in these clinical practice guidelines are conditioned by the requirement of applying SDM. Clinicians are encouraged to consider using PtDAs in supporting the process of SDM. Information about PtDA development methods, international standards, and a decision aid inventory can be found at the Patient Decision Aids website of The Ottawa Hospital Research Institute.

Deborah Matthews\textsuperscript{40}, Trine Mikkelborg\textsuperscript{41}, Kristian Havmand Mortensen\textsuperscript{42}, Leena Nahata\textsuperscript{43},
Mackenzie Norman\textsuperscript{44}, Sheetal R. Patel\textsuperscript{45}, Charmian Quigley\textsuperscript{46}, Lukas O. Ridder\textsuperscript{4}, Richard J.
Santen\textsuperscript{47}, Nicole Sheanon\textsuperscript{48}, Arlene Smyth\textsuperscript{49}, Helen Turner\textsuperscript{50}, Franciska Verlinde\textsuperscript{51}, Mette Hansen
Viuff\textsuperscript{52}, Malgorzata Wasniewska\textsuperscript{53}, Berber van der Weijde\textsuperscript{54}, Joachim Woelfle\textsuperscript{55} and Jeanne
Wolstencroft\textsuperscript{56}.

\textsuperscript{1}Carrera de Biologia, Universidad Central del Ecuador, Quito, Ecuador; \textsuperscript{2}Centre for Psychiatry
Research, Department of Clinical Neuroscience, Karolinska Institute & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden; \textsuperscript{3}Department of Endocrinology, Aarhus University Hospital, Denmark; \textsuperscript{4}Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, USA; \textsuperscript{5}Department of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Gießen, Germany; \textsuperscript{6}Department of Clinical Science, Intervention and Technology, Department of Otorhinolaryngology, Karolinska Institutet and Medical Unit ENT, Karolinska University Hospital, Stockholm, Sweden; \textsuperscript{7}Department of Pediatrics, Northwestern University’s Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois; \textsuperscript{8}Department of Pediatrics, Cincinnati Children’s Hospital, Cincinnati, Ohio; \textsuperscript{9}Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; \textsuperscript{10}Department of Gastroenterology and Hepatology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom; \textsuperscript{11}Division of Endocrinology, Cincinnati Children’s Hospital, Cincinnati, Ohio; \textsuperscript{12}Reference center for Inflammatory biliary diseases and Autoimmune Hepatitis, Saint-Antoine Hospital, Sorbonne University, Paris, France; \textsuperscript{13}Division of Genetics, Johns Hopkins All Children’s Hospital, St. Petersburg, Florida; \textsuperscript{14}Department of Women’s Health, University College London Hospitals, UK; \textsuperscript{15}Endocrinology Division, Sheikh Shakhbout Medical City & faculty of health and science, Khalifa University, Abu Dhabi, United Arab Emirate; \textsuperscript{16}Pediatric Psychology Unit, Department of Child and Adolescent Psychiatry and Psychology, Sophia Children’s Hospital, Erasmus Medical Center Rotterdam, The Netherlands; \textsuperscript{17}Pediatric and Adolescent Gynecology, Department of Surgery, Children’s Mercy Hospital, Kansas City, Missouri, USA; \textsuperscript{18}Pediatric Endocrinology, Nationwide Childrens Hospital, Columbus OH, USA;
Division of Pediatric Endocrinology and Diabetes, Emory University School of Medicine/Pediatric Institute, Children's Healthcare of Atlanta; Department of Pediatrics, University of Washington, Seattle, WA, USA; Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Pediatric Otolaryngology, eXtraOrdinarY Kids Clinic, Children’s Hospital Colorado, Aurora, CO, USA; Department of Paediatric Cardiology, Ghent University Hospital, Ghent, Belgium; Department of Pediatrics, Monash Childrens Hospital, Melbourne, Australia; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore; Khoo Teck Puat-National University Children’s Medical Institute, National University Health System; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA; eXtraOrdinarY Kids Clinic, Children’s Hospital Colorado, Aurora, Colorado, USA; Department of Pediatrics, Toranomon Hospital, Tokyo, Japan; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Gastroenterology, Nutrition, and Endocrinology, Osaka Women's and Children's Hospital, Japan; Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina; Department of Pediatrics and Human Development and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, USA; Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Clinical Science, Pediatrics, Umeå University, SE-90185 Umeå, Sweden; GeneDX, Gaithersburg, MD, USA; Division of Pediatric Endocrinology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Medical Genetics, MassGeneral for Children, Boston, Massachusetts, USA; Division of Pediatric Endocrinology, Connecticut Children's Medical Center, Farmington, USA; Division of Endocrinology, Diabetes & Metabolism, Nemours Children’s Health, Jacksonville, Florida; Children's Diabetes & Endocrine Service, Great North Children's Hospital, Newcastle upon Tyne, UK; Patient representative, Turner syndrome Society of Denmark; Cardiorespiratory Unit, Great Ormond Street Hospital for Children, London, UK; Division of Endocrinology, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA; Department of Counseling, Educational Psychology & Special Education, Michigan State University.
University, East Lansing, Michigan, USA; Fetal Cardiac Program, Ann & Robert H Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA; Sydney Children’s Hospital, Randwick NSW 2031, Australia; Department of Medicine, Endocrinology and Metabolism, University of Virginia School of Medicine, Charlottesville, Virginia; Division of Pediatric Endocrinology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; Patient Advocate, Executive Officer of Turner Syndrome Support Society of the United Kingdom; Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK; Belgian Society for Pediatric Endocrinology and Diabetology, Brussels, Belgium; Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark; Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy; Patient Advocate, Turner Contact Nederland, The Netherlands; Department of Pediatric Endocrinology, Children’s Hospital, University of Erlangen, Erlangen, Germany; Great Ormond Street Institute of Child Health, University College London, London, England

Conflicts of interest
P.F. Backeljauw has been a consultant for and has received honoraria from: Ascendis Pharma, BioMarin Pharmaceutical, Cavalry Biosciences, Ipsen Biopharmaceuticals, Inc., Novartis, Novo Nordisk, Sandoz, Tolmar Pharmaceuticals, and Upsher-Smith Laboratories. V. Bamba has received research funds from Lumos Pharma, Pfizer and Abbvie and is on the Scientific Advisory Board for Long Acting Growth Hormone, Novo Nordisk, Scientific Advisory Board for Turner Syndrome Society of the US and the Steering Committee for the INSIGHTS Committee
sponsored by the TSGA. I. Bedei has received speaker or consultancy fees from Pfizer and
Merck and is on the Advisory Board of the Turner Syndrome Society Germany. W.J. Brickman
has research funds from Ascendis Pharma. S. Chernausek is on the advisory board of Ascendis
Pharma. S. Christin-Maitre has received speaker or consultancy fees from Theramex, IBSA, Lilly
and Merck. J. Cobbled has received research funds from NIHR Oxford Biomedical Research
Centre. S.C. Corathers has received research funds from The Agency for Healthcare Research
and Quality and the National Institute of Diabetes and Digestive and Kidney Diseases. C.
Corpechot has received speaker or consultancy fees from Echosens, research funds from
Intercept Pharmaceuticals and Arrow Generiques, and is on the Advisory Boards of Ipsen,
CymaBay and GSK. M. L. Crenshaw is on the Turner Syndrome Society of the US Professional
Advisory Board, the Turner syndrome Research Registry Scientific Advisory Board and the
NSIGHTS Registry Advisory Board. M. Davies has received research funds from NIHR and is a
patron of the Turner Syndrome Support Society (UK), on the Medical Advisory Council of the
British Menopause Society, Chair of oversight committee UKStore, Premature Ovarian
Insufficiency guideline update group member at ESHRE, female hypogonadism clinical
guidelines group member at the British Endocrine Society and hormone replacement guideline
group member at the British Gynaecological Cancer Society. S. Davis has received research
funds from Ascendis Pharma, the Turner Syndrome Global Alliance, NIH and the Boettcher
Foundation. A. Deeb has received research funds from Abbott Diabetes. T. Dowlut-McElroy has
received research funds from Children’s Mercy Hospital, Kansas City, Missouri, U.S.A and is on
the Advisory Board of The INSIGHTS Registry. A. Duijnhouwer has received speaker or
consultancy fees from Johnson & Johnson, MSD and Bayer, research funds from Johnson &
Johnson, and is on the advisory board of Johnson & Johnson. D. Fadoju has received research
funds from Ascendis Pharma and is on the INSIGHT Registry Advisory Board and the Turner
syndrome Research Registry Scientific Advisory Board. P. Y. Fechner has received research
funds from Ascendis Pharma. K. Fleischer has received speaker or consultancy fees from
GoodLife and Ferring, and research funds from Merck Serono, GoodLife and Ferring. A. Gawlik
has received research funds from ESPE Research Unit and is coordinator of the ESPE Turner
Syndrome Working Group. M. Geffner has received speaker or consultancy fees from Spruce
Biosciences, research funds from Ascendis Pharma, Diurnal, Neurocrine Biosciences, Novo Nordisk, Pfizer and Spruce Biosciences, is on the Advisory Boards of Adrenas Therapeutics, Ascendis Pharma, Eton Pharmaceuticals, ICON Clinical Research, LLC/Aeterna Zentaris, Neurocrine Biosciences, Novo Nordisk, Pfizer, and Spruce Biosciences, and has royalties at McGraw-Hill and UpToDate. C. H. Gravholt has received speaker or consultancy fees from Novo Nordisk, Merck and AstraZeneca, and is on the Steering committee for the International Disorder of Sex Development Registry (i-DSD). D. Hong has received research funds from NIMH and is on the Advisory Boards of AXYS and Little Otter Inc. I. Gutmark-Little has received research funds from Novo Nordisk, Ascendis Pharma, Pfizer and Ipsen and is on the Advisory Board of The Turner Syndrome Society of the United States. M. Kawai has received research funds from Novo Nordisk and Pfizer. A. Keselman has received speaker or consultancy fees from Novo Nordisk, Pfizer, Merck, Alexion, Biosidus, Raffo and Sandoz, and is on the Advisory Board of Novo Nordisk Argentina. K. O. Klein has received research funds from Ascendis Pharma. B. Kristrøm, D. Matthews and T. C. J. Sas have received speaker or consultancy fees from Novo Nordisk. P. Kruszka is employed by GeneDx. J. Law has received speaker or consultancy fees from Ascendis Pharma, research funds from Ascendis Pharma and Turner Syndrome of the Carolinas and is on the Turner Syndrome Society of the United States Physician Advisory Board. A. E. Lin is on the Advisory Boards of The Turner Syndrome Society of the United States and the Myhre Syndrome Foundation. N. Mauras has received speaker or consultancy fees from Agios and research funds from Novo Nordisk, Pfizer, Abbvie, Toolbar and Dexcom. T. Mikkelborg is on the advisory board of the Danish Turner association. S. K. Prakash has received research funds from the National Institute of Health, the National Science Foundation and the John Ritter Foundation for Aortic Health and is on the Advisory Boards of The Turner Syndrome Society of the United States and the Turner Syndrome Global Alliance. C. Quigley is member of the Health and Research Advisory Committee, InterConnect (formerly Androgen Insensitivity-Differences of Sex Development Support Group, USA). R. Kanakatti Shankar has received research funds from BioMarin and is on the steering committee of the INSIGHTS registry. N. Sheanon has received travel fees from the American Diabetes Association, research funds from National Institute of Health and Helmsley, and is on the American Diabetes Association Camp Advisory
Board. A. Smyth has received travel fees from the Endocrine Academy Sandoz and is on Advisory Boards of the Scottish Paediatric Endocrine Group, the Data Access Committee European Registries for Rare Endocrine Committees, the European Reference Network, the European Society for Endocrinology, the European Society of Paediatric Endocrinology, the International Coalition of Organisations Supporting Endocrine Patients, the Scottish Cross Party Group for Rare and Undiagnosed Condition. J. A. van der Velden has received research funds from Merck. M. Wasniewska has received speaker or consultancy fees from Merck, Novo Nordisk, Pfizer and Sandoz, research funds from Pfizer and is on Advisory Boards of Merck, Novo Nordisk, Pfizer and Sandoz. J. Woelfle has received speaker or consultancy fees from Ascendis Pharma, Merck, Novo Nordisk, Pfizer and ICON, is on Advisory boards for Biomarin, Hexal, Novo Nordisk, Pfizer, Roche, and is a board member of the German society for pediatric endocrinology and metabolism (DGKED), and the patient support group BKMF (German association of short-statured people and their families). J. Wolstencroft has received research funds from the UK Medical Research Council and NIHR.

Acknowledgements: Special thanks need to go to Jeanette Simonsen (for the logistical support with the consensus meeting organization). The authors thank the members of the societies of the International Consortium of Pediatric Endocrinology for reviewing this manuscript and for their thoughtful feedback.

Funding: Claus H. Gravholt was supported by the Novo Nordisk Foundation (Nos. NNF15OC0016474 and NNF20OC0060610), sygesikringen danmark (No 2022-0189) and the Independent Research Fund Denmark (Nos. 0134-00406 and 0134-00130B). David E. Sandberg was supported by a grant from The Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD093450).


23. Hook EB & Warburton D. Turner syndrome revisited: review of new data supports the hypothesis that all viable 45,X cases are cryptic mosaics with a rescue cell line, implying an origin by mitotic loss. *Hum.Genet.* 2014 133 417-424.


59. Viuff MH, Stochholm K, Uldbjerg N, Nielsen BB, the Danish Fetal Medicine Study G & Gravholt CH. Only a minority of sex chromosome abnormalities are detected by the Danish national prenatal screening program for Down syndrome. Hum.Reprod. 2015 30 2419-2426.


72. Mardy AH & Norton ME. Diagnostic testing after positive results on cell free DNA screening: CVS or Amnio? *Prenat Diagn* 2021 **41** 1249-1254.


144. Isojima T & Yokoya S. Growth in girls with Turner syndrome. *Front Endocrinol (Lausanne)* 2022 **13** 1068128.


Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program. J Clin Endocrinol Metab 2019 104 379-389.


492. Campbell F, Biggs K, Aldiss SK, O'Neill PM, Clowes M, McDonagh J, While A & Gibson F. Transition of care for adolescents from paediatric services to adult health services. *Cochrane Database Syst Rev* 2016 **4** Cd009794.


512. Thomsen EL, Boisen KA, Hanghøj S, Hansson H, Grabow Scheelhardt HV, Christensen ST & Esbensen BA. A comprehensive transfer program from pediatrics to adult care for parents of adolescents with chronic illness (ParTNeRSTEPs): study protocol for a randomized controlled trial. *Trials* 2022 23 1034.


563. Ulrich ND, Raja N, Ellman E & Moravek MB. Outcomes of Fertility Preservation Consults for Women at Risk for Primary Ovarian Insufficiency Due to History of Cancer Treatment or Mosaic Turner Syndrome. J Adolesc Young Adult Oncol 2022 11 427-432.


Gravholt CH, Klausen IC, Weeke J & Christiansen JS. Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethisterone. *Atherosclerosis* 2000 **150** 201-208.


726. Han TS, Cadge B & Conway GS. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner's syndrome. *Clin Endocrinol (Oxf)*. 2006 65 643-647.


Green T, Naylor PE & Davies W. Attention deficit hyperactivity disorder (ADHD) in phenotypically similar neurogenetic conditions: Turner syndrome and the RASopathies. *J Neurodev Disord* 2017 **9** 25.


851. Willis ER & McDonagh JE. Transition from children's to adults' services for young people using health or social care services (NICE Guideline NG43). *Arch Dis Child Educ Pract Ed* 2018 103 253-256.


862. van de Grift TC & Kreukels BPC. Breast development and satisfaction in women with disorders/differences of sex development. *Hum Reprod* 2019 34 2410-2417.


873. Elwyn G, Rix A, Holt T & Jones D. Why do clinicians not refer patients to online decision support tools? Interviews with front line clinics in the NHS. *BMJ Open* 2012 **2**.


Figure legends

Figure 1  Summary of the issues discussed and questions raised in relation to puberty and hormone replacement therapy.

Figure 2. Suggested workflow for cardiovascular follow-up from gestation to transition. TTE: transthoracic echocardiogram; BAV: bicuspid aortic valve; CoA: aortic coarctation; PAPVR: partial anomalous pulmonary venous return; HLHS: hypoplastic left heart syndrome; ECG: electrocardiogram; BP: blood pressure; CMR: cardiovascular magnetic resonance; CT: computed tomography. a: Consider earlier visit if clinical concern for symptoms, murmur, or other abnormal cardiovascular exam finding. If neonatal images were reviewed by a cardiologist, clinically significant congenital lesions were ruled out, and there are no signs or symptoms concerning CHD, it is reasonable to defer cardiovascular follow up until age 9-11. b: Cardiologist may order additional imaging before or with visit if neonatal TTE inconclusive for valve morphology, coronary anatomy, or pulmonary venous anomaly; c: Consider 24-hour ambulatory blood pressure monitoring (ABPM) if available.

Figure 3 Indications to consider cardiology consultation

CV: cardiovascular; TTE: transthoracic echocardiogram; CMR: cardiovascular magnetic resonance; CT: computed tomography; CHD: congenital heart disease; QTc: corrected QT interval; ms: milliseconds. a: If neonatal images were reviewed by a cardiologist, clinically significant congenital lesions were ruled out, and there are no signs or symptoms concerning CHD, it is reasonable to defer cardiovascular follow up until age 9-11. b: In these situations, recommendations for cardiology surveillance and follow up may be more frequent and will depend on the type and severity of the lesion. c: Before pregnancy or fertility treatments, the most recent cardiovascular imaging should not be older than 2 years and should not be overdue based on the cardiologist’s last set of recommendations. CT or MRI is advised for the most thorough assessment.
**Figure 4** Suggested algorithm for the frequency of aortic surveillance of children and adolescents with TS, based on the perceived severity of aortic dilation and additional risk factors for aortic dissection. BAV: bicuspid aortic valve; HTN: hypertension; CoA: aortic coarctation; Z: Z-score. Frequency of surveillance may be affected by additional risk factors such as rapid aortic dilation. Aortic surveillance refers to measurement of aorta using transthoracic echocardiography, cardiovascular magnetic resonance, or computed tomography by a cardiovascular specialist.

**Figure 5** Suggested algorithm for the frequency of aortic surveillance of adults with TS based on the perceived severity of aortic dilation and additional risk factors for aortic dissection. BAV: bicuspid aortic valve; HTN: hypertension; CoA: aortic coarctation; ASI: aortic size index; AHI: aortic height index; Z: Z-score. Frequency of surveillance may be affected by additional risk factors such as rapid aortic dilation. If ASI > 2.5 cm/m\(^2\) (corresponding to AHI > 25 mm/m or Z > 4) or ASI > 2.3 cm/m\(^2\) (corresponding to AHI > 23 mm/m or Z > 3.5) with additional risk factors (see text), consider evaluation for elective aortic repair. Aortic surveillance refers to measurement of aorta using transthoracic echocardiography, cardiovascular magnetic resonance, or computed tomography by a cardiovascular specialist.

**Figure 6** Algorithm for management of hypertension in TS

BP: blood pressure; LVH: evidence of left ventricular hypertrophy on electrocardiogram or echocardiogram; ABPM: ambulatory blood pressure monitoring; HBPM: home blood pressure monitoring; SBP: systolic blood pressure; DBP: diastolic blood pressure; BAV: bicuspid aortic valve; TAV: tricuspid aortic valve; AHI: aortic height index (mm/m); ASI: aortic size index (cm/m\(^2\)); ARB: angiotensin receptor blocker; ACEi: angiotensin converting enzyme inhibitor; CCB: dihydropyridine calcium channel blocker; Aortic disease: aortic dilation or dissection. *For children, diagnosis of hypertension is dependent on normative values based on age, sex, and height that may vary between regional guidelines\(^{426, 428}\).
Figure 7: Proposed TS transition timeline (adapted from White, 2018)
Figure 8 Comprehensive neuropsychological evaluation (see also table 18)
Figure 2
56x79 mm (x DPI)
Figure 3
39x55 mm (x DPI)

Figure 4
41x57 mm (x DPI)
Figure 5
45x64 mm (x DPI)

Figure 6
34x48 mm (x DPI)
Figure 7
58x82 mm (x DPI)
Table 1 Type and frequency of karyotypes associated with Turner Syndrome

<table>
<thead>
<tr>
<th>Karyotype</th>
<th>Frequency (%)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>45,X</td>
<td>40-50</td>
<td>Monosomy X</td>
</tr>
<tr>
<td>45,X/46,XX</td>
<td>15-25</td>
<td>Mosaicism with 46,XX</td>
</tr>
<tr>
<td>45,X/47,XXX; 45,X/46,XX/47,XXX</td>
<td>3</td>
<td>Mosaicism with 47,XXX</td>
</tr>
<tr>
<td>45,X/46,XY</td>
<td>10-12</td>
<td>Mosaicism with 46,XY</td>
</tr>
<tr>
<td>45,X/46,X,r(X)</td>
<td>Rare</td>
<td>Ring X chromosome</td>
</tr>
<tr>
<td>46,X,i(Xq); 46,X,idic(Xp)</td>
<td>15</td>
<td>Isochromosome Xq</td>
</tr>
<tr>
<td>46,XX,del (p11)</td>
<td></td>
<td>Proximal deletion of Xp</td>
</tr>
<tr>
<td>X-autosome trans, unbalanced</td>
<td>Rare</td>
<td>Various</td>
</tr>
</tbody>
</table>
Table 2 Karyotypes not associated with Turner Syndrome

<table>
<thead>
<tr>
<th>Karyotype</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>46,XX,del(p22.3)</td>
<td>Distal deletion Xp22.3 (Leri-Weill syndrome)</td>
</tr>
<tr>
<td>46,XX,del(q24)</td>
<td>Premature ovarian insufficiency</td>
</tr>
<tr>
<td>46,X,idic(X)(q24)</td>
<td>Isodicentric Xq24</td>
</tr>
</tbody>
</table>
Table 3: Indications for genetic testing to diagnose Turner syndrome

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>As the only clinical feature:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fetal cystic hygroma, or hydrops, especially when severe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unexplained short stature</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided outflow congenital heart defects (excluding bicuspid aortic valve)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unexplained delayed puberty/ menarche, failure to progress puberty or secondary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infertility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Characteristic physical features</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal anomaly (horseshoe, absence, or hypoplasia)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madelung deformity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropsychologic problems, and/or psychiatric issues</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple typical or melanocytic nevi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysplastic or hyperconvex nails</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other congenital heart defects (including bicuspid aortic valve)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hearing impairment &lt;40 years of age together with short stature</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As the only clinical feature:
- Coarctation; aortic stenosis; mitral valve anomalies; hypoplastic left heart syndrome.
- Down-slanted palpebral fissures; epicanthal folds; low-set anomalous pinnae; micrognathia; narrow palate; short broad neck; webbing of the neck.
- Partial anomalous pulmonary venous return/connection; atrial septal defect, secundum type; ventricular septal defects, muscular or membranous; bicuspid aortic valve.

As least two of the following:
- Renal anomaly (horseshoe, absence, or hypoplasia)
- Madelung deformity
- Neuropsychologic problems, and/or psychiatric issues
- Multiple typical or melanocytic nevi
- Dysplastic or hyperconvex nails
- Other congenital heart defects (including bicuspid aortic valve)
- Hearing impairment <40 years of age together with short stature
### Table 4: Recommended 17β-estradiol (E2)-dose escalation for puberty induction in girls with Turner syndrome

<table>
<thead>
<tr>
<th>Timing early onset or late onset with growth potential*</th>
<th>Timing late diagnosis without growth potential</th>
<th>TD E2 dose**</th>
<th>Oral E2 dose**</th>
<th>Breast stage goal</th>
<th>Serum E2 goal (measure 2 days after patch placed if TD)</th>
<th>Uterine size Endometrium *** (ultrasound)</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Use this regimen for late onset with growth potential</td>
<td>** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)</td>
<td>** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)</td>
<td>** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)</td>
<td>** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)</td>
<td>** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)</td>
<td>** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)</td>
</tr>
<tr>
<td>Year 1 (1-12 m)</td>
<td>11-12 years old (if FSH high)</td>
<td>7 µg (1/2 of 14 µg or 1/4 of 25 µg patch)</td>
<td>0.025 mg/d</td>
<td>Stage 2 by end of time period</td>
<td>&lt;50 pmol/L (13 pg/mL)</td>
<td>1.6 cm³</td>
</tr>
<tr>
<td>Year 2 (13-24 m)</td>
<td>1-4 m (based on available patch)</td>
<td>12.5–14 µg/d</td>
<td>0.5 mg/d</td>
<td>Stage 3</td>
<td>50-150 pmol/L (12-30 pg/mL)</td>
<td>10 cm³</td>
</tr>
<tr>
<td>Year 3 (25-36 m)</td>
<td>4-12 m</td>
<td>25–37.5 µg/d</td>
<td>1 mg/d</td>
<td>Stage 4</td>
<td>150-450 pmol/L (30-120 pg/mL)***</td>
<td>50 cm³</td>
</tr>
<tr>
<td>Year 4 (37-48 m)</td>
<td>12-24 m</td>
<td>50-200 µg/d</td>
<td>2-4 mg/d</td>
<td>Stage 4- 5</td>
<td>375 pmol/L (100 pg/mL)</td>
<td>50 cm³</td>
</tr>
</tbody>
</table>

---

* Use this regimen for late onset with growth potential

** More or less based on serum E2 and breast stage (for ethinylestradiol 20–30 mcg/d and only after year 4)

*** add progesterone if spontaneous bleed AND > 2y on E2 OR endometrial stripe > 4-8 mm if < 2 y on E2. If endometrial stripe < 4 mm and E2 time > 2 y, we recommend checking serum E2 and increasing E2 dose, prior to adding progestin.
<table>
<thead>
<tr>
<th>Progesterone/Progestins</th>
<th>Sequential combined HRT – Std dose</th>
<th>Sequential combined HRT – High dose</th>
<th>Continuous combined HRT – Std dose</th>
<th>Continuous combined HRT – High dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Micronized Progesterone (oral/per vagina) (mg)</td>
<td>200</td>
<td>≥200</td>
<td>100</td>
<td>≥200</td>
<td>Devoid of androgenic properties, does not induce metabolic side effects but confers a high degree of endometrial protection</td>
</tr>
<tr>
<td>Dydrogesterone (oral) (mg)</td>
<td>10</td>
<td>20</td>
<td>5</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone acetate (oral) (mg)</td>
<td>5</td>
<td>10</td>
<td>2.5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Norethisterone acetate (oral) (mg)</td>
<td>2.5-5</td>
<td>2.5-10</td>
<td>1.25-2.5</td>
<td>5</td>
<td>Absorbed well orally and TD, significant binding to AR giving rise to unwanted acne, oily skin and weight gain</td>
</tr>
<tr>
<td>Desogestrel (oral) (mcg)</td>
<td>150</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>“not inferior” to MPA for endometrial protection, high affinity for the PR and little effect on AR, GR and MR</td>
</tr>
<tr>
<td>Levonorgestrel (oral) (mcg)</td>
<td>50-250</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>some androgenic effects but no effect on the GR, excellent endometrial protection and can be administered orally, TD or intra-uterine</td>
</tr>
<tr>
<td>Levonorgestrel (oral) (TD) (mcg)</td>
<td>10/24hrs</td>
<td>n/a</td>
<td>n/a</td>
<td>7/24hrs</td>
<td>20/24hrs</td>
</tr>
<tr>
<td>Levonorgestrel (oral) (IUD) (mcg)</td>
<td>n/a</td>
<td>n/a</td>
<td>20/24hrs</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>E2/Progesterone/Progestins combined regimens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2/Micronized Progesterone (oral) (mg)</td>
<td>1-2/100-200</td>
<td>&gt;2/&gt;200</td>
<td>1-2/100-200</td>
<td>3-4/300-400</td>
<td></td>
</tr>
<tr>
<td>E2/dydrogesterone (oral) (mg)</td>
<td>1-2/10</td>
<td>3-4/20</td>
<td>0.5-1/2.5-5</td>
<td>3-4/7.5-10</td>
<td></td>
</tr>
<tr>
<td>E2/norethisterone (oral) (mg)</td>
<td>1-2/1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2 E2 - 17β-estradiol, Std – standard, mg – milligrams, TD – transdermal, IUD – intra uterine device, PR – progesterone receptor, AR – androgen receptor, GR – glucocorticoid receptor, MR – mineralocorticoid receptor
Table 6 What is new with progesterone treatment?

| Use of Micronized progesterone or dydrogesterone as first-line product |
| Dosing – to use progesterone for at least 12 days in every month (or daily) |
| Doses of progesterone should be proportionate to the dose of E2 |
| Studies of adherence and acceptability of different approaches and regimens are needed in view of reports of poor concordance with HRT |
| Intra-uterine device with levonorgestrel is licensed for endometrial protection and contraception and has minimal side effects and lasts for 5 years. Non-sexually active women may need a brief general anesthesia for its insertion. |

E2 - 17β-estradiol

Table 7 Clinical, laboratory and radiological markers of estrogenization

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Laboratory</th>
<th>Radiological</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Breast development: every visit</td>
<td>● Serum E2 concentration in relation to E2 dose and treatment goal</td>
<td>● Ultrasound of uterus /endometrium: at first bleeding or when progesterone treatment is considered. At adult height – if uterus is still smaller than normal, a higher E2 dose for 5 years will not hamper her growth/height but stimulate uterine growth for 320</td>
</tr>
<tr>
<td>● Growth velocity: every visit till final height</td>
<td>● FSH, LH are used by some</td>
<td>● Bone age X-ray rate of maturation</td>
</tr>
<tr>
<td>● Monitoring of vaginal bleeding/menstruation</td>
<td></td>
<td>● DXA and pQCT (estimation of peak bone mass) at last pediatric visit when adult height is attained (approx. age 18 years). As we do not have knowledge on when TS women attain their peak bone mass it may be wise to repeat DXA and pQCT at age 21 years.</td>
</tr>
<tr>
<td>● Quality of life</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● Sexuality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● Neurocognition</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
E2 - 17β-estradiol, DXA – dual x-ray absorptiometry, FSH – follicle-stimulating hormone, LH – luteinizing hormone, pQCT – peripheral quantitative CT

Table 8 Estrogen replacement therapy in adulthood - estrogen type, route and dose

<table>
<thead>
<tr>
<th>Estrogen Type</th>
<th>Route of administration</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol</td>
<td>Patch (TD)</td>
<td>50-200 µg/24hrs</td>
</tr>
<tr>
<td></td>
<td>Gel sachet (TD)</td>
<td>1.5-3 mg/day</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>2-4 mg/day</td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>Patch (TD)</td>
<td>34 µg/24hrs</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>20-30 µg/day</td>
</tr>
</tbody>
</table>

TD - transdermal

Table 9 Estrogen replacement therapy (ERT) effects on other outcomes

<table>
<thead>
<tr>
<th>Issue</th>
<th>Outcomes</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid metabolism</td>
<td>● Studies differ on whether oral E2 vs. TD E2 leads to increased total cholesterol and decreased HDL&lt;br&gt;● Studies differ on impact of dose of E2 and absence of E2 treatment on lipids&lt;br&gt;● Oral contraceptive pills vs. other ERT: higher total cholesterol, LDL cholesterol and triglyceride</td>
<td>1, 280, 284, 286, 319, 327, 876-879</td>
</tr>
</tbody>
</table>
| Glucose metabolism | • Dose and route of E2 do not affect glucose and insulin concentration and tolerance  
• Time of day of E2 dose may affect glucose metabolism with evening oral E2 leading to lower glucagon and insulin levels (during an OGTT), lower insulin resistance  
• One report of lower use of antidiabetics with E2 treatment |
| Liver function | • No evidence of liver toxicity  
• Studies vary on effect of E2 treatment on liver function and disease |
| Bone | • Studies vary on report of changes in bone mineral density (BMD) based on dose and route of E2  
• Earlier initiation of ERT does affect BMD with higher BMD/better bone quality/greater trabecular bone score |
| Blood pressure | • Oral E2 or TD E2: lowers blood pressure, although E2 may cause salt and water retention  
• Ethinyl estradiol containing contraceptives (unless containing an anti-mineralocorticoid progestin): raise blood pressure  
• Lower or higher dose of oral E2: increase of systolic and diastolic blood pressure was observed in late adolescence and early adulthood  
• ERT (2mg E2, 12 weeks): higher central systolic blood pressure and indices that showed impaired endothelial function |
| Cardiovascular risk | - Oral conjugated estrogens: no studies in children in view of thromboembolic and cardiovascular disease risks  
- Lack of association with ASI and aortic dissection |
|---------------------|-------------------------------------------------------------------------------------------------|
| Uterine volume/puberty issues | - Increases the uterine volume, dose and duration dependent  
- Ethinylestradiol: satisfactory pubertal induction and maintenance, but 20–30 µg/daily failed to induce a fully mature uterus in 50% of the girls  
- ERT type: no differences in uterine volume  
- Fixed dose of ERT (RCT) produces a satisfactory pubertal development not inferior to an individualized dose |
| Psychological aspects and brain development | - ERT vs. non-ERT: better performance on measures of overall IQ, expressive vocabulary, and visuospatial processing but does not exclude characteristic neurocognitive profiles in some women with TS |
| QoL | - Age-appropriate pubertal development and satisfaction with breast development has a positive influence on self-esteem, social adjustment |
| Thromboembolic risk | - There is no sign of elevated thromboembolic risk associated with HRT in TS |
| GH-IGF1 axis | - Ethinyl estradiol exerts dose-related suppression of IGF-I in GH-naïve patients  
- Studies differ on influence of E2 routes on IGF-I concentration in GH-treated subjects |
| Other aspects | - TD vs oral ERT: no significant differences in protein turnover, lipolysis, osteocalcin, C-reactive protein, |
Table 10 Areas where further research is required

<table>
<thead>
<tr>
<th>Study design / epidemiology/ cancer research</th>
<th>Related to estrogen replacement</th>
<th>Related to other components of HRT</th>
</tr>
</thead>
<tbody>
<tr>
<td>QoL studies across the lifespan</td>
<td>Serum E2 levels during HRT need further study in relationship to:</td>
<td>Frequency of progestin withdrawal and progestin regimens (agent, dose)</td>
</tr>
<tr>
<td></td>
<td>• Bone health</td>
<td>• Effect on breast growth?</td>
</tr>
<tr>
<td></td>
<td>• Uterine growth</td>
<td>• Effect on uterine growth?</td>
</tr>
<tr>
<td></td>
<td>• Height – long term studies from initiation of puberty through adult height</td>
<td>• Effect on bleeding pattern and abnormal uterine bleeding</td>
</tr>
<tr>
<td></td>
<td>• Onset of menses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Cardiovascular profile</td>
<td></td>
</tr>
</tbody>
</table>

Comparison of who uses which preparations and why

E2 dosing - rate of increase, effect on height, BMD, vaginal bleeding, uterine development and QoL

- Should dose be?
  - Low while height still a factor but how low for

The need and role of androgen replacement therapy
how long?
• High for young women
• Medium for 30 – 40 years
• Lower ~50 years

Adherence studies
Comparison oral and TD E2 with continued GH (pubertal gain in height, uterine size/form, peak bone mass

Long term outcomes in TS (Endometrial cancer, cardiovascular risks, QoL) - may be different from postmenopausal studies
Comparison of oral and TD E2 effect on:
• Bone health
• Uterine growth
• Height – long term studies from initiation of puberty through adult height
• Onset of menses
• Cardiovascular profile

Table 11 Prevalence of congenital heart disease (CHD) in Turner syndrome compared to general population

<table>
<thead>
<tr>
<th>Lesion</th>
<th>TS (%)</th>
<th>General population (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall incidence of CHD</td>
<td>23 – 50</td>
<td>0.8</td>
</tr>
<tr>
<td>Bicuspid aortic valve</td>
<td>14 - 40</td>
<td>1 – 2</td>
</tr>
<tr>
<td>Aortic coarctation(^a)</td>
<td>4 – 15</td>
<td>0.34</td>
</tr>
<tr>
<td>Bovine arch(^b)</td>
<td>6 – 29</td>
<td>13</td>
</tr>
<tr>
<td>Aberrant right subclavian artery</td>
<td>6 – 8</td>
<td>0.5 – 2.5</td>
</tr>
<tr>
<td>Persistent left superior vena cava</td>
<td>2– 13</td>
<td>0.3 – 0.5</td>
</tr>
</tbody>
</table>
Partial anomalous pulmonary venous return | 4 – 16 | 0.4 – 0.7
---|---|---
Hypoplastic left heart | 4 – 5 | 0.0002 – 0.0003

1. a: Prevalence strongly depends on definition, e.g., hemodynamic significance and grade of stenosis, including pseudo-coarctation (appearance of stenosis due to kinking of the aorta). b: Common origin of brachiocephalic artery and left common carotid artery from the aortic arch.

**Table 12** Methods to index ascending aortic diameter to body size

<table>
<thead>
<tr>
<th>Method</th>
<th>Calculation</th>
<th>Dilation cutoff</th>
<th>High risk cutoff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute diameter (cm)</td>
<td>Direct measurement</td>
<td>&gt; 4.0</td>
<td>&gt; 4.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Aortic Height Index (AHI, mm/m)</td>
<td>Absolute diameter / Height</td>
<td>&gt; 2.0</td>
<td>&gt; 25</td>
</tr>
<tr>
<td>Aortic Size Index&lt;sup&gt;b&lt;/sup&gt; (ASI, cm/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>Absolute diameter / BSA&lt;sup&gt;c&lt;/sup&gt;</td>
<td>&gt; 2.0</td>
<td>&gt; 2.5</td>
</tr>
<tr>
<td>Z-score&lt;sup&gt;b&lt;/sup&gt; (Z, dimensionless)</td>
<td>Z = (x-μ)/σ&lt;sup&gt;d&lt;/sup&gt;</td>
<td>&gt; 2.5</td>
<td>&gt; 4</td>
</tr>
</tbody>
</table>

6. a: Consider this absolute diameter threshold for individuals at extremes of BSA (< 1.3 or > 2.4 m<sup>2</sup>)<sup>394</sup>.
7. b: Use ASI or Z-score with caution at extremes of BSA (< 1.3 or > 2.4 m<sup>2</sup>).
8. c: Use Dubois or Haycock methods to calculate body surface area (BSA).
9. d: Calculated according to Campens et al. 900 or Quezada et al. 234. Z-score calculators are available online or may be downloaded from Prakash et al. 397, Supporting Information.

**Table 13** Effect of Increasing Body Weight on Ascending Aortic Size Indices for a Female Age 40 Years and Height 150 cm

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>50</th>
<th>60</th>
<th>70*</th>
<th>70*</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>22.2</td>
<td>26.7</td>
<td>31.1</td>
<td>31.1</td>
</tr>
</tbody>
</table>

12. **Table 13** Effect of Increasing Body Weight on Ascending Aortic Size Indices for a Female Age 40 Years and Height 150 cm

13. **Table 13** Effect of Increasing Body Weight on Ascending Aortic Size Indices for a Female Age 40 Years and Height 150 cm

---

281
### Table 14

Selected testing and interventions to complete prior to transfer from pediatric to adult care; for full recommendations leading up to and post transfer, see relevant sections.

<table>
<thead>
<tr>
<th>Clinical Focus</th>
<th>Testing or Intervention to be completed prior to transfer*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular health</td>
<td>Imaging (echocardiogram or cardiac MR), blood pressure</td>
</tr>
<tr>
<td>Neuropsychology</td>
<td>Full neuropsychological testing</td>
</tr>
<tr>
<td>Reproductive and HRT</td>
<td>Provide counseling about risk for premature ovarian insufficiency; offer fertility specialist visits, as indicated; evaluate for ovarian insufficiency in those not already progressed to premature ovarian insufficiency; ensure adequate HRT regimens for those with premature ovarian insufficiency**</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>Obtain relevant screening labs (e.g., liver and function, diabetes and celiac screening) and baseline DXA; clinical screening for other conditions (skeletal, sleep, ophthalmologic, otologic)</td>
</tr>
</tbody>
</table>

*Values considered to indicate aortic dilation are bolded. *Note that the absolute diameters (3.3 or 3.7 cm) in the two columns with the same weight of 70 kg are not considered to be dilated according to current guidelines.

*Depending on region, often difficult to access expert care and/or obtain payor coverage in adulthood

** Refer to HRT and fertility section for additional details
Table 15 Considerations for fertility counselling in individuals with Turner Syndrome

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Option/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comprehensive review of options for family building or the choice to remain childless</td>
<td>Adoption/fostering, gestational carriers, oocyte or embryo donation, family without children; oocyte cryopreservation has unknown livebirth rate (one case report of successful live birth) and ovarian tissue cryopreservation remains experimental (no reported live births).</td>
</tr>
<tr>
<td>Discussion of maternal health risks associated with pregnancy</td>
<td>Cardiovascular risks including hypertensive disorders, aortic dissection or death. Increased risk of spontaneous abortion and increased risk of operative delivery.</td>
</tr>
<tr>
<td>Discussion of fetal health risks associated with pregnancy</td>
<td>Risk of fetal aneuploidy, preterm birth, intrauterine growth restriction.</td>
</tr>
<tr>
<td>Complexity of procedures for fertility preservation</td>
<td>Ovarian stimulation and oocyte cryopreservation involves serial parenteral hormonal stimulation. Possible complications: deep venous thromboembolism, pelvis inflammation, pelvic/vaginal bleeding, mood disorders. Burden to girl/women: frequent blood testing, transabdominal or transvaginal ultrasound, transabdominal or transvaginal oocyte collection. Ovarian tissue cryopreservation involves surgery under anaesthesia and should occur</td>
</tr>
</tbody>
</table>
under research protocols with research ethics approved informed consent.

<table>
<thead>
<tr>
<th>Skeletal findings</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased sitting/height index</td>
<td>24-97</td>
</tr>
<tr>
<td>Scoliosis</td>
<td>3-59</td>
</tr>
<tr>
<td>Kyphosis</td>
<td>75</td>
</tr>
<tr>
<td>Short neck (webbed)</td>
<td>36-87</td>
</tr>
<tr>
<td>Short sternum – shield chest</td>
<td>14-100</td>
</tr>
<tr>
<td>Pectus excavatum</td>
<td>13-20</td>
</tr>
<tr>
<td>Cubitus valgus</td>
<td>21-79</td>
</tr>
<tr>
<td>Madelung deformity</td>
<td>0-7</td>
</tr>
<tr>
<td>Short 4th and/or 5th metacarpal</td>
<td>10-75</td>
</tr>
<tr>
<td>Developmental dysplasia of the hup</td>
<td>1-20</td>
</tr>
<tr>
<td>Genu valgum</td>
<td>35-68</td>
</tr>
<tr>
<td>Prominent, misplaced tibial tuberosities</td>
<td>46</td>
</tr>
<tr>
<td>Hypertrophic medial femoral condyle</td>
<td>54</td>
</tr>
<tr>
<td>Hyperextension of the great toe</td>
<td>78</td>
</tr>
<tr>
<td>Foot arch abnormalities</td>
<td>62</td>
</tr>
</tbody>
</table>

Sources 16, 99, 345, 412, 641, 730, 901-907.
## Table 17 Surveillance Across the Lifespan

<table>
<thead>
<tr>
<th>Minimum Visit Frequency</th>
<th>Infancy (~2-9 y)</th>
<th>Childhood (~9-11 y)</th>
<th>Peri-Puberty (~12-17 y)</th>
<th>Adolescence (~18-21 y)</th>
<th>Adulthood</th>
<th>Reference Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feeding concerns and/or hypoglycemia symptoms</td>
<td>every visit</td>
<td>every 6m</td>
<td>every 12m</td>
<td>every 2y</td>
<td>7.1-4</td>
<td></td>
</tr>
<tr>
<td>Sleep concerns; sleep disordered breathing</td>
<td>every visit</td>
<td>every 3-5y or other risk factors</td>
<td></td>
<td></td>
<td>7.4</td>
<td></td>
</tr>
<tr>
<td>Lymphedema and skin concerns</td>
<td></td>
<td></td>
<td>annually</td>
<td></td>
<td>7.5</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal (pain, fractures)</td>
<td></td>
<td></td>
<td>annually</td>
<td></td>
<td>7.10, 7.11</td>
<td></td>
</tr>
<tr>
<td>Ear infections; Hearing concerns</td>
<td></td>
<td></td>
<td>annually</td>
<td></td>
<td>7.3</td>
<td></td>
</tr>
<tr>
<td>Symptoms of autoimmune disease</td>
<td>if high risk²</td>
<td>annually</td>
<td></td>
<td></td>
<td>7.8, 7.9, 7.13</td>
<td></td>
</tr>
<tr>
<td>Lifestyle (diet and physical activity)</td>
<td></td>
<td></td>
<td>annually</td>
<td></td>
<td>7.6, 7.10</td>
<td></td>
</tr>
<tr>
<td>Developmental and/or academic concerns</td>
<td>every 3m</td>
<td>annually (also see Table 18)</td>
<td></td>
<td></td>
<td>8.2, 8.3</td>
<td></td>
</tr>
<tr>
<td>Psychosocial concerns</td>
<td></td>
<td></td>
<td>annually (also see Table 18)</td>
<td></td>
<td>8.2, 8.3</td>
<td></td>
</tr>
<tr>
<td>Physical Examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight, height, and weight-for-length or BMI</td>
<td>every 3m</td>
<td>every 6m</td>
<td>every 6-12m</td>
<td>annually</td>
<td></td>
<td>2.1, 7.6</td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
<td>annually</td>
<td></td>
<td>4.6</td>
</tr>
<tr>
<td>Complete cardiovascular exam³</td>
<td>neonatal</td>
<td>if clinically indicated</td>
<td></td>
<td></td>
<td>4.2</td>
<td></td>
</tr>
<tr>
<td>Ophthalmology exam</td>
<td>6-12m</td>
<td>as needed if not done in infancy, new concerns, or follow up of abnormalities</td>
<td></td>
<td></td>
<td>7.2</td>
<td></td>
</tr>
<tr>
<td>Otoscopy</td>
<td>annually and with symptoms</td>
<td></td>
<td></td>
<td></td>
<td>7.3</td>
<td></td>
</tr>
</tbody>
</table>

1. Table 17 Surveillance Across the Lifespan
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Frequency</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hip stability</td>
<td>&lt;6m</td>
<td></td>
</tr>
<tr>
<td>Back (scoliosis)</td>
<td>annually until linear growth complete</td>
<td></td>
</tr>
<tr>
<td>Dental exam and care</td>
<td>every 6-12m</td>
<td></td>
</tr>
<tr>
<td>Orthodontic exam</td>
<td>if clinically indicated</td>
<td></td>
</tr>
<tr>
<td>Breast exam</td>
<td>every 6-12m for pubertal staging</td>
<td>per local recommendations</td>
</tr>
</tbody>
</table>

**Laboratory**

<table>
<thead>
<tr>
<th>Test</th>
<th>Frequency</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-feed blood glucose</td>
<td>First 48 hrs</td>
<td>if clinically indicated</td>
</tr>
<tr>
<td>Anti-Mullerian Hormone (AMH)</td>
<td>consider annually</td>
<td>offer annually if POI not already established</td>
</tr>
<tr>
<td>Follicle Stimulating Hormone (FSH)</td>
<td>4-12 weeks</td>
<td>annually if clinically indicated</td>
</tr>
<tr>
<td>Estradiol (E2)</td>
<td>4-12 weeks</td>
<td>to assist with HRT every 5y to eval HRT dose; if clinically indicated</td>
</tr>
<tr>
<td>Thyroid Stimulating Hormone (TSH)</td>
<td></td>
<td>every 1-2y and with new symptoms</td>
</tr>
<tr>
<td>Tissue Transglutaminase (TTG) IgA + Total IgA</td>
<td></td>
<td>every 2-5y and with new symptoms</td>
</tr>
<tr>
<td>Liver enzymes (ALT +/- AST, GGT, Alk Phos)</td>
<td>x1</td>
<td>every 1-2y</td>
</tr>
<tr>
<td>HbA1c and/or fasting glucose</td>
<td>if clinically indicated</td>
<td>x1 every 1-2y and with new symptoms</td>
</tr>
<tr>
<td>Complete Blood Count (CBC)</td>
<td>if clinically indicated</td>
<td>x1 every 1-2y</td>
</tr>
<tr>
<td>25-hydroxyvitamin D</td>
<td>if clinically indicated</td>
<td>x1 every 2-3y</td>
</tr>
<tr>
<td>Lipid profile (total cholesterol, triglycerides, HDL)</td>
<td>per local recommendations</td>
<td>x1 every 3y</td>
</tr>
<tr>
<td>Insulin-like Growth Factor 1 (IGF-1)</td>
<td></td>
<td>annually if on growth hormone</td>
</tr>
<tr>
<td>Urine analysis</td>
<td>if renal anomaly is present</td>
<td>Annually if clinically indicated</td>
</tr>
</tbody>
</table>

**Diagnostics**
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Frequency Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal ultrasound</td>
<td>At diagnosis; repeat if new diagnosis of hypertension or recurrent urinary tract infections</td>
</tr>
<tr>
<td>Electrocardiogram (ECG)</td>
<td>x1 if clinically indicated x1 every 5-10y</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>2-3 days of age if clinically indicated x1 every 5-10y</td>
</tr>
<tr>
<td>Cardiac magnetic resonance (CMR)</td>
<td>if clinically indicated x1 after growth complete before planned pregnancy; if clinically indicated</td>
</tr>
<tr>
<td>Tympanometry</td>
<td>annually until 5y if clinically indicated</td>
</tr>
<tr>
<td>Behavioral Audiogram</td>
<td>every 2-3y and if concerns for hearing</td>
</tr>
<tr>
<td>Uterine ultrasound</td>
<td>to assist with HRT if clinically indicated (abnormal uterine bleeding, etc)</td>
</tr>
<tr>
<td>DXA: spine and hip</td>
<td>x1 every 5-10y</td>
</tr>
<tr>
<td>Comprehensive neuropsychological assessment</td>
<td>x1 at 5-11y of age (see also Table 18)</td>
</tr>
<tr>
<td>Psychosocial screening / evaluations</td>
<td>see Table 18</td>
</tr>
<tr>
<td><strong>Counseling</strong></td>
<td></td>
</tr>
<tr>
<td>Healthy lifestyle (diet, physical activity)</td>
<td>annually</td>
</tr>
<tr>
<td>Genetic Counseling</td>
<td>with caregivers at diagnosis and as needed with patient and as needed if new diagnosis; pre-conception planning; and as needed</td>
</tr>
<tr>
<td>Transition Planning</td>
<td>Start transition ~12-15 y Cont. transition + transfer</td>
</tr>
<tr>
<td>Fertility Counseling</td>
<td>at diagnosis with family; as developmentally appropriate (patient) with patient and as-needed if clinically indicated</td>
</tr>
<tr>
<td>Sexual health and sexual wellbeing</td>
<td>intermittently</td>
</tr>
<tr>
<td>Contraception / Preconception Counseling</td>
<td>if clinically indicated prior to pregnancy</td>
</tr>
</tbody>
</table>
This table represents routine follow up of persons with Turner syndrome (TS) who do not have identified pathology including but not limited to congenital heart disease, structural renal anomalies, hearing loss, hypertension, autoimmune disease, etc. If any of these pathologies are identified, the relevant clinical guidelines should be followed. White boxes are universal recommendations in TS; lightly shaded boxes may be recommended in specific circumstances; dark shaded boxes are generally not recommended. "If clinically indicated" means that if there are indications other than a TS diagnosis alone, such as other risk factors or symptoms.  

1. Visits do not necessarily need to occur with a specific specialist, but clinicians should be familiar with TS care and competent to conduct the recommended evaluations.  
2. Examples of high risk includes presence of one or more autoimmune conditions, strong family history of autoimmunity, isochromosome, etc.  
3. Complete cardiovascular exam includes auscultation, femoral pulses, four extremity blood pressure, pulse oximetry.  
4. Obtaining labs during the mini-puberty period of infancy offer an opportunity to evaluate ovarian function at a time when the hypothalamic-pituitary-gonadal axis is active, however clinical significance has not yet been shown.  
5. Alternatively, universal vitamin D supplementation may be advised rather than laboratory assessment;  
6. Calculate height-adjusted z-score; obtain baseline T-score.  

<table>
<thead>
<tr>
<th>DEVELOPMENTAL STAGE</th>
<th>Before Time of TS Diagnosis</th>
<th>Infancy (0-12 months)</th>
<th>Early Childhood (1-4)</th>
<th>Middle Childhood (5-11)</th>
<th>Adolescence (13-18)</th>
<th>Young Adulthood (19-25)</th>
<th>Middle Adulthood</th>
<th>Older Adulthood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parent Education/Co counseling/Anticipatory Guidance</td>
<td>○ ○</td>
<td></td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parental Depression Screening</td>
<td>○ ○</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motor Milestones and Developmental Surveillance</td>
<td></td>
<td>q 3 months</td>
<td>annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Developmental</td>
<td>○</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service</td>
<td>Frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveillance/Screening*</td>
<td>every three years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social Cognition/Autism Disorder Screening</td>
<td>annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Learning/Education Screening</td>
<td>annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attention/ADHD/Executive Function/Processing Speed Screening</td>
<td>annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety/Mood Screening</td>
<td>annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vocational Screening/Guidance</td>
<td>● ● ● ●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-advocacy/Transition Readiness</td>
<td>● ●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social Determinants of Health</td>
<td>● ● ● ● ●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychosexual/Reproductive Counseling</td>
<td>● ● ● ●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive Neuropsychological</td>
<td>● ●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**evaluation for conservatorship prior to transition to adulthood and age of majority**
q: every
*every 3 years for TS; increase frequency w/recurrent otitis media
**if clinically indicated (refer to Figure x.3.1 Neuropsychological Evaluation Triage Flowsheet)

○ = Recommendations specific to TS
● = Recommendations consistent with larger AAP screening guidelines (additional information here: https://www.aap.org/perodicitieschedule)